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Abstract 
This thesis is part of a large project granted by the Italian Association for Cancer 
Research (AIRC) on “Application of Advanced Nanotechnology in the development of 
innovative cancer diagnostic tools”. One of the aims of this project, coordinated  by the 
italian cancer institute of Aviano (Centro di Riferimento Oncologico -CRO) is the 
development of point of care devices for the therapeutic drug monitoring (TDM) of 
anticancer drugs.  
Chemotherapy consists of cancer treatment by administration of a single or a 
combination of anticancer drugs that are often characterized by a high variability of 
pharmacokinetic among patients and a high toxicity leading to the appearance of many 
side effects and decreasing the therapy efficiency. Therefore, the development of point 
of care devices able to measure directly and rapidly the drug blood levels in small 
volumes from finger pricks, would be very useful in the development of personalized 
therapies.  
This thesis investigates the potential of soluble imprinted polymeric nanoparticles 
(MIPs) as sensing elements for the direct detection of the anticancer drugs sunitinib, 
paclitaxel, SN38 and its produg irinotecan in human plasma. The employment of these 
soluble MIPs as sensing units in optical devices with fluorimetric or colorimetric 
detection represents a good chance to obtain simple and cheap point of care devices. 
To this aim, soluble molecularly imprinted nanoparticles were synthesized by high 
dilution radical polymerization using different functional monomers. All polymers were 
characterized by 
1
H-NMR, Nanosight, and Dynamic Laser Light Scattering. The polymers 
binding capabilities and selectivity were investigated by rebinding tests using an HPLC 
method for the quantification of captured drug, while the fluorescence properties of 
some of these polymers were exploited to study the polymers binding affinities at low 
Abstract 
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drug concentrations. MIPs containing N-acryloyl-tyrosine methyl ester, N-acryloyl-
tryptophan methyl ester, 4-vinyl pyridine or 7-acryloyloxy-coumarin were investigated 
as possible fluorescent polymers or possible quencher of target fluorescence. A MIP 
containing 7-acryloyloxy-coumarin as functional monomer and having specific binding 
sites for sunitinib was used as fluorescence sensor to quantify the drug in plasma 
samples treated with four volumes of DMSO. The system turned out to be robust and 
satisfactory as to its precision and accuracy. It was able to quantify sunitinib within 5 
µmol·L
-1 
- 100 µmol·L
-1 
range with a LOD of 400 nmol·L
-1
, using a calibration curve 
obtained in 4:1 DMSO : water mixture.  
Moreover, two  fluorescence tests for irinotecan quantification in methanol : plasma 
mixtures were developed as proof on concept of fluorimetric sensors. The first test is 
based on the quenching of the intrinsic fluorescence of irinotecan using a MIP 
containing N-acryloyl-tyrosine methyl ester as functional monomer. The test showed a 
linear response between 0.5 µmol·L
-1 
to 8 µmol·L
-1
 drug and turned out to be robust 
since it had the same behavior also in DMSO : plasma mixture. As second approach a 
highly fluorescence polymer containing a naphthalimide-based functional monomer 
was synthesized. Measuring the quenching of MIP fluorescence upon interaction with 
irinotecan, a calibration curve was obtained with a linear response between 20 nmol·L
-1
 
and 100 nmol·L
-1
.  
Moreover, a competition technique has been employed to set up a FRET system for 
paclitaxel quantification. The test is based on the competition between the free 
paclitaxel and the drug covalently linked to DABCYL dye, for the binding in to an 
imprinted polymeric nanoparticle containing EDANS fluorescent functional monomer. 
Since DABCYL is a FRET quencher of EDANS, its binding into the polymer gives a change 
in the polymer fluorescence. The obtained calibration curve in DMSO has a linear 
response between 1 µmol·L
-1 
and 30 µmol·L
-1
. 
Finally, a colorimetric test for irinotecan quantification was developed using an 
imprinted polymer containing 2-acrylamido-2-methylpropane sulfonic acid as 
functional monomer. The test is based on the binding of aniline yellow dye inside the 
remaining free binding sites of the polymer after treatment with drug samples. The 
interaction between the dye and the sulfonic acid in to the polymer gives a change of 
colour from yellow to red. Using this test irinotecan samples in acetonitrile were 
quantified from 3.6 µmol·L
-1
 to 75 µmol·L
-1
. The irinotecan concentrations usually found 
in patients samples are within the dynamic range of the obtained calibration curve. 
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Riassunto 
Questa tesi prende parte ad un progetto finanziato dall’Associazione italiana per la 
Ricerca sul cancro (AIRC) intitolato: “Application of Advanced Nanotechnology in the 
development of innovative cancer diagnostic tools”. Uno degli obbiettivi di questo 
progetto, coordinato  dal Centro di Riferimento oncologico (CRO) di Aviano, consiste 
nello sviluppo di dispositivi point of care per il Therapeutic Drug Monitoring (TDM) di 
farmaci antitumorali.  La chemoterapia consiste nell’impiego di uno o di una 
combinazione di farmaci antitumorali per il trattamento del cancro. Tuttavia tali 
farmaci sono caratterizzati da una famacocinetica molto variabile e da una elevata 
tossicità che porta alla comparsa di molti effetti indesiderati nei pazienti, diminuendo 
l’efficienza della terapia. In questo contesto l’impiego del dispositivi point of care in 
grado di misurare direttamente e rapidamente la concentrazione di farmaco in una 
goccia di sangue risulta particolarmente importante in quanto permette per lo sviluppo 
di terapie personalizzate per i pazienti aumentando l’efficienza della terapia e la qualità 
della vita dei pazienti.  
Questa tesi ha come obbiettivo lo studio di nanoparticelle polimeriche ad imprinting 
molecolare (MIP) solubili, come possibili sensori in grado di catturare e quantificare i 
farmaci antitumorali sunitinib, tassolo, SN38 ed irinotecano nel plasma umano. Tali MIP 
potrebbero infatti essere impiegati come sensori fluorimetrici o colorimetrici per lo 
sviluppo di dispositivi point of care semplici ed economici. A tale scopo sono state 
sintetizzate diverse nanoparticelle polimeriche solubili mediante polimerizzazione 
radicalica ad elevata diluizione utilizzando diversi monomeri funzionali. Tutti i polimeri 
sono stati caratterizzati mediante 
1
H-NMR, Nanosigh e Dynamic Laser Ligh Scattering. 
La capacità di legame e la selettività dei polimeri è stata studiata mediante test di 
recupero utilizzando un metodo HPLC per la quantificazione del farmaco catturato. 
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Utilizzando le proprietà fluorescenti di alcuni MIPs sono state studiate le capacità di 
legame anche a basse concentrazioni di farmaco. Inoltre è stata valutata la possibilità di 
utilizzare i polimeri contenenti N-acriloil-tirosina metil estere, N-acriloil triptofano metil 
estere, 4-vinilpiridina e 7-acriloilossicumarina come polimeri fluorescenti o come 
quencher della fluorescenza della molecola target. In particolare un MIP contenente il 
monomero funzionale 7-acriloilossicumarina e siti di legame specifici per il sunitinib è 
stato utilizzato come sensore fluorescente per la quantificazione del farmaco in plasma 
dopo trattamento con quattro volumi di DMSO. Il sistema ha mostrato una buona 
robustezza e una precisione e accuratezza soddisfacente. Utilizzando tale sistema è 
stato possibile quantificare il sunitinib in un intervallo di concentrazioni comprese tra 5 
µmol·L
-1 
- 100 µmol·L
-1
, utilizzando una retta di calibrazione in 4:1 DMSO : acqua. E stato 
inoltre stimato un LOD pari a 400 nmol·L
-1
. 
Inoltre, come esempio di possibili sensori fluorescenti, sono stati sviluppati due diversi 
test fluorimetrici per la quantificazione dell’irinotecano in metanolo : plasma. Il primo 
test si basa sul quenching della fluorescenza intrinseca dell’irinotecano utilizzando un 
MIP contenente  N-acriloil-tirosina metil estere come monomero funzionale. Il test ha 
fornito una risposta lineare a concentrazioni di farmaco comprese tra 0.5 µmol·L
-1 
e 8 
µmol·L
-1 
ed ha dimostrato un comportamento molto simile anche in DMSO : plasma, 
indicando una buona robustezza. 
Invece il secondo approccio si basa sulla sintesi di un MIP fluorescente contenente un 
monomero funzionale naftalimidico, la cui fluorescenza viene spenta in seguito al 
legame con l’irinotecano. Utilizzando questo sistema è stata costruita una retta di 
calibrazione avente una risposta lineare tra 20 nmol·L
-1
 and 100 nmol·L
-1
. 
Inoltre unaa tecnica competitivaè stata utilizzata per lo sviluppo di un sistema FRET per 
la quantificazione del tassolo. Il test si basa sulla competizione tra il farmaco libero ed il 
farmaco legato covalentemente al DABCYL per il legame ad un polimero ad imprinting 
molecolare contenente EDANS come monomero funzionale fluorescente. Infatti  il 
DABCYL è un FRET quencher dell’EDANS che, legandosi al polimero, genera una 
variazione della sua fluorescenza. Utilizzando tale sistema è stata ottenuta una retta di 
calibrazione tra 1 µmol·L
-1 
and 30 µmol·L
-1 
in DMSO che rappresenta un punto di 
partenza per lo sviluppo di un sensore FRET per la quantificazione del tassolo in 
campioni reali. 
Infine è stato sviluppato un test colorimetrico per la quantificazione dell’irinotecano 
utilizzando un polimero ad imprinting molecolare contenente l’acido 2-acrilamido-2-
metil propansolfonico come monomero funzionale. Il test si basa sul legame del 
colorante giallo anilina  nei siti di legame del polimero rimasti liberi dopo interazione 
con i campioni di farmaco, infatti l’interazione tra il colorante e l’acido solfonico nel 
polimero genera un viraggio di colore da giallo a rosso. Utilizzando questo test è stato 
possibile quantificare dei campioni di iriotecano in acetonitrile a concentrazioni 
comprese tra 3.6 µmol·L
-1
 and 75 µmol·L
-1
. Le concentrazioni di irinotecano solitamente 
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riscontrate nei campioni dei pazienti sono all’interno del range dinamico della curva di 
calibrazione ottenuta.   
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1.1 Anticancer Drugs 
 
Sunitinib 
 
Sunitinib (SUTENT, SU11248) is a tyrosine kinases (RTK) inhibitor approved by the Food 
and Drug Administration for the treatment of gastrointestinal stromal tumors and as 
first line therapy of metastatic  clear cell renal cell carcinoma (ccRCC), a disease that is 
resistant to traditional chemotherapy and radiotherapy and that has a very poor 
patient survival rate.
 1  
Furthermore sunitinib showed the ability to directly inhibit the survival and 
proliferation of a wide variety of cancer cells, including small cell lung carcinoma, 
gastrointestinal stromal tumors, acute myelogenous leukemia and chronic 
myelogenous monocytic leukemia. Sunitinib is also under investigation as a treatment 
for several other tumors like breast cancer, colorectal cancer and non-small cell lung 
cancer.
2
 
The high efficiency of sunitinib as anticancer drug could be attributed to its ability to 
inhibit a wide range of receptors in particular the vascular endothelial grown factors 
(VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived grown factor receptors (PDGFR-α, 
PDGFR-β) and fms-related tyrosine kinase 3 (FLT3), cKIT and RET.
3,
 
4
 
The inhibition of tyrosine kinases and in particular of the vascular endothelial growing 
factor (VEGFR) plays a critical role in cancer therapy as these proteins are involved in 
the angiogenesis and lymphangiogenesis mechanisms that are among the main causes 
of tumor growth.
5
 
Angiogenesis and lymphangiogenesis are the processes of new blood and lymphatic 
vessels growth from preexisting vasculature. Both have an essential role in the 
formation of a new vascular network to supply nutrients, oxygen and immune cells, 
moreover they are involved in the removal of catabolites. All these process are 
fundamental for tissue growth, physiological processes, embryonic development, and 
wound healing, however not only immune cells but also tumor cells can penetrate 
blood or lymphatic vessels and circulate inside the intravascular stream to reach 
another site where the tumor can grow (metastasis). Therefore cancer has the ability to 
spread to adjacent or distant organs by circulating through the vascular network. For 
these reasons angiogenic and lymphangiogenic factors are two of the main targets for 
cancer therapy. 
6
 
 
Tyrosine Kinases 
 
Kinases are enzymes responsible for the phosphoryl transfer from high-energy donor 
molecules, for example adenosine triphosphate (ATP), to specific substrates. Kinases 
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are called also phosphotransferases because they phosphorylate proteins substrates 
leading to conformational and functional changes in their target proteins.
7
 
The human genome encodes 518 protein kinases, 90 of them belong to the group of 
tyrosine kinases while other groups contains kinases able to phosphorylate first serine 
and threonine residues. The tyrosine kinases group is further divided in 30 families 
among which it is possible to distinguish the vascular endothelial grown factors (VEGFR) 
family, the platelet-derived grown factor receptors (PDGFR) family, the fibroblast 
growth factor receptor (FGFR) family and the epidermal growth factor receptor (EFGR).
8
 
Apart from classification in families, within the group of tyrosine kinases it is also 
possible to distinguish between 58 receptor tyrosine kinases (RTK) and 32 non-receptor 
(cytoplasmic) tyrosine kinases.
9
 The receptor tyrosine kinases are essential for the 
transduction of extracellular signals into the cell and therefore for the cellular signaling 
pathways that are active during embryonic development and adult homeostasis, while 
non-receptor tyrosine kinases are involved in the intracellular communication.
10
  
Receptor tyrosine kinases are multifunctional transmembrane proteins, expressed at 
the cell surface. These features make them potential multisite targets for cancer 
therapy using small molecules as cell permeable kinases inhibitors or water soluble 
macromolecules like antibodies or binding antagonists. 
All receptor tyrosine kinases consists of a large glycosylated N-terminal ligand-binding 
domain, a single transmembrane region and an intracellular portion containing  a 
conserved protein tyrosine kinase domain with catalytic activity, a juxtamembrane 
region, called also activation loop, and a C-terminal tail.
11
 
The kinase domain has a bilobar structure, with an ATP-binding site situated between 
the N and the C-terminal lobes. The ATP-binding cleft consists into three sub-regions: 
the adenosine region, the sugar region and the phosphate binding region.
12
  
 
 
Figure 1.1: structure of a receptor tyrosine kinase (From ref 7) 
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Receptor tyrosine kinases are generally activated by the ligand binding to its 
extracellular domain, inducing an oligomerization, typically a dimerization of the 
receptor. In this phase the two cytoplasmic tyrosine kinase domains of the dimer are 
juxtaposed, facilitating the auto-phosphorylation in trans of tyrosine residues in the 
kinase activation loop, inducing conformational changes that are necessary for the 
stabilization of the kinase active state.
13
 Moreover, when the receptor tyrosine kinase is 
activated it could bind some interacting proteins by its auxiliary phosphorylation sites. 
The subsequent phosphorylation of these interacting proteins lead to signaling proteins 
that are able to phosphorylate other proteins activating a signaling pathway that will 
lead to a biological response, like cell activation, proliferation, differentiation, 
migration, survival and vascular permeability.
14
 
 
Kinase Inhibitors 
 
Human protein kinases present different primary amino acid sequence but they share a 
great degree of similarity in their 3D structures, in particular in their catalytically active 
kinase domain where the ATP-binding pocket is located. In fact they are characterized 
by a β sheet containing an N-terminal lobe, a C-terminal lobe containing mainly α 
helices, and a connecting hinge region where the ATP-binding site is situated in 
correspondence of a cleft between the two lobes.
15
  
ATP binds in the cleft with the adenine ring forming hydrogen bonds, while the ribose 
and triphosphate groups of ATP bind in a hydrophilic channel extending to the protein 
binding site.  
Moreover a flexible activation loop, characterized by the conserved specific amino acid 
sequences DFG at the start of the loop and APE at the ends of the loop, regulate the 
access to the ATP-binding site by assuming different conformations.
16
  
Tyrosine kinases inhibitors could be divided in two categories in base of the binding 
modes: irreversible and reversible. In the irreversible mode the inhibitor binds 
covalently to the reactive nucleophilic cysteine residue of the kinase proximal to the 
ATP-binding site, preventing the access of ATP and leading to an irreversible kinase 
inhibition. In the reversible mode the binding occurs by weak interactions. In the last 
case it is possible to distinguish between: 
 
 Type I inhibitors that are ATP-competitive inhibitors able to bind to the active 
form of kinases by one to three hydrogen bonds, mimiking the interaction 
between ATP and the residues in the binding site. Moreover, since the kinase 
is in its active form, the aspartate residue of the DFG sequence in the 
activating loop is faced towards the active site of the kinase. Type I inhibitors 
typically consist of a heterocyclic ring system able to interact with the purine 
binding site, and some side chains that occupy the adjacent hydrophobic 
region I and II.  
Introduction 
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 Type II inhibitors, able to bind to specific pockets adjacent to the ATP-binding 
site when the kinase is in the inactive form. In this case hydrophobic binding 
pockets are accessible thanks to the rotation of the activating loop when the 
protein is in the inactive form with the aspartate residue of the DFG sequence 
protruding outward from the ATP-binding site of the kinase. These inhibitors 
indirectly compete with ATP by the binding to hydrophobic pocket that is 
closer to the ATP-binding site.  
 
 Type III inhibitors, binding exclusively allosteric pockets adjacent to the ATP-
binding site without making any interaction with it. These inhibitors exhibit the 
highest degree of kinase selectivity because they exploit binding sites and 
regulatory mechanisms that are unique to a particular kinase. 
 
 Type IV inhibitors able to bind inside an allosteric pocket away from the ATP-
binding site  
 
  type V,  bivalent inhibitors because exhibit more than one of the previous 
described binding modes.
17
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
b) 
Hydrophobic pocket II 
 
Hydrophobic pocket I 
 
Adenine 
Ribose 
Figure 1.2: a) co-crystal structure of PDK1 with ATP (adenine and ribose in green backbone, phosphate 
groups in orange). b) Four types of reversible binding mode.(From ref 17) 
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The presence of a higher conserved region in all tyrosine kinases at the level of the 
binding site of ATP is due to the necessity of these receptors to bind ATP to perform 
their activity. Type I kinase inhibitors  are not highly selective because are able to bind 
to ATP-binding sites of a wide number of kinases involved in different signaling 
processes, while the inhibitors that bind less conserved allosteric pockets or multi 
domain inhibitors are more selective.
18, 19
 
 
Sunitinib Pharmacology 
 
Sunitinib belongs to the I type inhibitors, it binds the ATP-binding site with the indole 
moiety making hydrogen bonds with the kinase, while the pyrrole of the side chain is 
placed inside the hydrophobic pocket I and the fluorine atom inside the hydrophobic 
pocket II. 
16
 
 
 
 
 
 
 
 
 
 
Scheme 1.1: structure of sunitinib and interactions in the binding site of kinases 
 
It is administered orally as the  malate salt at a fixed dose once or twice a day because 
the variability in its pharmacokinetic is not significantly affected by weight.
20
 
Pharmacokinetic and pharmacodynamic preclinical studies showed that the therapeutic 
total plasma concentrations of sunitinib and of its primary metabolite (SU12662) are 
between 50 ng/mL and 100 ng/mL (0.125 µM-0.25 µM). Concentrations lower than 50 
ng/mL decrease the therapeutic efficiency while concentrations higher than 100 ng/mL 
are associated to an increase of the drug toxicity.
21
 The common dosage administered 
to patients is between 25-50 mg to 150 mg of sunitinib malate every day.
22
 
Pharmacokinetic studies showed that sunitinib has an half life in plasma of 40-60 h, and 
is metabolized by the cytochrome P450 enzyme CYP3A4 leading to the primary 
metabolite. This metabolite has a biochemical activity and potency as anticancer drug 
similar to sunitinib. Both sunitinib and its active metabolite showed a high tendency to 
bind serum albumin in vitro: 90% for SU12662 and 95% for sunitinib.
23
 The active 
metabolite half life is 80-110 h after that it is further metabolized by CYP3A4 to its 
secondary inactive metabolite.
 24
 
 
 
 
 Hydrophobic pocket I 
Hydrophobic pocket II 
Adenine pocket 
Solvent region 
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Scheme 1.2: a) active metabolite of sunitinib (SU12662). b) inactive metabolite of sunitinib 
 
Elimination of sunitinib occurs primarily via feces (61%)
25
 and in a low amount via urine 
(16%).
26
 
Even if sunitinib has a discrete toxicity profile, the majority of patients showed some 
side effects, in particular fatigue, gastrointestinal disorders as diarrhea, nausea and 
stomatisis, nervous system disorders like dysgeusia, and hypertension.
27
 
 
Irinotecan and SN38 
 
 
Colorectal carcinoma (CRC) is one of the most common types of cancers in Western 
countries. Usually, patients who develop recurrent or metastatic CRC, undergo surgical 
resection and start a chemotherapy based on the administration of a combination of 
oxaliplatin and 5-fluorouracil (5-FU), as first line treatment. If the cancer still advances 
after this treatment, irinotecan therapy is started as second line chemotherapy. In fact 
clinical trials showed that irinotecan improves pain-free survival, quality of life, 
progression-free survival and overall survival in advanced colorectal cancer.
28
 
This drug was first discovered and synthesized in Japan by Yakult Honsha Co,Ltd, in 
1983.
29
 
During the first phase of study, irinotecan was used in combination with 5-Fluorouracil 
and Leucovorin  that, before irinotecan, were the only chemotherapeutic option for the 
treatment of colorectal cancer. 
Further studies approved the administration of irinotecan for the treatment of 
advanced colorectal cancer either as a first therapy in combination with 5-FU or alone 
in the treatment of 5-FU refractory cases. 
30, 31 
 
Chemistry 
 
Irinotecan (CPT-11) is a semisynthetic analogue of camptothecin, the quinolone-based 
alkaloid isolated by Wall and Co-workers in 1966 from the Chinese/Tibetan ornamental 
a) b) 
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tree Camptotheca accuminata.
32
 Starting from camptothecin, different analogues, 
including irinotecan and topotecan, were synthesized to decrease the toxicity and 
increase the antitumor activity of this drug.
33
 
The structure of these alkaloids is characterized by a planar pentacyclic ring with a 
pyrrolo[3,4-β]-quinolinone moiety (rings A, B and C), a conjugated pyridine moiety (ring 
D) and an α-hydroxy lactone ring containing a chiral centre at position 20 (ring E) 
(Scheme 1.3). The planar structure and the presence of the lactone ring are the most 
important factors in the pharmacological activity of this molecule.
34 
In the case of irinotecan, an ethyl group is linked to the ring B of the camptopthecin, in 
position 7, while a bipiperidine group is linked in position 10 by a carbamide ester to 
increase the solubility of the drug. This group is cleaved in vivo by esterase to obtain 
the active metabolite: 7-ethyl-10-hydroxy campthotecin (SN38). 
 
 
 
 
 
 
 
 
 
 
Scheme 1.3: a) structure of irinotecan prodrug. b) structure of SN38 active metabolite 
 
Irinotecan hydrochloride trihydrate is a pale yellow crystalline solid with a solubility 
greater than 20 mg/mL in water at pH 3-4, thanks to the presence of the basic 
piperidine group whose pKa is 8.7
35
, so the molecule is protonated at both acid and 
neutral pH.
 
The α-hydroxy-δ-lactone of irinotecan and of all the camptothecins, undergoes to rapid 
pH-dependent equilibration with the corresponding open chain carboxylic acid, called 
irinotecan carboxylate. The lactone form of camptothecins is favoured at pH<5, while 
the carboxylate form is favoured at pH>8. At pH between 6 and 7 the rates of lactone 
hydrolysis and formation is similar yielding similar amounts of each species at 
equilibrium.
36
 
 
b) a) 
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Scheme 1.4: equilibrium between the lactone form and the carboxylate form of irinotecan 
 
SAR 
 
Camptothecins (CPT) are a potent inhibitors of DNA topoisomerase I (TOP I).  
Topoisomerases are ubiquitous and essential enzymes that solve the topological 
problems related to the DNA replication, transcription, chromatin assembly, 
recombination and chromosome segregation, by introducing transient breaks into the 
DNA helix. Strand cleavage by all topoisomerases involves nucleophilic attack by a 
catalytic tyrosine residue on the scissile phosphodiester bound and the formation of a 
covalent bond between the enzyme and one 
of the ends of the broken strand. After 
modification of the DNA topology, the double 
helix is re-ligated and the enzyme is released. 
The enzymes that cleave only one strand of 
DNA are defined as type I and can be further 
classified as either type IA subfamily if the 
protein links to the 5’ phosphate or type IB if 
the protein is attached to the 3’ phosphate. 
The topoisomerases able to cleave both 
strand of DNA are defined as type II.
37
 
Human topoisomerase I wraps around DNA 
and cleaves one single strand through trans-
esterification of Tyr723 leading to a 3’-
phosphotyrosine intermediate, so the 5’-end is 
free to rotate, twisting it about the other 
strand, to release the torsional strain of DNA, 
 
 
Figure 1.3: The domain structure of human 
topoisomerase I: co.crystal structure of 
human topoisomerase I containing a 22 
base pair duplex oligonucleotide (pdb entry 
1K4T) 
Chapter 1-Introduction 
 
11 
 
that occurs during the synthesis of a new strand of DNA. Finally the broken strands are 
re-joined by the enzyme.
38
 Human topoisomerase I represents an important target in 
cancer chemotherapy because it is overexpressed in tumour cells and when the enzyme 
is covalently linked to the DNA, forming the enzyme–DNA complex, it is  vulnerable to 
campthothecins that reversibly trap the complex by intercalating between DNA base 
pairs at the cleavage site, inhibiting the re-annealing of the parent DNA. This stabilized 
complex collides with the replication fork of DNA during cell division, leading the DNA 
break and tumour cell death.
39
 
The 3.0 Å X-ray crystal structure of the ternary campthothecin top1-DNA complex 
reveals that the heterocyclic ring structure of CPT intercalates at the site of DNA 
cleavage, making π-stacking interactions, while the E-ring of CPT is positioned closely 
toward the active site of top1 by which it makes H-bonds mainly with three amino acid 
residues. The C21 lactone oxygen is 4.0 Å away from the bridging phosphodiester 
oxygen between Tyr723 and thymidine-10, as well as 3.8 Å from the ε nitrogen of 
Lys532. The pyridone ring oxygen is 4.0 Å from the side chain nitrogen of Asn722. The 
C20 hydroxyl is 3.4 Å from the Oδ1 side chain atom of Asp533, a residue known to be 
required for enzyme sensitivity to campthothecin. The closest protein-drug interaction 
in the CPT ternary complex structure is 2.9 Å from an Nε of Arg364 to a free electron 
pair of the B-ring N1 of CPT.
40
 Also the docking study of the complex SN38-
topoisomerase I-DNA reveals an additional H-bounds between Asn352 and the hydroxyl 
on the A-ring of the drug that increases the inhibitor activity with respect 
campthothecins.
41
 
 
 
 
Figure 1.4: a) camptothecin on the Top1 active site viewed down the DNA helix alxis, hydrogen bonds and π-
staking ineractions are shown in red and orange respectively. b) camptothecin intercalation with DNA (in 
green) by π-staking interactions. (From ref 39) 
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Pharmacology  
 
SN38 and camptothecins can not be administered directly to patients due to their very 
poor water solubility (2-3 g/mL for SN38) that makes difficult an intravenous 
administration.
42
 
To overcome the solubility and stability issues associated to camptothecins, various 
derivatives have been developed.
43
 Irinotecan, pro-drug of the active form SN38, was 
synthesized to improve the solubility by the protonation of the tertiary amino group of 
the piperidyl ring at low pH. Despite the fact that the efficacy of SN38 to inhibit 
topoisomerase I is 1000 times higher than that of irinotecan, such pro-drug is 
sufficiently water soluble to permit a stable aqueous solution and decrease the drug 
toxicity.  
Irinotecan is administered intravenously using a sterile aqueous solution marketed as 
Camptosar
©
 and containing 20 mg/mL of irinotecan HCl trihydrate, 45 mg/mL of 
sorbitol and 0.9 mg/mL of lactic acid formulated at pH 3-3.8. This solution has to be 
diluted until 0.18-2.8 mg/mL in an injection solution containing 5% dextrose or 0.9% 
sodium chloride, before the injection.
44 
After injection, irinotecan is converted by caboxyesterases to the active form SN38, and 
it undergoes to a rapid conversion of both irinotecan and SN38 from the lactone to the 
carboxylate form with a mean half-life of 9.5 min leading to an equilibration in vivo 
between the two forms. Only the closed lactone form is able to inhibit the 
topoisomerase I.
45
 
 
    
 
Scheme 1.5: hydrolysis of irinotecan by carboxyesterase to obtain the active drug 
 
Both irinotecan and SN38 are able to bind to plasma proteins, in blood  irinotecan is 
80% bound to erythrocytes, whereas SN38 is bound for at least 99% mainly to albumin 
and lymphocytes, but also to erythrocytes and neutrophiles. Binding to albumin 
increases the stability of the lactone form in SN38. Finally, the active molecule SN38 is 
converted to the inactive glucuronide derivative (SN38-G) and is excreted into the 
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intestinal lumen via the bile.
46
 The enzyme responsible to the SN38 glucuronidation is 
uridine diphosphate glucoronosyltransferase 1A1.
47
 
The commonly observed plasma concentrations of irinotecan and SN38 are respectively 
10 -10000 µg/L (17 nM-17 µM) and 1-500 µg/L (2.5 nM-1.3 µM). 
The most frequent irinotecan toxic effects include severe diarrhoea and suppression of 
the immune system (neutropenia). Other side effects include nausea, 
hyperbilirubinaemia, fatigue, emesis, fever, weight loss, alopecia, oedema, dyspnoea 
and thromboembolism.
48
 
 
 
Paclitaxel 
 
 
Paclitaxel is one of the most popular anticancer drugs. It was originally extracted from 
the bark of Taxum Brevifolia, but it was also found in leaves, roots and stems of other 
types of Taxus.
49 
Some of Taxus properties were known since ancient times when Native Americans used 
the bark of Taxum Brevifolia to treat skin problems, rheumatism and colds,
50
 or as 
disinfectant to treat wounds and as abortifacient.
51
 Primary uses of Taxus Baccata and 
Taxus Brevifolia were also in North America to treat  pulmonary problems and 
tuberculosis.
52
  
Only in 1962 botanists of the United State Department of agriculture created the first 
collection of Taxus Brevifolia for screening purposes and the anticancer activity in its 
bark was confirmed one year later.
53
 In 1966 Wall and Wani extracted paclitaxel from 
Taxum Brevifolia with a very low yield and its chemical structure was identified by NMR 
and XR-crystallography.
54
  
However, the difficulties in understanding the paclitaxel mechanism of action, its low 
solubility and the low yield of extraction, slowed down the study of this drug. Only in 
1979 Susan Horwitz discovered the paclitaxel mechanism increasing the overall interest 
on this drug that during the 80’ started the 1
st
 and 2
nd
 clinical phase.
55
 First tests 
showed some cases of hypersensitivity due to the use of the Cremophor EL surfactant 
necessary to solubilize the drug. The development of an infusion procedure in 
continuous mode avoiding the hypersensitivity reactions, allowed Paclitaxel to be 
approved and commercialized.
56
 
Paclitaxel was approved by FDA in 1992 for the treatment of ovarian cancer, breast 
cancer, non-small-cell lung cancer (NSCLC), esophageal cancer and AIDS-related Kaposi 
sarcoma. The high popularity of paclitaxel is mainly due to two factors: its efficiency 
against ovarian and breast cancer
57 
and the particularity of its mechanism of action. 
Paclitaxel stabilizes microtubules inhibiting the cell replication.
58, 59 
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Microtubules 
 
Microtubules are non-covalent  α- and β- tubulin heterodimers assembled in a 
filamentous tube-shaped structure. α- and β- tu ulin are highly homologous proteins 
each of    450 amino acids.  ach monomer  inds guanosine triphosphate        hich is 
nonexchangea le in α-tubulin, for this reason the nucleotide binding site of this protein 
is called N-site,  hile in β-tubulin the guanine nucleotide is exchangeable and it is 
called E-site.
60
 GTP at the E-site is required for microtubules assembly since the energy 
provided by its hydrolysis (leading to the GDP) is used for the addition of a new dimer 
to the microtubule end, upon which it becomes non-exchangeable. The rate of tubulin 
addition is faster than the rate of GTP hydrolysis during polymerization allowing the 
creation of the protofilament.
61
 
Therefore the polymerization of microtubules occurs by a nucleation-elongation 
mechanism in  hich the relatively slo  formation of a short microtu ule ‘nucleus’ is 
followed by rapid elongation of the microtubule at its ends by the reversible, non-
covalent addition of tubulin dimers.
62
 
In the polymerization stage, the tubulin heterodimers undergo head-to-tail 
arrangement in which the α-subunit of one dimer is in contact with the β-subunit of the 
next. The resulting protofilaments comprise the backbone of the hollow, cylindrical 
microtubule that is approximately 25 nm in diameter. The arrangements of 13 parallel 
protofilaments in an imperfect helix, lead to a microtubule.
63
 The head-to-tail order of 
the α and β tubulin dimers confers polarity on the microtubule with one end ringed 
with α-tubulin and the other end ringed with β-tubulin. These are considered the minus 
end and the plus end respectively.
64
 The microtubules organizing center (MTOC) is a 
network of microtubules-associated proteins (MAP) to witch the microtubules are 
attached. In particular the minus end of microtubules are attached to the MTOC, while 
the plus ends are distal.  
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Figure 1.5: microtubule polymerization (from ref. 62) 
It is important to emphasize that microtubules are not simple equilibrium polymers.
65
 
The stability of the microtubules depends on whether the exchangeable site of β-
tubulin is occupied by GTP or GDP. A GTP-capped microtubule is stable and will 
continue to grow, while a microtubule capped with GDP-bound tubulin at the plus end 
is unstable and will depolymerize rapidly.
66
 So the microtubules exhibit two dynamic 
behaviours: dynamic instability and treadmilling. The dynamic instability is 
characterized by the switching of microtubules between periods of slow growth, rapid 
shortening and attenuation, while treadmilling is the net addition of a tubulin subunit 
to the plus end and the corresponding loss at the minus end. 
67
 
Figure 1.6: microtubules depolymerization (from ref. 62) 
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Microtubules dynamics are crucial in the mitosis process, particularly for the proper 
function of the mitotic spindle. During interphase, that is the first stage of cellular cycle, 
microtubules exchange their tubulin with the soluble tubulin pool in relatively long 
times, with half-times that range from several minutes to several hours. At the onset of 
mitosis, the interphase microtubule network disassembles and is replaced by a new 
population of spindle microtubules that are more dynamic than the microtubules in the 
interphase cytoskeleton. The spindle microtubules exchange their tubulin in the soluble 
pool rapidly, with half-times in the order of 10–30 seconds. Mitosis progresses rapidly 
and the high dynamic spindle microtubules are required for all stages of mitosis in 
particular to allow the correct attachment of chromosomes to the spindle during 
prometaphase after nuclear-envelope breakdown; to allow the proper alignment of 
chromosomes at the metaphase plate, called congression; and for the synchronous 
separation of chromosomes in anaphase and telophase.
68, 69
 
 
Antimitotic Drugs 
 
Cell proliferation could be inhibited by antimitotic agents that act on the 
polymerization dynamics of spindle microtubules. The disruption of microtubules 
dynamic leads to the arrest of the cell cycle in the G2/M phase, eventually resulting in 
apoptotic cell death. Antimitotic drugs are usually classified in two main groups: 
microtubules destabilizing agents and microtubules stabilizing agents. Vinca alkaloids, 
like vincristine and vinblastine, and other drugs like colchicine, cryptophycins and 
halicondrins are microtubules destabilizing agents in fact at high concentrations they 
inhibit microtubule polymerization, depolymerize microtubules and decrease polymer 
mass.
70
 
Instead microtubules stabilizing agents operate by promoting polymerization and 
increasing the microtubule polymer mass in cells. Taxanes, like paclitaxel and docetaxel, 
belong to this group of antimitotic drugs.
71, 72
 All the antimitotic drugs act also at low 
concentrations suppressing microtubules dynamics without changing the polymer 
mass.
73, 74
 
 
SAR 
 
Paclitaxel belongs to the family of taxanes, complex ditherpenes with a tetracyclic core 
consisting of two cyclohexanes, a cyclooctane and an oxethane. This nucleus, called 
baccatin core, is the molecule skeleton and is common to all the taxane derivate. The 
13
th
 position of paclitaxel is occupied by an ester side chain of phenylisoserine. Also 
paclitaxel contains 11 stereocenters but only the (-)-paclitaxel is the active 
stereoisomer.
75
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Paclitaxel is the first drug able to promote the polymerization of microtubules. After 
paclitaxel discovery many other derivatives were synthesized in order to maintain the 
paclitaxel efficiency and decrease the drug toxicity. The structure-activity relationship 
of paclitaxel showed that removing the C7 or the C10 hydroxyl group the cytotoxicity of 
paclitaxel remains almost the same
76,77
, while on modifying  position 4 leading to 4-
deacetyltaxol
78
 and 4-deacetoxytaxol
79
 the drug activity decreases. The presence of a 
substituent in ortho or in meta in the 2-benzoyl side chain increases the drug activity 
while the para substituent has the opposite behaviour.
80
 
 
Paclitaxel Interaction with Tubulin 
 
The interaction between paclitaxel and tubulin was widely studied to understand its 
mechanism of inhibition. Observing the three dimensional map of tubulin complexed 
with paclitaxel in presence of zinc ions, obtained by electron crystallography, the 
binding site of drug was founded in the β-subunit in the internal surface of the 
microtubule.
81
 Therefore paclitaxel binds on the other side of the core helix from the 
GTPase domain on β-tubulin.
82
 
Probably paclitaxel axesses to its binding site by diffusing through small breaks in the 
microtubule or fluctuations of the microtubule lattice. There is one paclitaxel binding 
site on every tubulin molecule in microtubules. The binding of paclitaxel with free 
tubulin is difficult due to the different polarity of paclitaxel and the soluble tubulin. 
However when tubulin is bound into the microtubule, the interaction with paclitaxel 
increases considerably.  
Scheme 1.6: Chemical structure of paclitaxel 
Baccatin core Side chain 
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The interaction between the drug and its 
binding site leads to the stabilization of 
microtubules and to the increasing of 
microtubules polymerization probably by 
inducing a conformational change in the 
tubulin that increases its affinity for 
neighbouring tubulin molecules.
 654
 
Observing the electron crystal structure of 
tubulin complexed with paclitaxel also the 
presence of arginine 369, glycine 370 and 
hystidine 229 was found in the drug 
binding site.
81
 Only after the studies of 
molecular modelling and NMR NAMFIS of 
Snyder and co-workers, one of the most 
probable tubulin conformation, called T-
Taxol conformation was obtained. They 
started from the data obtained by 
electron crystallography to perform some 
molecular modelling studies and NMR 
analysis of molecular flexibility in solution, 
to obtain the T-Taxol conformation. In this 
structures the phenyl groups of the side 
chain of paclitaxel are arranged 
perpendicularly to the benzyl group in position 2 leading to a “ ” shape. Furthermore in 
this structure hydrophobic interactions leads hystidine 229 to a particular position, the 
 enzyl group in position 2 and the  enzamide group in position 3’. Ho ever in this 
structure one of the main interactions involved in the structure-activity relationship of 
paclitaxel, that is the hydrogen bound creation between arginine 369 and the hydroxyl 
group in 2’ position of paclitaxel was not found. An interaction between the carbonyl 
group of the side chain in position 2’ and the amide proton of glycine 370 was 
observed.
83
 
Further studies with rotational echo double resonance (REDOR) NMR a REDOR-taxol 
structure was identified and accepted as more truthful structure. In fact in this case the 
interaction  et een the hydroxyl in 2’ position of paclitaxel and hystidine 229 of 
tubulin was observed and the arrangement of the side chain phenyl of the drug is 
similar to that described in the T-Taxol conformation.
84
 
 
 
 
 
 
Figure 1.7: the three dimension conformation of 
cow tubulin dimers, as predicted from 3.7Å 
resolution map determined by electron 
crystallography.(From ref 82) 
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Clinical Use of Paclitaxel 
  
Paclitaxel is used for the treatment of ovary, breast cancer, non-small cell lung 
carcinoma and AIDS-related Kaposi sarcoma. Depending on the State in which it is 
commercialized, it could be used as mono-therapy or in association with platinum salts, 
antracycline or trastuzumab. The administration of paclitaxel is intravenous using a 
mixture of paclitaxel complexed with Cremaphor® EL (polyoxyethylated castor oil) and 
49.7% (v/v) of dehydrated alcohol.  
In blood 80-90% of paclitaxel is bound to plasmatic proteins showing a high distribution 
volume of this drug in tissues, while the elimination is hepatic. The paclitaxel plasma 
concentration is between 1.17 nM and 11.71 µM. 
Since paclitaxel administration is associated to many side effects like hypersensibility, 
alopecia, neutropenia and leukopenia, the determination of personalized dosage 
among patients becomes very useful to decrease side effects and increase the therapy 
efficiency.
 85
  
 
 
                                                          
1
 Motzer R. J., Michaelson M. D., Redman B. G., Hudes G. R., Wilding G., Figlin R. A., Ginsberg M. 
S., Kim S. T., Baum C. MDePrimo., S. E., Li J. Z., Bello C. L., Theuer C. P., George D. J., Rini B. I. 
(2006) “Activity of SU11248 , a multitargeted inhi itor of vascular endothelial gro th factor 
receptor and platelet-derived gro th factor, in patients  ith metastatic renal cell carcinoma” J. 
Clin. Oncol. 24:16-24 
Figure 1.8: a) structure obtained by electrocrystallography and NMR studies: T-taxol 
conformation. b) structure obtained by REDOR NMR experiments: REDOR-taxol conformation 
(From ref 83) 
a) 
b
) 
Introduction 
 
20 
 
                                                                                                                                               
2
 Huang D., Ding Y., Li Y., Luo W., Zhang Z., Snider J., VandenBeldt K., Qian C., The B. T. (2010) 
“Sunitini  acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of 
renal cell carcinoma” Cancer Res. 70(3):1053-1062 
3
 Roskoski Jr. R.  2007  “Sunitini : a V  F and  D F receptor protein kinase and angiogenesis 
inhi itor” Biochem. Biophy. Res. Commun. 356:323-328 
4
 Joosten S. C., Hamming L., Soetekouw P. M., Aarts M. J., Veeck J., Van Engeland M., Tjan-
Heijnen V. C.  2015  “Resistance to sunitini  in renal cell carcinoma: from molecular mechanisms 
to predictive markers and future perspectives” Biochim. Biophy. Acta 1855:1-16 
5
 Ker el R.S.  2008  “ umor angiogenesis” N. Engl. J. Med. 358: 2039-2049. 
6
 Folkman J.  1971   “ umor angiogenesis: therapeutic implications” N. Engl. J. Med. 285: 1182-
1186 
7
  otink K. J., Verheul H. M. W.  2010  “Anti-angiogenic tyrosine kinase inhibitors: what is their 
mechanism of action?” Angiogenesis 13:1-14 
8
 Manning  ., Whyte D. B., Martinez R., Hunter  ., Sudarsanam S.  2002  “ he protein kinase 
complement of the human genome” Science 298: 1912-1934. 
9
 Ro inson D. R., Wu Y. M., Lin S. F.  2000  “ he protein tyrosine kinase family of the human 
genome” Oncogene 19:5548-5557 
10
 Hu  ard S. R., Miller W.  .  2007  “Receptor tyrosine kinases: mechanism of activation and 
signaling” Curr. Opini. Cell Biol. 19:117-123 
11
 Bennasroune A.,  ardin A., Aunis D., Crémel  ., Hu ert  .  2004  “ yrosine kinase receptors as 
attractive targets of cancer therapy” Criti. Revi. Oncol./Hematol. 50:23-38 
12
 Liu Y.,  ray N. S.  2006   “Rational design of inhi itors that  ind to inactive kinase 
conformations” Nat. Chem. Biol. 2: 358-364. 
13
 Schlessinger J.  2000  “Cell signaling  y receptor tyrosine kinases” Cell 103:211-225 
14
  a son  .  2004   “Specificity in signal transduction: from phos-photyrosine-SH2  domain  
interactions  to  complex  cellular  systems” Cell 116:191–203 
15
 Knighton D. R. Zheng J. H., Ten Eyck L. F., Ashford V.A., Xuong N. H., Taylor S. S., Sowadski J. M. 
 1991   “ Crystal structure of the catalytic su unit of cyclic adenosine monophosphate-dependent 
protein kinase” Science 253: 407–414 
16
 Zhang J., Yang  . L.,  ray N. S.  2009  “ argeting cancer  ith small molecule kinase inhi itors” 
Nat. Rev. 9:28-39 
17
 Wu  ., Nielsen  .  ., Clausen M. H.  2015   “FDA approved small-molecules kinase inhi itors” 
Trends Pharmacol. Sci. 36(7):422-437 
18
  skens F. A., Ver eij J.  2006  “ he clinical toxicity profile of vascular endothelial gro th factor 
 V  F  and endothelial gro th factor receptor  V  FR  targeting angiogenesis inhi itors” Eur. J. 
Cancer 42: 3127-3139. 
19
 Klein S., McCormick F., Levitzki A.  2005  “Killing time for cancer cells” Nat. Rev. Cancer 5: 573-
580. 
Chapter 1-Introduction 
 
21 
 
                                                                                                                                               
20
 Houk B.  , Bello C. L., Kang D., Amantea M.  2009   “A population pharmacokinetic  meta-
analysis  of  sunitinib  malate  (SU11248) and its primary metabolite (SU12662) in healthy 
volunteers and oncology patients” Clin Cancer Res. 15:2497–250 
21
 Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., Bello C., Deprimo S., Brega N., 
Massimini G., Armand J. P., Scigalla  ., Raymond  .  2006  “Safety, pharmacokinetic, and 
antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with 
cancer” J. Clini. Oncol. 24(1): 25-35. 
22
 Kollmannsberger C., Bjarnason G., Burnett P., Creel P., Davis M., Dawson N., Feldman D., 
George S., Hershman J., Lechner T., Potter A., Raymond E., Treister N., Wood L., Wu S., Bukowski 
R.  2011   “Sunitini  in metastastic renal cell carcinoma: recommendations for management of 
non-cardiovascular toxicities” The Oncologist 16: 543-553. 
23
 Bukowski R. M., Figlin R. A., Motzer R. J.  2009  “Renal cancer carcinoma: molecular targets and 
clinical applications” Humana Press, II edition p.152 ISBN 978-1-4939-1622-1 
24
 Goodman V. L., Rock E. P., Dagher R., Ramchandani R. P., Abraham S., Gobburu J. V., Booth B. 
P., Verbois S. L., Morse D. E., Liang C. Y., Chidambaram N., Jiang J. X., Tang S., Mahjoob K., Justice 
R.,  azdur R.  2007   “Approval summary: sunitini  for the treatment of imatini  refractory or 
intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma” Clin. Cancer Res. 
13:1367–1373 
25
 Adams V. R., Leggas M.  2007  “Sunitini  malate for the treatment of metastatic renal cell 
carcinoma and gastrointestinal stromal tumors” Clin. Ther. 29:1338–1353 
26
 Cavalli F., Kaye S. B., Hansen H. H., Armitage J. O., Piccart- e hart M.J.  2009  “ ext ook of 
medical oncology” Informa Healtcare, IV edition p.432 
27
 Kollmanns erger C., Soulieres D., Wong R., Scalera A.,  arpo R., Bjarnason  ., “Sunitini  
therapy for metastatic renal cell carcinoma: recommendations for management of side effects” 
Can. Urol. Assoc. J. (2007) 1(2):S41-S54 
28
 Weekes J., King-Yin Lam A., Se esan S., Ho J.H.  2009  “Irinotecan therapy and molecular 
targets in colonrectal cancer: a systemic revie ” World J. Gastroenterol 15(29):3597-3602 
29
 Fukuoka M.  2001  “Current status of irinotecan in lung cancer” Oncol. 15(suppl 1):6-7 
30
 Saltz L. B.  1997  “Clinical use of irinotecan: current status and future considerations” The 
Oncologist 2:402–409 
31
 Sa ada S., Yokokura  ., Miyasaka  .  1995  “Synthesis and antitumor activity of A-ring or E-
lactone modified water-soluble prodrugs of 20(S)-camptothecin, including development of 
irinotecan hydrochloride trihydrate (CPT-11 ” Curr. Pharm. Design. 1:113–132  
32
 Wall M. E., Wani M. C., Cook C. E., Palmer K. H., McPhail A. T., Sim G. A. (1996) “ lant 
antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and 
tumor inhi itor from camptotheca acuminate” .J Am. Chem. Soc. 88: 3888–90. 
33
 Adamovics J. A., Hutchinson C. R.  1979  “ rodrug analogues at the antitumor alkaloid 
camptothecin” J. Med. Chem. 22:3  
34
 Lu A., Zhang Z., Zheng M., Zou H., Luo X., Jiang H.  2007  “3D-QSAR study of 20 (S)-
camptothecin analogs” Acta Pharmacol Sin. 28(2): 307-314 
Introduction 
 
22 
 
                                                                                                                                               
35
 Karadas N., Sanli S., Akmese B., Dogan- opal B., Can A., Ozkan S. A.  2013  “Analytical 
application of polymethylene blue-multiwalled carbon nanotubes modified glassy carbon 
electrode on anticancer drug irinotecan and determination of its ionization constant value” 
Talanta 115: 911-919 
36
 Fass erg J., Stella V. J.  1992  “A kinetic and mechanicistic study of hydrolysis of camptothecin 
and some analogues” J. Pharm. Sci. 81:676–684 
37
 Champoux J. J.  2001  “DNA  O OISOM RAS S: structure, function, and mechanism” Annu. 
Rev. Biochem. 70:369-413 
38
 Ste art L., Redin o M. R., Qiu X., Hol W.  . J., Champoux J. J.  1998  “A model for the 
mechanism of human topoisomerase I” SCIENCE 279:1534-1541 
39
 Drwal M. N., Agama K., Wakelin L. P. G.,  ommier Y.,  riffith R.  2011  “ xploring DNA 
topoisomerase I ligand space in search of novel anticancer agents” PLoS ONE 6:9 
40
 Staker B. L., Feese M. D., Cushman M., Pommier Y., Zembower D., Stewart L., Burgin A. B. 
 2005  “Structures of three classes of anticancer agents bound to the human topoisomerase I-
DNA covalent complex” J. Med. Chem. 48:2336-2345 
41
 Laco G. S., Collins J. R., Luke B. T., Kroth H., Sayer J. M., Jerina D. M., Pommier Y. (2002) 
“Human topoisomerase I Inhi ition: docking camptothecin and derivatives into a structure-based 
active site model” Biochemistry 41:1428-1435 
42
 Xu Y., Villalona-Calero M. A.  2002  “Irinotecan: mechanisms of tumor resistance and novel 
strategies for modulating its activity” Annals Oncol. 13:1841-1851 
43
 Venditto V.J., Simanek  . .  2010  “Cancer therapies utilizing the camptothecins: a revie  of 
the in vivo literature” Mol. Pharm. 2(2): 307-349 
44
 Hageman M. J., Morozo ich W.  2007  “Case study: Irinotecan  C  11 , a  ater-soluble 
prodrug of SN38” Prodrugs 5.12: 1269-1279 
45
 Rivory LP, Chatelut E, Canal P, Mathieu-Boue A, and Ro ert J.  1994  “Kinetics of the In Vivo 
interconversion of the carboxylate and lactone forms of irinotecan and of its metabolite SN-38 in 
patients” Cancer. Res. 54:6330–6333 
46
 Mathijssen R. H. J., Van Alphen R. J., Jaap V., Loos W. J., Nooter K., Stoter G., Sparreboom A. 
 2001  “Clinical pharmacokinetics and meta olism of irinotecan  C  -11 ” Clin. Cancer Res 
7:2182–2194 
47
  limelius B.  2005  “Benefit-risk assessment of irinotecan in advanced colonrectal cancer” Drug 
Saf. 28:417-433 
48
 Cunningham D., Pyrhönen S., James R. D., Punt C. J. A., Hickish T. F., Heikkila R., Johannesen T. 
B., Starkhammar H.,  opham C. A., A ad L., Jacques C., Herait  .  1998  “Randomised trial of 
irinotecan plus supportive care versus suppoertive care alone after fluorouracil failure for 
patients ith metastatic colonrectal cancer” Lancet 352:1413-1418 
49
 Manfredi J. J.,  arness J., Hor itz S. B.  1982  “ axol  inds to cellular microtu ules” J. Cell Biol. 
94:688-696 
50
 Selin H., Moerman D.  .  2008  “ ncyclopaedia of the history of science, technology, and 
medicine in non- estern cultures” Spinger. p. 323 ISBN 978-1-4020-4960-6  
Chapter 1-Introduction 
 
23 
 
                                                                                                                                               
51
 Wang Y., Shi Q.,. Dong M, Kiyota H.,  u Y., Cong B.  2011   “Natural taxanes: developments 
since 1828” Chem. Rev. 111:7652-7709 
52
 Le is W. H.  2003  “Medical  otany: plants affecting human health” Wiley, 2
nd
 edition, p. 196 
ISBN: 978-0-471-62882-8  
53
 Kingston D.  . I.  2007  “ he shape of things to come: structural and synthetic studies of taxol 
and related compounds” Phytochemistry 68:1844-1854 
54
 Wani M. C.,  aylor H. L., Wall M.  ., Coggon  ., Mc hail A.  .  1971  “ lant antitumor agents. VI. 
The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus 
 revifolia” J. Am. Chem. Soc. 93(9):2325-7 
55
 Shiff  . B., Fant J., Hor itz S. B.  1979  “ romotion of microtu ule assem ly in vitro  y taxol” 
Nature 27:665-667 
56
 Ro inksy  . K., Doneho er R. C.  1991  “ axol: t enty years later, the story unfolds” J. Nat. 
Cancer Instit. 83(24):1778-1781 
57
 Na holtz J.,  onkin K., Smylie M., Au H., Lindsay M., Mackey J.  2000  “Chemotherapy of  reast 
cancer: are the taxanes going to change the natural history of  reast cancer?” Exp. Opin. 
Pharmacother 1(2).187-206 
58
  atel R. N.  1998  “ our de paclitaxel:  iocatalysis for semisynthesis” Annu. Rev. Microbiol. 
98:361-95 
59
 Orr G. A, Verdier- inard  ., McDaid H., Hor itz S. B.  2003  “Mechanism of  axol resistance 
related to microtu ules” Oncogene 22:7280-7295 
60
 Downing K. H., Nogales E. (1998  “ u ulin and microtu ule structure” Curr. Opin. Cell Biol. 
10:16-22 
61
  erez A.  2009  “Microtu ule inhi itors: differentiating tu ulin-inhibiting agents based on 
mechanism of action, clinical activity, and resistance” Mol. Cancer. Ther. 8(8):2086-2095 
62
 Jordan M. A., Wilson L.  2004  “Microtu ules as a target for anticancer drugs” Nature reviews 
4:253-264 
63
 Zhou J.,  iannakakou  .  2005  “ argeting microtu ules for cancer chemotherapy” Curr. Med. 
Chem.-Anti-cancer Agents 5:65-71 
64
 Fan J., Griffiths A. D., Lockhart A., Cross R. A., Amos L. A.  1996  “Microtu ule minus ends can 
be labeled with a phage display antibody specific to alpha-tu ulin” J .Mol. Biol 259:325-330 
65
 Nogales  .  2001  “Structural insights into microtu ule function” Annu. Rev. Biophys. Biomol. 
Struct. 30:397-420 
66
 Wilson L., Jordan, M. A.  1995  “Microtu ule dynamics: taking aim at a moving target” Chem. 
Biol. 2: 569-573 
67
 Rodionov V. I., Borisy  .  .  1997  “Microtu ule treadmilling in vivo” Science 275(5297):215-
218 
68
 Saxton W. M., Stemple D. L., Leslie R. J., Salmon E. D., Zavortink M., McIntosh J. R. (1984) 
“ u ulin dynamics in cultured mammalian cells” J. Cell Biol.  99:2175-2186 
Introduction 
 
24 
 
                                                                                                                                               
69
 Wads orth  .  2001  “Cell cycle-dependent changes in microtubule dynamics in living cells 
expressing  green fluorescent protein-α tu ulin” Mol. Bio. Cell. 12: 971-980 
70
 Jordan M. A.  2002  “Mechanism of action of antitumor drugs that interact  ith microtu ules 
and tu ulin” Curr. Med. Chem. Anticancer agents 2(1):1-17 
71
 Altmann K. H.  2001  “Microtu ule-stabilizing agents: a growing class of important anticancer 
drugs” Curr. Opin. Chem. Biol. 5:424-431 
72
 Yeung  . K.,  ermond C., Chen X., Wang Z.  1999  “ he mode of action of taxol: apoptosis at 
lo  concentration and necrosis at high concentration” Biochem. Biophysi. Res. Communi. 
263:398-404 
73
 Jordan M. A., Toso R. J., Thro er D., Wilson l.  1993  “Mechanism of mitotic  lock and 
inhi ition of cell proliferation  y taxol at lo  concentrations” Proc. Natl. Acad. Sci. USA  
90(20):9552-6 
74
 Chen J.  ., Hor itz S. B.  2002  “Differential mitotic responses to microtu ule-stabilizing and- 
desta ilizing drugs” Cancer Res. 62:1935-1938 
75
 Mastropaolo D., Camerman A., Luo Y., Brayer  . D., Camerman N.  1995  “Crystal and 
molecular structure of paclitaxel  taxol ” Proc. Natl. Acad. Sci USA  92:6920-6924 
76
 Chaudhary A. G., Kingston D. G. I.  1993  “Synthesis of 10-deacetoxytaxol and 10-
deoxytaxotere” Tetrahedron Lett. 34:4921-4924 
77
 Chaudhary A.  ., Rimoldi J. M., Kingston D.  . I.  1993  “Modified taxols 10.  reparation of 7-
deoxytaxol, a highly bioactive taxol derivative, and interconversions of taxol and 7-epi-taxol” J. 
Org. Chem. 58(15):3798-3799 
78
 Neidigh K. A., Gharpure M. M., Rimoldi J. M., Kingston D. G. I., Jiang Y. Q., Hamel E. (1994) 
“Synthesis and  iological evaluation of 4-deacetylpaclitaxel” Tetrahedron Lett. 35:6839–6842. 
79
 Chordia M. D., Chaudhary A.  ., Kingston D.  . I., Jiang Y. Q., Hamel  .  1994  “Synthesis and 
biological evaluation of 4-deacetoxypaclitaxel” Tetrahedron Lett. 35:6843–6846 
80
 Chaudhary A. G., Gharpure M. M., Rimoldi J. M., Chordia M. D., Gunatilaka A. A. L., Kingston D. 
 . I.,  rover S., Lin C. M., Hamel  .  1994  “Unexpectedly facile hydrolysis of the 2-benzoate 
group of taxol and synthesis of analogs  ith increased activities” J. Am. Chem. Soc. 116:4097–
4098. 
81
 Nogales E., Wolf S. G., Downing K. H. (1998) “Structure of the αβ tu ulin dimer  y electron 
crystallography” Nature 391:199-203 
82
 Amos L. A., Lö e J.  1999  “Ho   axol sta ilizes microtu ule structure” Chem. Biol.  6(3):R65-
R69 
83
 Sun L., Simmerling C., Ojima I.  2009  “Recent advances in the study of the  ioactive 
conformation of taxol” Chem. Med. Chem. 4:719-731 
84
 Alcaraz A. A., Mehta A. K., Johnson S. A., Snyder J.  .  2006  “ he  - axol conformation” J. Med. 
Chem. 49:2478-2488  
85
 Gerritsen-van Schieveen P., Royer B.  2011  “Level of evidence for therapeutic drug monitoring 
of taxanes” Fundamen. Clini. Pharmacol. 25:414-424 
Chapter 1-Introduction 
 
25 
 
 
1.2 Therapeutic Drug Monitoring (TDM) 
 
Chemotherapeutic agents are commonly administered to patients according to body 
size measurements (mgm
-2
 or mgkg
-1
), however, in spite of this “individualized” 
dosage, the chemotherapy efficacy and the toxicity vary considerably among patients. 
Since the toxicity, maybe due to drug overdose, is closely related to the appearance of 
many side effects, chemotherapy can often lead to a decrease of patient compliance. 
The highly inter-individual variability of toxicity and efficacy outcomes of chemotherapy 
can be in part explained by highly variable pharmacokinetics of anticancer drugs among 
patients, in terms of variation in rate and extent of absorption, distribution, metabolism 
and elimination. The variability in pharmacokinetic could be due to genetic factors or 
physiological status of patients. For example when the same dosage is administered to 
different patients, the drug plasma concentration may vary over a 10-fold range, due to 
the inter-patient variability in pharmacokinetics. 
In this context therapeutic drug monitoring (TDM) is a valuable tool to maximize the 
therapeutic outcomes, minimize toxicities and increase the patient compliance. TDM 
involves the measurements and interpretation of drug concentrations in biological 
fluids to allow the determination of drug dosage for the individual patient.  
TDM is widely used in the clinical care of patients from the early 1960s for the 
monitoring of a broad range of drugs, as cardiovascular agents, antiepileptics, 
antibiotics, anti-inflammatory agents, immunosupressants and antidepressants.    
However, not all the drugs are suitable for TDM, and they have to fulfill several criteria: 
 
 The drug should have a narrow therapeutic index, for example the exposure 
needed for a therapeutic outcome is in the same range of that associated with 
a high risk of toxicity. 
 Small changes in drug dosage should lead to large changes in the therapeutic 
effect. 
 The drug pharmacokinetic should be highly variable. 
 The drug should have a small intra-individual variability, so the 
pharmacokinetic is predictable along time within the same patient. 
 The drug must be repeatedly administered. 
 A sensitive, accurate, precise and reproducible assay must be available for this 
drug. 
 A technically feasible dose-adaptation strategy must be developed and 
validated for this drug. 
1, 2
 
 
Since anticancer drugs fulfill most of these criteria, they could be subjected to TDM.  
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The main techniques applied for the detection and quantification of sunitinib, 
irinotecan, SN38 and paclitaxel are based on mass spectrometry, HPLC or fluorescence 
spectroscopy.  
A routine feasible analysis method based on HPLC with an UV detector was developed 
by Etienne-Grimaldi and co-workers to extract and quantify sunitinib and its main 
metabolite in plasma. The method showed a recovery  of 60% and a LOD of 1.4 ngmL.
 3
 
Also Blancket and co-workers developed an HPLC-UV method able to quantify sunitinib 
in human plasma between 20 ngmL
-1 
and 200 ngmL
-1
,
4
 while also methods based on 
HPLC coupled with tandem mass spectrometry were developed at 0.2-50 ngmL
-1
 with a 
limit of quantification of 0.2 ngmL
-1
. 
5, 6
 
Finally many LC/MS/MS methods were developed for sunitinib quantification at 
concentrations between 2 ngmL
-1 
and 250 ngmL
-1
,
7
 or 20 ngmL
-1
 and 10 µgmL
-1
.
8
 
Regarding irinotecan and SN38, Mohammadi and co-workers developed a method 
based on HPLC using an UV detector able to quantify the drugs in 0.1-10 µgmL
-1
 range,
9
 
while the group of Poujol used the HPLC with a fluorescence detector to quantify 
irinotecan and its metabolites at concentrations between 0.5 and 1000 µgL
-1
.
10
 
Moreover LC coupled with electrospray mass spectrometry was used to detect 
irinotecan and SN38
11
 with LOD of 2.5 ngmL
-1
.
12
 Finally, an HPLC-tandem mass 
spectrometry method was developed by Marangon and co-workers for the 
simultaneous determination of irinotecan and its metabolites at concentrations of 10-
10000 ngmL
-1 
for irinotecan and 1-500 ngmL
-1
 for SN38.
13
  
Several methods were developed to quantify paclitaxel using liquid chromatography 
with UV detector 
14
 or coupled with mass spectrometry.
15
 However these methods are 
characterized on long times for the analisys and large sample volumes (0.5 -1 mL), while 
the method developed by Gao and co-workers, based on a liquid-liquid extraction and 
analysis by liquid chromatography coupled with electrospray ionization tandem mass 
spectrometry was able to quantify paclitaxel from plasma samples at 10-1000 ng/mL 
concentrations with amount of sample (100 µL) and in a short time (4.5 min).
16
 
A nanoparticle-based immunoassay was developed by Cline and co-workers for the 
paclitaxel quantification. The assay is based on the turbidimetric measurement of the 
degree of aggregation of paclitaxel monoclonal antibodies-coated nanoparticles and  
was able to quantify the drug with a limit of detection of 11 ngmL
-1
 ad a limit of 
quantification of 19 ngmL
-1
.
17
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1.3 Point of Care Devices 
 
In addition to the TDM as a useful technique to monitor the drug concentrations in 
blood samples during chemotherapy, the application of point of care devices 
represents a crucial step to improve the patient quality of life.  
During the past 40 years, the number of available point of care devices is considerably 
increased, aimed at making the healthcare more centered around patient, thanks also 
to the development of highly sensitive and miniaturized technologies that found many 
applications in sensor technique.  
Within the point of care devices market, those for glucose monitoring and for 
pregnancy test are the most popular ones, while other devices including critical care, 
infectious disease, cardiac markers, diabetes, lipids coagulation and haematology are 
mainly used by clinicians.
1
 
Point of care devices are small and portable systems based on sensors able to provide a 
rapid response of the sample with no human intervention besides adding the sample 
and collecting the data. The main required features of a point of care device are the 
simplicity to use, the use of cheap and stable reagents. They should be robust in 
storage and usage, and the results should be concordant with an established laboratory 
method. The overall device with associated reagents and consumables must be safe to 
use.
2
  
Two different types of point of care devices can be distinguished: small handheld ones 
including qualitative and quantitative strips that are the most popular, and those which 
are larger benchtop devices with more complex built-in fluidics, often variants to that 
used in conventional laboratories. Test strips are based on dipsticks, lateral flow assays 
(LFAs) and microfluidic paper-based devices (µPADs).
3
 Dipsticks, such as pH test strips 
and urine test strips are simple to design and easy to manufacture and to use. These 
tests, usually based on a colorimetric reaction, give a qualitative or semi-quantitative 
response. A qualitative strip test is able to discriminate “plus” and “minus” results by a 
simple visualization or by optical detection using a simple readout device, where the 
observed optical signal can be produced by a chemical indicator 
reaction or by an immunological reaction. The strips are made of 
a porous matrix, usually a cellulose filter paper or 
chromatography paper, mixed with dried reagents onto a 
carried element. The sample, urine or blood, is settled onto the 
matrix and, after soaking the strip, penetrates inside the matrix 
and reacts with other components leading to a coloured 
response. Using this method different point of care devices were 
obtained for pregnancy testing, detection of blood in stool, 
Figure1.9: example of 
glucometer, from ref 4 
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detection of infectious agents in swab materials and detection of analytes in urine.
4
  
Lateral flow assays  strips are typically composed of a nitrocellulose membrane, sample 
pad, conjugated pad, wicking or absorbent pad and backing pad. The recognition 
element is placed on the nitrocellulose support to form test and control lines, and after 
placing a small amount of sample in the sample pad, it migrates along the strip and 
reaches the recognition elements giving a qualitative and quantitative response.
5
  In the 
µPAD technique, 2D or 3D microfluidic channels are created on paper which are able to 
transport liquids in the predesigned pathways on paper where the analyte detection 
and semi-quantification occurs.
6
 
The simplest method to obtain a quantitative device is that applied for glucose 
quantification in blood. The test is based on a biosensor incorporating an enzyme 
containing redox groups that change redox state during the biochemical reaction. 
Enzymes of this type are glucose oxidase and glucose dehydrogenase. The detection 
occurs by potentiometric or electrochemical measurement, where the latter is usually 
preferred since the it gives a device less subjected to interferences, more compact and 
able to produce a rapid response analyzing small sample amounts.
7
 
Finally integrated cartridges were applied as point of care devices for the rapid 
measurement of sodium, potassium, chloride, urea, nitrogen, glucose and hematocrit. 
The system is composed of a portable hand-held analyzer and a disposable cartridge 
where the sample analysis takes place. The analyzer consists of a mechanical system 
that controls the flow of calibrator and sample within the cartridges, an electrical 
connector to receive signal from the cartridge, an electronic system that measures and 
monitors signals from the biosensors in the cartridges and a liquid crystal screen that 
displays the results. The cartridge contains a calibrator solution, a sample-handing 
system, conductivity pads that make electrical contact with the analyzer and a series of 
biosensors. Different analytes are quantified by different 
mechanisms: sodium potassium and chloride are measured 
by direct ion-selective electrode potentiometry, urea is 
hydrolyzed by urease and the ammonium ions are 
measured by ion selective electrode, while glucose is 
measured amperometrically via the hydrogen peroxide 
product of glucose oxidase reaction. Finally, hematrocrit is 
determined by conductivity.
8
        
Despite the widespread application of point of care devices 
in clinical diagnostic, these systems are not commercialized 
yet in the therapeutic drug monitoring field.
9
 
  
 
 
Figure 1.10: example of 
disposable cartridge, from 
ref 5 
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1.4 Sensors, Point of Care Devices and Imprinted 
Polymers  
 
 
Sensors 
 
A sensor is a device able to detect and quantify with high specificity and selectivity the 
target molecule. The core of the sensor is a recognition element, a receptor able to 
bind selectively the target molecule. The chemical signal generated by the recognition 
process is used by the transducer to produce an electrochemical, optical, mass or 
thermal signal that could be finally amplified by a computer.
1, 2
  
 
 
 
Figure 1.11: general structure of a sensor 
 
Over the past few decades, chemical and (bio)sensors have attracted considerable 
attention within the field of analytical chemistry, in particular food
3,4,5
 and 
environmental analysis
6
, production monitoring as well as detection of illicit drugs
7,8
 
and clinical diagnostic.
9,10
 These sensors, could be used for the development of new 
devices that are less expensive, simpler to construct and operate, reliable and able to 
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quantify the analyte with an adequate detection limit and a good selectivity and 
accuracy. 
A biosensor is a sensor containing a biological component such as an antibody, enzyme, 
nucleic acid, proteins or whole cells as recognition elements. Initially these bio-
elements were isolated from living systems, while with the development of 
recombinant antibodies and phage display antibody libraries, biosensors could be 
obtained now also for analytes for which a natural receptor does not exist.
11
  
The choice of antibodies as recognition elements is very convenient thanks to their high 
specificity, but the main problems are related to the cost of antibodies production and 
to their stability.
12,13
 Numerous attempts were done to obtain smaller and more stable 
receptors, like bio-engineered antibodies  fragments and affibodies, single domain 
proteins obtained by phage display and characterized by affinity and specificity to any 
given protein target. Other types of artificial receptors are nucleic acids and small 
peptides. However the majority of these biomolecules showed a poor chemical and 
physical stability preventing their application under harsh conditions.
14
 
To overcome this problem, artificial receptors could be obtained by rational design and 
chemically synthetized, however this approach is more appropriate for targeting small 
molecules, such as inorganic ions and it is usually requires many synthetic steps.
15
 This 
approach may proves difficult if the analyte is a large molecule; in this case the 
molecularly imprinting of synthetic polymers becomes one of the most preferred 
techniques. In fact the binding sites generated during the imprinting process have 
affinities and selectivities similar to those of antibody-antigen systems, but due to their 
highly crosslinked polymeric matrix, the imprinted polymers are more stable and robust 
than natural antibodies.
16
 For these reasons they could be easily applied as artificial 
receptors in sensor development able to work also in extreme environments such as 
the presence of acids or bases, inorganic solvents, of high pressures and temperatures. 
Moreover these polymers are  cheap and fast to produce and they could be stored in 
the dry state at room temperature for long time.
17
 
 
 
Molecular Imprinting Technology 
 
In the molecular imprinting process, functional monomers and a crosslinker are co-
polymerized in the presence of the target molecule that acts as a template. The 
functional monomers are molecules containing particular functional groups able to 
interact with the target molecule, and the presence of a polymerizable acryloyl or vinyl 
group allow their incorporation in the polymeric matrix during the synthesis.  
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In the non-covalent approach,  a complex between the functional monomer and the 
template is created before polymerization, and during the synthesis the functional 
groups involved in the interaction are held in position by the highly crosslinked 
polymeric matrix that surrounds the complex. Subsequent removal of the template 
molecule reveals binding sites that complement in shape, structure and functional 
groups, the analyte. In that way, a molecular memory is introduced inside the polymer, 
which is now capable to rebind the target molecule with high specificity.
18
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: imprinting process 
 
In this first approach a pre-polymerization complex is created between the functional 
monomer and the template by weak interactions (self assembly) like hydrogen-bonds, 
ion pair interactions, Van der Waals forces, ion pair interactions and dipole-dipole 
bonds. In this process, originally developed by Mosbach,
19
 functional monomers are 
positioned in a particular orientation with respect the template prior to polymerization. 
The number of non-covalent interaction must be sufficient  to allow the organization of 
the binding pocket during polymerization. Also the use of a cross linking functional 
monomer during polymerization allows to create a three dimensional rigid structure 
around the template molecule  and produces stable binding cavities. The non-covalent 
process is the most used imprinting technique due to the large availability of functional 
monomers and the possibility to use the imprinting process with a large number of 
target molecules. This technique is not particularly successful for  templates lacking 
appropriate functional groups able to create many strong non-covalent interaction with 
the functional monomers.
20, 21
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To overcome this limitation Wulff  et al. introduced the covalent approach that is based 
on the creation of reversible covalent interactions between the target molecule and the 
functional monomer before polymerization. The covalent bonds are cleaved after 
polymerization to release the template, while the active functional groups are renewed 
to allow them to make the same covalent interactions with the target molecule in the 
obtained binding cavities of the polymer.
22
 
Despite the high specificity of binding sites created by the covalent approach, it is 
limited by the rather small number of useful reversible covalent interactions that can 
be used. Therefore both the template and functional monomers must possess 
appropriate functional groups able to create a covalent bond. The most common 
functionalities involved in this process are boronic acid, aldehyde, diol or amine 
groups.
23, 24, 25 
 
Composition and Synthesis of Imprinted Polymers 
 
The choice of functional monomers and crosslinker is an important step in the synthesis 
of molecularly imprinted polymers because the functional monomer allow to create 
characteristic interaction with the template molecule, while the co-monomer and the 
crosslinker give to the polymer the necessary stability and rigidity to maintain a 
memory for the template molecule. Moreover,  the crosslinker is important in 
controlling the morphology of the polymeric matrix, whether it be gel-type, 
macroporous or a microgel powder, and it imparts the mechanical stability to the 
polymer.
 26
 
The majority of imprinted polymers are based on polystyrene or polyacrylamide. The 
attractiveness of vinyl and acrylic polymers arises for the large availability in commerce 
of these types of functional monomers. Moreover these molecules can be positively or 
negatively charged, hydrogen bonding, hydrophobic or metal coordinating, allowing the 
interaction with the template molecule.
27
 
The imprinting technique was also applied to obtain inorganic materials like xerogels 
using tetraalkoxysilanes as precursors.
28
  
The most important synthetic method to obtain organic imprinted polymers is the free 
radical polymerization, a widely exploited technique in industry field for the production, 
on a multi-tone scale, of numerous commercially important plastics. Radical 
polymerization can be performed under mild reaction conditions, like room 
temperature and atmospheric pressure, in bulk or in solution, with a wide range of low 
cost functional monomers like styrene, ethylene, methyl methacrylate which are of 
particular industrial importance. Since this technique is simple, cheap and very tolerant 
of functional groups in the monomers and impurities in the system (eg. water), it 
represents a good choice for the synthesis of molecularly imprinted polymers. 
In radical polymerization, (Scheme 1.7) a reactive species, produced from the initiator, 
adds to the π-bond of the functional monomer to form a new radical that reacts with 
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another monomer molecule to propagate the reactive center increasing the chain 
length. Polymer growth terminates by destruction of the reactive center, leading to a 
polymer that could be linear or cross-linked depending on the properties of the 
functional monomers used.
29
  
Three main steps could be distinguish in the radical polymerization process: initiation, 
propagation and termination. The initiation step involves two reactions: the production 
of free radicals by homolytic dissociation of the initiator giving a pair of radicals, and 
the addition of one of ex radicals to the first monomer molecule, by reaction on the π-
bond, to produce the chain initiating radical. 
The second step, called propagation, consist of the growth of the chain initiating radical 
by the successive addition of large numbers of monomer molecules in sequence, where 
each addition creates a new radical that has the same identity as the one previously, 
except that it is larger by one monomer unit. The propagation step occurs very rapidly 
with a rate constant of 10
2
-10
4
 Lmol
-1
s
-1
 for most monomers. 
Finally, the polymer stops growing and the polymerization terminates. The termination 
process consist at the annihilation of the radical centers by bimolecular reaction 
between two radicals that could occurs by combination (coupling) or, more rarely by 
disproportionation. In the combination process  a covalent bond is created between 
two radical chains or molecules, leading to a single macromolecule. Instead, in 
disproportionation, a hydrogen that is beta to one radical center is transferred to 
another radical center giving two polymer molecules, one saturated and one 
unsaturated. Typical termination rate constants are in the range of 10
6
-10
8
 Lmol
-1
s
-1
.  
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Scheme 1.7: radical polymerization 
 
The structural arrangements of monomer units during the polymer synthesis is 
influenced by the presence of substituents (R) on the double bond of the monomer. 
The propagating radical could be on carbon 1: 
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Or on carbon 2: 
 
           
 
If during the propagation step the subsequent  addition of monomers occurs  always in 
the same manner, the final product will have an arrangement of monomer units in 
which the substituents are on alternate carbon atoms leading to the head-to-tail 
arrangement. On the other hand, if the monomer additions occurs alternatively by 
equations 1 and 2, the head-to-head placement is obtained.  
 
 
                                                     Head-to-tail placement 
 
 
                                                   Head-to-head placement 
 
Scheme 1.8: monomers arrangements in the obtained polymeric chain 
 
The head-to-tail propagation is the most common process because the propagating 
radical obtained by the addition on carbon 2 of the monomer unit is more stable than 
that generated by the reaction on carbon 1 of the monomer. Stabilization is due to 
both a resonance effect of the substituents, and a steric effect, since the approach of a 
propagating radical at the unsubstituted carbon of a monomer molecule is much less 
sterically hindered compared to the approach at the substituted carbon.   
The propagation process characterized of only head-to-tail placement is regioselective 
and lead to polymer structures called isoregic, while it is called syndioregic if the 
resulting polymer structure contains alternated regions of head-to-tail and head-to-
head arrangements, finally if there are random arrangements of head-to-head and 
head-to-tail the resulting structure is called aergic. 
30
 
Equation 1 
Equation 2 
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 Structure of the Polymers 
Different structures can be obtained during polymerization depending on the way of 
synthesis and on the types of functional monomers used. Functional monomers 
containing only one polymerizable double bound could lead to only linear polymers by 
a radical polymerization. In the presence of both functional monomers and crosslinker 
(a molecule containing two or more double bonds) linear chains are chemically linked 
each other to obtain reticulated co-polymers. Depending on the extent of crosslinking, 
branched macromolecules or crosslinked polymers are created.  
Figure 1.13: polymer structure 
Branched Macromolecules 
Branched macromolecules are polymers containing side chains that could be placed at 
irregular intervals along the polymer backbone or could be arranged into layers 
extending from the center of the polymer to obtain a regular structure called 
dendrimer. The possibility to obtain monodisperse dendrimers with a known number of 
end groups, due to their ordered structure, makes dendrimers attractive candidates for 
the development of drug delivery systems, gene-delivery or of supports for catalysis. 
For example the group of Zimmerman developed a molecularly imprinted polymer 
based on dendrimer technique and containing only one binding site. The porphirin 
target molecule was covalently linked to eight dendrons to obtain a dendrimer whose 
termini were after polymerized. The target molecule was removed by hydrolysis to 
obtain the imprinted dendrimer. This technique is advantageous because of a good 
efficiency of the imprinting process, an easy removal of the template and good 
solubility properties of the imprinted dendrimer in organic solvents.
 31
 
Since the dendrimer synthesis requires multiple reaction-purification steps with a 
difficulty to obtain large amounts of polymers, this technique is not appropriate for 
large scale applications. Moreover, this synthetic approach is incompatible with the 
majority of target molecules. 
32 
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Figure 1.14: example of a molecularly imprinted dendrimer (from ref 31) 
 
Crosslinked Polymers 
 
If the branches of a polymeric backbone are covalently linked to other polymer chains, 
a polymeric network is created to obtain a crosslinked polymer. Since this is a simple, 
fast and cheap reaction, it is particularly useful for large scale applications. 
 In a co-polymerization process involving functional monomers and a crosslinker, the 
physical nature of the product is mainly dependent on the nominal crosslinking ratio, 
defined as the percentage of cross-linker with respect to the total number of moles of 
monomer, and the volume and the nature of the solvent in which the polymerization is 
carry out. If the polymerization occurs with a high ratio of crosslinker and high 
concentration of monomers, macroporous polymers are obtained by precipitation from 
the polymerization mixture. These polymers are characterized by a permanently porous 
structure even in the dry state, that leads to an high specific surface area and allow the 
access to the pores also with thermodynamically non-compatible solvents. These 
features added to a high mechanical robustness of the polymer due to the high 
percentage of crosslinker used, make the macroporous polymers very attractive for the 
development of molecularly imprinted polymers.
33, 34 
This technique is widely used to obtain molecularly imprinted resins for affinity 
chromatography, HPLC and solid-phase extraction (SPE) to extract and quantify a wide 
range of analytes from biological samples.
35, 36, 37, 38, 39,40 
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Figure 1.15: example of solid phase extraction, from ref41
 
When the volume of solvent in the polymerization mixture is higher than that normally 
used for the synthesis of macroporous polymers, small particles are synthetized of 
micro or nano scale and their aggregation during the synthesis is prevented by the high 
dilution conditions.
42
 
In recent times, this technique was widely applied for the synthesis of molecularly 
imprinted micro or nano-particles, characterized by an high surface-volume ratio and 
an easy accessibility to a high number of binding sites. Thank to these properties, MIPs 
have found application in the drug delivery field for the controlled release of drugs, as 
recognition elements for the development of specific sensors, or as artificial enzymes in 
catalysis.
43
 
Changing the polymerization conditions, also core-shell nanoparticles could be 
obtained. The group of Perez, for example, synthesized core-shell nanoparticles 
containing specific binding sites for cholesterol by emulsion polymerization. The 
process consists of a preliminary synthesis of 30-40 nm non-imprinted nanoparticles 
followed by polymerization of the same functional monomers in the presence of the 
nanoparticles and the template to obtain a thin layer of imprinted polymer around the 
non-imprinted particle.
44
 Since they used a covalent approach for the imprinting 
process, the removal of template was achieved by hydrolysis, however other examples 
are reported in literature of synthesis of imprinted core-shell nanoparticles for caffeine, 
atrazine and propranolol by a non-covalent approach.
 45,
 
46, 47 
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To increase the surface area available in the imprinted polymer and to facilitate the 
removal of template, other polymeric structures were exploited. Nanowires and 
nanotubes were synthetized with the imprinting technique. The group of Xie 
synthetized nanowires containing binding sites for 2,4,6-trinitrotoluene (TNT) on the 
surface. During the synthesis, a modified alumina membrane was used to bind the 
template that interacts also with the functional monomers. The following 
polymerization and removal of the membrane and the template, gives the imprinted 
nanowire.
48
 
To increase the surface to volume ratio, nanotubes were synthesized and applied in 
particular to  develop specific sensors for β-estradiol detection.
49
 
Figure 1.17: example of molecularly imprinted nanowire 
 (in red: target molecule, in grey: MIP matrix, in blue: alumina support), (From ref 48) 
Figure 1.16: examples of MIP nanoparticles and MIP-core-shell nanoparticles. 
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Sensors Based on Molecularly Imprinted Polymers 
 
The high stability, the simple and low cost synthesis and the binding affinities and 
selectivities similar to those of antibodies, enzymes or hormones receptors, make 
molecularly imprinted polymers very useful for the development of sensors. 
In this field the imprinted polymer could be used as the recognition element of the 
sensor where the polymer is immobilized on a transducer able to convert the chemical 
signal generated from the binding process, to a quantifiable output signal, usually an 
electrical signal. 
Alternatively, the imprinted polymer could be a sensor itself if some reporter groups 
are incorporated in to the polymeric matrix giving characteristic properties to the 
polymer, like fluorescence or colour, that could change upon binding with the target 
molecule. 
50
 
 
MIP Immobilized on the Transducer 
 
The general structure of a MIP-based sensor consists of the recognition element, that is 
the imprinted polymer, immobilized on a transducer able to create quantifiable signal 
that is after amplified and analyzed by a computer. The first sensor developed with MIP 
was a capacitance sensor based on a MIP membrane imprinted with phenylalanine 
anilide placed on a field-effect capacitor.
51
 The binding of the analyte leads to a change 
in capacity that is detected, however this sensor is only qualitative, while later, the 
same transducer method was applied to set up a quantitative sensor containing 
electropolymerized polyphenols layers on gold electrodes to quantify phenyalanine.
52
  
Subsequently, different electrochemical sensors were synthesized.
53, 54
 Mass-sensitive 
acoustic transducers such as the quarz crystal microbalance (QCM) have found large 
application in MIP sensor field. A sensor for glucose was set up by 
electropolymerization of a poly(o-phenylenediamine) template with the target 
molecule, directly on the transducer surface. The sensor was able to detect glucose 
with a good selectivity against ascorbic acid, paracetamol, cysteine and fructose, but 
the limit of detection was high and only millimolar concentrations could be measured.
55
  
To improve the limit of detection, conductometric sensors were developed. In this case 
two electrodes are separated by an imprinted polymer, usually in a membrane form. 
The binding of the analyte to the polymer changes its conductivity, which is translated 
into an electrical signal. Using this method a sensing device to quantify atrazine was 
obtained. The sensor is based on atrazine imprinted acrylic polymer membrane whose 
flexibility and stability was regulated changing the kind and molar ratio of crosslinker 
and the amount of porogenic solvent in the imprinting mixture. The conductometric 
response seems to be dependent on the ability of the polymer to change its 
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conformation upon analyte binding. For these reason the membrane flexibility is an 
important factor in this type of sensor. This sensor showed an excellent low detection 
limit of 5 nmolL
-1
, rapid measurement times between 6-10 min and high selectivity for 
atrazine over structurally related triazine herbicides.
56
 
Recently, also the cyclic voltammetry technique was applied to develop a MIP-based 
sensor to quantify atrazine with high sensitivity between 5 nmolL
-1
  and 140 nmolL
-1
  
with a limit of detection of 1 nmolL
-1
.
57
 
Also optical techniques could be used, in particular  surface plasmon resonance (SPR) 
was widely applied. Thin films of electropolymerized imprinted polymer for 
theophylline detection were synthesized on gold coated glass slides to obtain a SPR 
sensor, able to capture the target molecule in a 10-50 µmolL
-1
 range and a limit of 
detection of 3.36 µmolL
-1
.
58
 Thermal and radical polymerization methods were 
developed by Xu and co-workers to cover a gold chip with a molecularly imprinted 
polymer for Sudan I dye. The radical initiator was covalently linked to 1-dodecanethiol 
that is immobilized on the gold chip. After thermal radical polymerization or photo-
initiated polymerization of methyl methacrylate and ethylene glycol dimethacrylate in 
the presence of Sudan I dye, a thin layer of imprinted polymer was obtained on the 
gold surface. The resulting SPR sensor exhibited high sensitivity with a limit of detection 
of 30 ng*mL
-1
 and a good selectivity. 
59
 
During the recent years many efforts were spent to miniaturize these sensors. In this 
context  Surface Enhanced Raman Spectroscopy (SERS) becomes a useful analytical 
technique to detect, quantify and in some cases identify the target molecule. In fact 
micro-Raman spectroscopy was used to develop MIP nanosensors for propranolol, 
however the first sensor was characterized by low sensitivity and reproducibility.
60
 To 
overcome these problem, the recognition properties of MIP were combined with noble 
metal nanocomposities for signal amplification and optical readout to obtain a single 
particle nanosensor. The obtained Au-MIP core-shell nanoparticle is a single particle 
nanosensor for SERS measurements, able to detect propranolol at concentrations as 
low as 10
-7 
molL
-1
.
61
 Core-shell Au nanoparticles containing an imprinted shell based on 
triethoxysilane (AuNPs) were also synthesized to detect bisphenol A by SERS technique 
with a limit of detection of 0.52 µmolL
-1
.
62
 
 
 
MIPs-embedded Sensors 
 
Fluorescent Molecularly Imprinted Polymers 
 
Fluorescence spectroscopy represent a valid technique  in MIP sensors mainly due to its 
high sensitivity in comparison to other spectroscopic techniques, allowing the detection 
and quantification of low analyte concentrations. If the analyte is not a fluorescent 
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molecule, these sensors can be based on two different detection schemes: a 
fluorescent imprinted polymer can be obtained incorporating a fluorescent functional 
monomer into the polymeric matrix. These functional monomers are placed inside the 
binding sites of the polymer and are able to interact with the target molecule leading to 
a change of the emission intensity, lifetime or emission wavelength of the resulting MIP 
upon analyte binding. Using this technique the imprinted polymer is a sensor itself 
because an intrinsic property of the MIP is used as the transducing system. Otherwise if 
both the analyte and the polymer are not fluorescent, a competitive or displacement 
assay can be set up synthesizing a fluorescent analogue that can compete with the 
analyte for the polymer binding sites.
63
 
Following the first approach a fluorescent chemosensor was developed for the aqueous 
detection of cAMP. The MIP was synthesized by a radical polymerization of 2-
hydroxyethyl methacrylate (HEMA) and trans-4-[p-(N,N-dimethylamino)styryl]-N-
vinylbenzylpyridinium chloride, a fluorescence functional monomer able to bind cAMP 
by electrostatic interactions, π-stacking and hydrogen bonds, leading to a quenching of 
its fluorescence. Therefore observing the fluorescence quenching of the obtained bulk 
MIP, aqueous cAMP could be quantified using this sensor in a micromolar range.
64
 
 
 
 
Figure1.18: quenching of MIP fluorescence due to the analyte binding 
A fluorescent sensor based on molecularly imprinted polymer was also developed to 
detect highly explosive compound such as TNT. In this case, MIP micro-particles based 
on acrylic acid and ethylene glycol dimethacrylate (EGDMA) were covalently linked to 
fluorescence CdSe quantum dots by a coupling reaction between the carboxylic acid of 
the MIP and the amine-functionalized surface of the quantum dots. The resulting 
sensor exhibits a quenching of fluorescence upon the binding of TNT, allowing the 
analyte quantification with a detection limit of 40.7 µmolL
-1
.
65
 
The interactions between the fluorescence functionality into the MIP and the target 
analyte could lead also to an increase of the fluorescence emission. Using this approach 
a molecularly imprinted polymer was synthetized with 2-acrylamidoquinoline 
fluorescent monomer to detect cyclobarbital, where the fluorescence enhancement 
was generated by the hydrogen bonds created between amino and carbonyl groups of 
both the analyte and the quinoline mojety. The MIP was able to detect cyclobarbital in 
a 0.1 - 2 mmolL
-1
 range.
66
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Figure 1.19: fluorescence enhancement due to target binding to MIP 
The same approach was also used to synthetize a fluorescent imprinted polymer for 
(D)-fructose using an antracene-boronic acid conjugate with a methacrylate molecule 
as functional monomer. The interaction between the analyte and the fluorescent 
functionality in the polymer gives a fluorescence enhancement that is proportional to 
the amount of analyte bound. Using this fluorescent polymer, D-fructose was 
quantified at concentrations between 1 mmolL
-1
 and 100 mmolL
-1
.
67
  
A fluorescence-based optical fiber sensor was constructed to detect cocaine using 
molecularly imprinted polymer containing acrylamidofluorescein (AAF) as functional 
monomer, EDGMA as crosslinker and acrylamide as co-monomer. The carboxylate 
group of AAF can be deprotonated by cocaine that acts as a base in the ion pair 
complex leading to an increase of fluorescence, since the deprotonated form of 
fluoresceine is much more fluorescent than the protonated one. The imprinted polymer 
was covalently attached to an optical fiber to obtain a portable system able to detect 
cocaine at concentrations between 2 µmolL
-1
 and 500 µmolL
-1
  in aqueous acetonitrile 
mixtures with good reproducibility over one month.
68
 
In order to improve the sensitivity, gold nanoparticles could be embedded in the 
polymeric matrix. In particular MIP-based fiber optic sensors were developed by Ton 
and co-workers, using 4-vinyl pyridine and a piperazinyl naphtalimide derivate 
fluorescent molecule as functional monomers and EDGMA as cross-liker. The presence 
of gold nanoparticles allow to increase the sensitivity lowering the LOD, using this 
technique the herbicide 2,4-dichlorophenoxyacetic acid was detected at 250 pmolL
-1
 
concentration, LOD comparable to LC/MS technique.
69
 
An alternative approach to obtain fluorescent sensors to detect non-fluorescent 
analytes, is the development of a competitive binding assay using a fluorescent tracer. 
For example a competitive flow-through assay for chloramphenicol was developed by 
Suàrez-Rodrìguez and co-workers based on the competition between the analyte and 2-
amino-1-(4-nitrophenyl)-1,3-propanediol, a  fluorescent molecule characterized by a 
similar structure of chloramphenicol. The analyte was detected in a 8 µgmL
-1
-100 
µgmL
-1
 (25 µmolL
-1
-310 µmolL
-1
) range.
70
  
An automated flow-through assay based on the dye displacement technique was also 
developed for zearalenone mycotoxin sensing using a molecularly imprinted polymer 
containing 1-allyl piperazine as functional monomer, trimethylolpropane 
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trimethacrylate as crosslinker, AIBN as initiator and a zearalenone mimic: cyclododecyl 
2,4-dihydroxybenzoate as template. Measuring the fluorescence emission of 2,4-
dihydroxybenzoic  acid  2-[(pyrene-l-carbonyl)amino]  ethyl  ester  (PARA), displaced 
from the MIP binding sites upon addition of the analyte, a calibration curve for 
zearalenone in acetonitrile was obtained with a dynamic range between 50 µmolL
-1
 
and 500 µmolL
-1
and a limit of detection of 25 µmolL
-1
.
71
 
An automated molecularly imprinted sorbent assay for the rapid and sensitive analysis 
of penicillin-type -lactam antibiotics in human urine was developed by Urraca and co-
workers. The assay was obtained using a bulk MIP containing ethyleneglicol 
dimethacrylate as crosslinker, methacrylamide as co-monomer and N-[3,5-bis-
(trifluoromethyl)phenyl]-N’-(4-vinylphenyl)urea as functional monomer and imprinted 
with penicillin G procaine salt. The concentration of penicillin G was calculated 
measuring the emission signal of the highly fluorescent competitor 
pyrenemethylacetamido penicillanic acid (PAAP) displaced by the target molecule from 
the polymer binding sites. The sensor showed a dynamic range from 6.80·10
-7 
molL
-1
 to 
7.21·10
-6 
 molL
-1 
and a detection limit of 1.97·10
-7
 molL
-1
.
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Colored Molecularly Imprinted Polymers 
Optical sensing represent in principle a valuable technique in the development of 
simple and portable sensors. For these reasons the molecularly imprinted technology 
was applied in the construction of colored optical sensors. To these aim, many articles 
reported  dye displacement methods  based on the competition between the free 
analyte and a modified dye, for the binding into the polymer, leading to a change in the 
polymer color (Figure 1.20). 
Using this technique, Levi and co-workers synthesized a molecularly imprinted polymer 
for chloramphenicol by  radical polymerization of the functional monomer 
(diethylamino)-ethylmethacrylate and the crosslinker EDGMA. The MIP was first 
saturated with chloramphenicol covalently linked to methyl red dye. Free 
chloramphenicol  displaces the modified drug from the binding sites of the polymer due 
to the better affinity of the MIP for the free analyte with respect to the modified dye. 
The release of methyl red modified-chloramphenicol upon addition of chloramphenicol 
was monitored by an HPLC method. This system allowed to discriminate well between 
the analyte and other similar molecules and was able to detect chloramphenicol within 
a range of 3 and 1000 µgmL
-1
 (9.3 µmolL
-1
-3.1 mmolL
-1
).
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Greene and Shimizu developed a colorimetric sensor array based on dye displacement 
strategy and composed of seven molecularly imprinted polymers able to capture seven 
different aromatic amines.  
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The imprinted polymers containing methacrylic acid and EDGMA, were first saturated 
with a benzofurazan dye giving a strong yellow color to the polymer. In this case the 
dye was used directly, without further modification. Benzofurazan is a small molecule 
with shape and functionalities similar to the target molecules, so it can easily interact 
with the functional monomers into the 
binding site of the polymer. After 
addition of the analyte, the dye was 
displaced and the intensity of the 
polymer color decreases.  
One of the main advantages of this 
strategy is the possibility to develop a 
colorimetric test to detect analytes that 
do not possess a colour itself. Also the 
use of imprinted polymers without 
colored functional monomers makes the 
synthesis cheaper, for the test it is only 
required an appropriate dye able to bind 
into the MIP and to be displaced by the 
analyte.
74
 
 
 
Analyte Generating Signal 
 
In some cases the target molecule possesses some properties like fluorescence or color 
that could be exploited as the signal in the sensor. 
A flow injection system based on a molecularly imprinted polymer was developed for 
the selective and sensitive monitoring of carbaryl in water samples by measuring its 
fluorescence emission. The system has demonstrated an high specificity for the target 
molecule against other methyl-carbamate pesticides and a limit of detection of 0.27 
µg/mL.
75
 
A flow-through optosensing device based on the fluorescence of a flavonol target 
molecule was set up containing a molecularly imprinted polymer synthetized with 
methacrylic acid and EDGMA by a non-covalent approach. This system was able to 
detect flavonol in oily matrix and in general it could be an useful tool for the 
determination of analytes in hydrophobic samples without a separation step.
76
 
 
 
 
 
 
 
Figure 1.20: MIP sensor array using dye displacement 
(from ref  74) 
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Figure 1.21: binding of fluorescent molecules 
 
Finally, the group of Rachkov developed a fluorescent sensing system to quantify β-
estradiol using a molecularly imprinted polymer as recognition element and exploiting 
both the intrinsic fluorescence of the target molecule as sensing element and the 
fluorescence led by a fluorescent dye that could bind to the polymer by a competitive 
mode.
77
 
A fiber optic sensor based on MIP was also developed to capture the basic red 9 dye. 
The polymer was based on EDGMA and the functional monomer 2-acrylamido-2-
methyl-1-propane sulfonic acid. The absorbance of the captured dye was detected with 
a fiber-coupled spectrometer until µM concentrations.
78
 
 
 
Molecularly Imprinted Polymers for Taxoids and 
Camptothecins 
 
 
Recently some molecularly imprinted polymers were synthesized to capture 
campthotecins, like irinotecan, and taxanes, as paclitaxel, while MIP specific for 
sunitinib are not developed yet.   
A molecularly imprinted sorbent resin was synthesized for the simultaneous 
enrichment and separation of four taxoids: 10-deacetylbaccatin III, baccatin III, 
cephalomannine and paclitaxel, from the twigs of T. x media. The resin is based on 
Fe3O4 particles coated with silica and functionalized with vinyl groups that were after 
used to create a molecularly imprinted polymeric matrix containing both the metal 
nanoparticles and specific binding sites for taxoids. In this case, since the polymer has 
to capture different molecules having a very similar structure, and cephalomannine was 
selected as template molecule.  Using the MIP resin 74% of 10-deacetylbaccatin III, 52% 
of baccatin III, 84% of cephalomannine and 60% of paclitaxel were recovered from the 
initial extracts. Moreover the highest recovery of cephalomannine with respect other 
taxoids verified the selectivity of the MIP for this molecule, since it was the template 
molecule.
79
 
Silica nanoparticles coated with molecularly imprinted polymer layers were also 
synthesized by Li and co-workers to capture paclitaxel. The imprinted polymer was 
Introduction 
 
50 
 
synthesized at the surface of uniform silica nanoparticles using tetraetoxysilane (TEOS) 
and aminopropyltriethoxysilane (APTES) as functional monomers and paclitaxel as 
template. The Scatchard analysis obtained by rebinding tests in 0.005-0.2 mgmL
-1
 (8-
340 µmolL
-1
) paclitaxel concentration range, showed the presence of two types of 
binding sites with different affinities for the target molecule. The association constants 
(KD) obtained were 0.0094 gL
-1
 for high affinities binding sites  and 0.0509 gL
-1
  for low 
affinities binding sites.
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Recently a MIP to detect campthotecin was also synthesized for purification and 
extraction purposes. A solid phase extraction method based on carbon nanotube 
supports coated with molecularly imprinted polymers, was developed to detect and 
extract campthotecin in Camptotheca acuminate fruit, bark and leaf. The imprinted 
polymer was synthesized with EDGMA and methacrylic acid using camptothecin as 
template molecule, while the extraction method based on MIP was coupled with high 
performance liquid chromatography for the quantification of the analyte. The method 
showed a good linearity of camptothecin in the range of 1-200 µgmL
-1
 (2.9-574.2 
µmolL
-1
) and a limit of detection of 0.13 µgmL
-1
 (0.4 µmolL
-1
).
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A MIP for the selective solid phase extraction of irinotecan from human serum samples 
was synthesized. The polymerization was performed in dichloroethane with methacrylic 
acid and 4-vinyl pyridine as functional monomers, EDGMA as crossliker and irinotecan 
free base as template molecule. The obtained bulk polymer was grounded until 25-36 
µm and packed into a cartridge. The drug detection was performed by LC-PDA showing 
an extraction recovery of 88% for human serum spiked with 10 µgmL
-1
 (17 µmolL
-1
). 
82
 
 
 
MIPs and Plasma 
 
The behavior of soluble imprinted polymers in plasma has never been investigated in a 
systematic way, usually bulk imprinted polymers were applied as recognition elements 
of electrochemical, quantum dots or fiber optic based sensors for the drug 
quantification in plasma. Concerning anticancer drugs, a silica-molecularly imprinted 
polymer composite fiber using carboxylated multi-wallet carbon nanotubes was 
synthesized as electrochemical sensor able to quantify uracil and 5-fluorouracil in 
aqueous and blood plasma samples with an LOD of 1.3 ng·mL
-1
 for 5-fluorouracil and 
0.56 ng·mL
-1
 for uracil.
83
 Another electrochemical sensor for these drugs was developed 
by Prasad and co-workers using a drop coating method to coat a hanging mercury drop 
electrode with a specific MIP. Using this system uracil and 5-fluorouracil were 
quantified with an LOD of 3 nmol·L
-1 
and 2 nmol·L
-1 
respectively.
84
 While an 
electrochemical sensor based on carbon-nanotubes-modified pencil graphite electrode 
coated with a bulk MIP was synthesized for the quantification of 1,4-
dihidroxyanthraquinone, a molecule having the basic structure of anthraquinone-based 
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anticancer drugs like AQ4N and doxorubicin, in aqueous and blood samples. Using this 
system the analyte was quantified within 10 nmol·L
-1 
and 100 µmol·L
-1 
with an LOD of 4 
nmol·L
-1
.
85
 
Conversely, the quantification of other drugs in blood or plasma by sensors with MIP 
immobilized on metal nanoparticles or fibers was also reported. For example non 
soluble CdTe@SiO2 quantum dots coated with a MIP were used as fluorescent sensor 
for recognition of norepinephrine between 0.04 µmol·L
-1
 and 10 µmol·L
-1
 (LOD 8 
nmol·L
-1
) in water and in rat plasma.
86
 Moreover a fiber optic array based on a 
competition test, was developed by Carrasco and co-workers to quantify enrofloxacin 
in sheep serum. The fiber was chemically etched to create microwells where the bulk 
MIP was deposited. The analyte displace a modified fluorescent molecule from the 
polymer binding sites leading a change of fluorescence intensity. Using this system 
enrofloxacin was quantify from 0.29 µmol·L
-1
 to 21.54 µmol·L
-1
, with an LOD of 0.04 
µmol·L
-1
.
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In 2012, the Italian Association for Cancer Research (AIRC) granted a project on 
“Application of Advanced Nanotechnology in the development of innovative cancer 
diagnostic tools”. One of the aims of this very large project was the design and 
development of point of care devices for the therapeutic drug monitoring of anticancer 
drugs. The need for such fast methodologies has been outlined in the introduction of 
this thesis, it must be noted here that this target is very ambitious, as no point of care 
devices for the detection of drugs at the patient’s bed are reported or commercialized. 
The device should be able to perform directly on small volumes of blood from finger 
pricks and not from phlebotomy, separate plasma from blood cells and measure 
directly the drug level in plasma with a cheap technique.  
The Unit of the project at the Department of Chemical and Pharmaceutical Sciences of 
the University of Trieste has the task to investigate the potential of soluble imprinted 
polymeric nanoparticles as sensing elements for the direct detection of anticancer 
drugs in human plasma. 
Plasma is a very complex matrix, containing thousands of different molecules and 
binding proteins as albumins and immunoglobulins.  
Possible critical points on the feasibility of a MIP-based system for the detection in 
plasma include cross reactivity from the plasma pool of small molecules, competition 
for binding the target drugs from albumin, stability of the system with aggregation or 
precipitation of the polymer. 
This thesis is the first approach to such problems, and deals with soluble MIPs for the 
detection of sunitinib, irinotecan, SN38 and paclitaxel in plasma. As the final device has 
to be as simplest and as cheaper as possible, we have considered the possibility of 
using the MIPs as the sensing units themselves, in optical devices with fluorimetric or 
colorimetric detection. 
We have thus designed several examples of MIPs: 
 Containing a fluorescent functional monomer that generates a signal to be 
quenched by the target 
 Containing a quencher functional monomer that inhibits the emission of a 
fluorescent target 
 Containing a fluorescent functional monomer that establishes a FRET pair with 
a labelled target 
 Capable to recognize a colour dye that changes its colour upon displacement 
by the target 
The aims were therefore the selection of functional monomers, optimization of the 
syntheses, physical characterization of the MIPs, evaluation of their binding ability and 
of their selectivity, evaluation of their optical properties and of their performance in 
human plasma. 
Part of this work has been carried out at Queen Mary University of London and in 
cooperation with Cobik, a Slovenian centre of excellence in optical sensors. 
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In this PhD project different polymeric nanoparticles containing specific binding sites 
for the anticancer drugs sunitinib, paclitaxel, SN38 and its prodrug irinotecan were 
synthesized. The soluble binding materials were evaluated as sensing systems for the 
direct drug quantification in plasma (Scheme 3.1) 
 
 
 
 
Scheme 3.1: chemical structures of sunitinib (1), SN38 (2), paclitaxel (3), irinotecan (4) 
 
3.1 Synthesis of the Imprinted Polymers 
 
 
Functional Monomers 
 
In order to obtain specific polymers for anticancer drugs, is it necessary to select the 
best functional monomers able to interact with the target molecules. In this project the 
non-covalent imprinting process was only evaluated because it is an easy method that 
requires a low number of synthetic steps and it is applicable to a large variety of 
functional monomers and template molecules.
1
  
This process consists of the instauration of non-covalent interactions between the 
functional monomers and the template before polymerization. Among the possible 
non-covalent interactions, it is possible to distinguish between weak interactions like π-
staking, hydrogen bonding, hydrophobic interactions or van der Waals forces, and ion 
interactions that may be stronger depending on the environment and on the solvent 
polarity.  
Fluorescent MIPs 
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The first series of MIPs were synthesized planning only weak interactions during the 
imprinting process. Considering the aromatic structure and the presence of polar 
groups in the anticancer drugs studied in this project, four different functional 
monomers were evaluated as a first approach in the MIP synthesis:  
 
 N-acryloyl-tyrosine methyl ester (5b) and N-acryloyl tryptophan methyl ester 
(6b) are modified amino acids that can mimic the interactions occurring 
between the drug and a protein in its binding site.
2
 The presence of an 
aromatic structure can allow the formation of hydrophobic interactions with 
the target molecule, while hydrogen bonds can be created by the carbonyl and 
other polar groups of both the functional monomer and the template. 
Moreover, the tyrosine and tryptophan fluorescence properties could be 
exploited to investigate the polymer binding affinities at low drug 
concentrations.  
 
 7-acryloyloxycoumarin (7b) is a fluorescent molecule that could be used for 
the development of fluorescent sensors based on MIPs.
3,4
 It could also interact 
with the anticancer drugs by its aromatic structure and its polar groups. 
 
 4-vinyl-piridine (8) is one of the most common functional monomers used for 
the MIP synthesis and  it is cheap and commercially available.
5,6,7
 
 
The presence of an acryloyl-group in the functional monomers structure is necessary to 
allow the incorporation of these molecules in the polymeric matrix of the molecularly 
imprinted polymers upon polymerization. N-acryloyl tryptophan methyl ester and N-
acryloyl tyrosine methyl ester were synthesized from tyrosine methyl ester
8
 (5a) and 
tryptophan methyl ester
9
 (6a) by acylation on the amino group with acryloyl chloride in 
dichloromethane in the presence of triethylamine (Scheme 3.2). The same reagents 
were used to obtain 7-acryloyloxycoumarin, however in this case the acylation occurs 
on the hydroxyl group of 7-hydroxycoumarin (7a).
10
  
During the synthesis of N-acryloyl-tyrosine methyl ester, the formation of a side-
product was also observed. This side-product (5c) is generated by the acylation of both 
the phenolic chain of tyrosine methyl ester, and the amino group. The two products 
were separated by flash chromatography.  
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Scheme 3.2: synthesis of functional monomers 
1H NMR Titrations  
 
1
HNMR titration experiments were exploited to investigate the nature and the strength 
of possible interactions involved in the functional monomer–template complex during 
the synthesis of molecularly imprinted polymers. Furthermore, NMR allows to identify 
the specific functionalities that are involved in the formation of the functional 
monomer-template complex before polymerization.
11
  
In fact the complex formation (LR) between two molecules named ligand (L) and 
receptor (R) is a dynamic process where the free molecules are in equilibrium with the 
bond counterpart. 
 
                                                            L + R    LR 
 
Yield: 47% 
Yield: 81% 
Yield: 90% 
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In NMR the free receptor and the ligand-bond state have two different resonance 
frequencies, respectively R and LR , and the appearance of the characteristic signal of 
the two species depends on three main factors: the population of each state (PR and 
PLR), the chemical shift difference between the two frequencies (Δ=LR-R) and the 
relative values of the exchange rate: kex = kR + kRL. Therefore is possible to distinguish 
between three different situations during the complex formation, named slow, 
intermediate and fast exchange regimen, which lead to different NMR spectra (Figure 
3.1).  
In the slow exchange regimen, the ligand binding equilibrium has a very slow exchange 
rate compared to the NMR time scale (kex Δ), so there is not significant 
interconversion between the two states during the frequency detection period of NMR 
experiment. Therefore signals from both the free ligand and the bond-ligand are 
observed in the spectrum with different chemical shifts, also the intensity of each peak 
indicates the population of each species. 
While if the exchange regimen is fast, the ligand binding equilibrium has a very fast 
exchange rate compared to the NMR time scale (kexΔ), so a very fast 
interconversion between L and LR occurs during the detection period of the NMR 
experiment leading to averaged peaks. Therefore only one signal is observed with a 
population-weighted chemical shift (δobs= PRδR+ PLRδLR). 
Finally, in the intermediate exchange regimen, or coalescence, intermediate situation of 
the two previously described occurs, so kexΔ, and one signal is observed at a 
chemical shift between δR and δLR with a linewidth that is “exchange broadened” due to 
interference from the interconversion between L and LR during the detection period.
12, 
13 
 
 
      Figure 3.1: different situations that may occur during the 1H-NMR titration (from ref13) 
 
The experiment consists of the addition of increasing equivalents of functional 
monomer (from 0.5 to 14 equivalents) to a fixed concentration of template molecule, 
which in this case is the drug. Since in this project the synthesis of molecularly 
imprinted polymers was performed in DMSO, also the interactions between the target 
molecule and the functional monomer were studied in deuterated DMSO.  
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In all the spectra obtained from the 
1
H-NMR titrations only one set of signals is visible, 
indicating that the complexation equilibrium is close to a fast exchange regimen. In this 
context, the functional groups of both the target molecule and the functional monomer 
which are mainly involved in the complex are subjected to a large variation of their 
chemical shift that could be downfield or upfield with respect to the initial position of 
the signal.
14
 
The variation of the proton chemical shift (δfinal-δinitial) of the target drug after addition 
of 14 equivalent of functional monomer is shown in Figure 3.2. In the same figure the 
functional monomers protons involved in the complex formation with the template are 
also indicated.  
Comparing the shifts of both the template and the functional monomers it was possible 
to identify the interactions between the two molecules. Also the hydrogen bond 
formation between polar groups can be easily identified because it is usually associated 
to a strong downfield variation of chemical shift, as is possible to see in these 
titrations.
15
 
Sunitinib, SN38, irinotecan and paclitaxel establish weak interactions with all the tested 
functional monomers.  
In particular, the large changes in the shifts of indole proton 4 and of the methylidene 
proton of sunitinib, and the changes occurring in all the protons of the coumarin rings, 
indicate that the indole and methylidene systems of sunitinib are likely to make 
hydrophobic interactions with the aromatic system of 7-acryloyloxy-coumarin. The 
formation of hydrogen bonds between the indole NH of sunitinib and acceptors of N-
acryloyl-tryptophan methyl ester and 4-vinyl pyridine is also observed. Furthermore the 
amide proton of sunitinib is involved in the interaction with N-acryloyl-tryptophan. The 
strength of N-acryloyl-tyrosine interactions is weaker than that of the other functional 
monomers; however a hydrogen bond with the amide group of sunitinib is observed 
(Figure 3.2a). 
SN38 makes hydrogen bonds by its hydroxyl groups and π-stacking interactions by the 
aromatic rings, namely 4-vinyl pyridine molecules appear to interact with both the 
hydroxyls, while 7-acryloyloxy-coumarin and the amino-acids interact mainly with 
hydroxyl and other groups at the lactone side of the molecule (Figure 3.2b).  
Finally, binding between paclitaxel and the functional monomers involves mainly its 
side chain, in fact the aromatic rings of the drug makes π-stacking interactions with 7-
acryloyloxy-coumarin and N-acryloyl-tyrosine methyl ester leading to upfield variation 
of the chemical shift of aromatic protons. The hydroxyl and the amide group of 
paclitaxel establish hydrogen bonds with polar groups of the functional monomers 
(Figure 3.2c). 
The interaction between irinotecan hydrochloride and functional monomers 5b, 6b and 
7b seems to be stronger than that of other drugs, in particular on the piperidine 
moiety. A high variation of the piperidine protonated amino group signal, and low 
variations of the adjacent piperidine protons were observed. N-acryloyl-tryptophan 
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methyl ester interacts better than other functional monomers mainly by hydrogen 
bonds with the protonated piperidine group of irinotecan. Both hydrogen bonds with 
the NH of piperidine group and π-staking interactions with the aromatic rings are 
involved in the complex between irinotecan and 7-acryloxycoumarin. Even if the 
variation of drug NH chemical shift due to interaction with 7b is not stronger than that 
of 5b and 6b, its titration curve is the only one that reached a plateau after 14 
equivalents added (Figure 3.2d).  
 
 
 
 
 
 
 
3.2a 
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3.2c 
3.2b 
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Figure 3.2: variation of proton chemical shift of sunitinib (3.2a), SN38 (3.2b), paclitaxel (3.2c), irinotecan 
(3.2d) upon addition of 14 equivalents of functional monomer. The protons of functional monomers that 
mainly interact with the drug giving an high variation of chemical shift are also indicated on the chemical 
structure of each functional monomer. Every colour corresponds to the interaction with a functional 
monomer: N-acryloyl-tryptophan-OMe (blue), 4-vinyl-piridine (red), N-acryloyl-tyrosine-OMe (green) and 7-
acryloyloxy-coumarin (violet). 
 
For each drug it is possible to identify some particular functional group that best 
interact with the functional monomers. Large variations of chemical shift were 
observed for polar groups, as the NH amide and the NH indole of sunitinib, the hydroxyl 
group of SN38 and the OH2’ of paclitaxel, able to make hydrogen bonds with the 
functional monomers. However some large variation of chemical shift occurs also due 
to hydrophobic interactions that involve 7-acryloylxycoumarin monomer. 
3.2d 
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The variation of chemical shift of these groups after each addition of functional 
monomer was plotted in function of the equivalents of functional monomer added.  
The titration curves of sunitinib amide group with N-acryloyl-tryptophan methyl ester 
and N acryloyl-tyrosine methyl ester and that of the sunitinib NH indole with 4-
vinylpyridine and the H4 of sunitinib indole with 7-acryloxycoumarin showed mainly a 
linear behavior. Therefore the plateau is not reached after 14 equivalents added. The 
main variations of chemical shift were observed during the titration with N-acryloyl-
tryptophan methyl ester and 7-acryloxycoumarin, suggesting a preference of sunitinib 
for these functional monomers. However while the interaction with N-acryloyl-
tryptophan methyl ester occurs mainly by hydrogen bonds, that with 7-
acryloxycoumarin is based on hydrophobic and π-stacking interactions (Figure 3.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The trend of the titration curves of OH2’ and NH amide of paclitaxel is more variable 
among the different functional monomers. In fact the titration with N-acryloyl-
tryptophan methyl ester leads to a plateau after six equivalents added, that 
corresponds to the saturation point.  
In the titration curve with N-acryloyl-tyrosine methyl ester a first plateau is reached 
after 4 equivalents added, but increasing the functional monomer concentration, the 
variation of chemical shift further increased linearly and the second plateau is not even 
reached after 14 equivalents added. This behavior suggests a multiple interaction or 
weaker interaction with respect that with N-acryloyl-tryptophan methyl ester. The 
Figure 3.3: a) variation of amide and indole proton chemical shift of sunitinib upon interaction with the 
functional monomers; b): variation of amide chemical shift upon interaction with N-acryloyl-tryptophan 
methyl ester 
 
b) 
  NH drug 
  NH drug + 1 eq 6b 
   NH drug + 2 eq 6b 
  NH drug + 4 eq 6b 
  NH drug + 6 eq 6b 
 NH drug + 8 eq 6b 
  NH drug + 10 eq 6b 
  NH drug + 12 eq 6b 
  NH drug + 14 eq 6b 
a) 
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complex between paclitaxel and 4-vinyl pyridine is even weaker, and in its titration 
curve the plateau is not reached.  
The interaction with 7-acryloyloxycoumarin does not involves the hydroxyl 2’ of 
paclitaxel but rather its amide group, giving a plateau in the titration curve after 12 
equivalents added. So the complex between the drug and 7-acryloxycoumarin seems to 
be stronger than that with 4-vinyl pyridine but weaker than that with N-acryloyl-
tryptophan methyl ester (Figure 3.4). 
 
Figure 3.4: a) variation of the hydroxyl and amide protons of paclitaxel upon interaction of functional 
monomers; b) variation of OH2' of drug upon interaction with N-acryloyl-tryptophan methyl ester 
 
Also for SN38 the largest variation of chemical shift was due to the interaction with N-
acryloyl-tryptophan methyl ester by hydrogen bonding, which involves the hydroxyl at 
position 4 of the drug. However, for all the titrations of SN38 with the functional 
monomers the plateau was not reached after 14 equivalents added. Only the curve 
obtained by the titration with N-acryloyl-tyrosine-OMe decreases its slope after 10 
equivalents. Instead, 7-acryloyloxycoumarin does not interact with the hydroxyl group 
in position 4, but mainly with the methylene group at position 12 by hydrophobic and 
π-staking interactions with the aromatic rings (Figure 3.5). 
 
 
 
 
 
  OH2’ drug 
  OH2’ drug + 0.5 eq 6b 
   OH2’ drag + 2 eq 6b 
  OH2’ drug + 4 eq 6b 
  OH2’ drug + 6 eq 6b 
 OH2’ drug + 8 eq 6b 
  OH2’ drug + 10 eq 6b 
  OH2’ drug + 12 eq 6b 
  OH2’ drug + 14 eq 6b 
a) b) 
Chapter 3-Results and Discussion 
 
 
73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The main interaction with irinotecan occurs on its protonated piperidine group. The 
high field shift of this proton indicates a shield effect on the positive charged NH due to 
the interactions with functional monomers polar groups (Figure 3.6). 
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Figure 3.5: a) variation of the proton chemical shift of SN38 upon interaction with functional 
monomer; b) shift of OH-4 of SN38 upon interaction of N-acryloyl-tryptophan methyl ester 
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Figure 3.6: a) variation of proton chemical of irinotecan upon interaction with the functional monomers; 
b) shifts of NH group of irinotecan upon interaction with N-acryloyl-tyrosine methyl ester 
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Since all the investigated functional monomers showed the ability to interact relatively 
well with paclitaxel, sunitinib, SN38 and irinotecan, they were used in the synthesis of 
molecularly imprinted polymers. 
 
 
Synthesis of Molecularly Imprinted Polymers 
 
The nanogels were synthesized under high dilution radical polymerization conditions 
following a standard protocol developed in Prof. Resmini’s research group at the Queen 
Mary University of London. This approach is characterized by two main parameters: the 
choice of solvent and the overall monomer concentration.
16,17
 
During polymerization, unreacted double bonds on particle surface may induce inter-
particles crosslinking leading to macrogelation. However, under diluted conditions with 
a “good” solvent, each polymeric particle is stabilized avoiding intermolecular 
crosslinking. In fact the solvating power of the solvent prevents macrogelation via 
osmotic repulsion forces and steric hindrance, without adding surfactants.
18
 In this 
project DMSO was chosen as solvent for polymer synthesis since it allows dissolving 
well all the reagents involved in the polymerization. Furthermore, the choice of the 
concentration of all monomers in the pre-polymerization mixture is fundamental to 
obtain nanoparticles. It must be taken under a certain value obtained experimentally 
and called Critical Monomer Concentration (CM). The CM is the percentage by weight of 
all monomers used for the polymerization as compared to the percentage of the overall 
mass of monomers and solvent used for a polymer preparation.
19
  
              Figure 3.7: example of synthesis of a molecularly imprinted polymer for irinotecan 
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The amount of solvent necessary to obtain polymeric nanoparticles was calculated by 
the following equation: 
 
 
 ( )  
[ (  )   (  )   (  )]                     
                   (  )
 
 
 
Where m(fm), m(bm) and m(cl) are respectively the mass of the functional monomer, 
the co-monomer and the crosslinker.
20
 
In this project acrylamide was chosen as co-monomer due to its high solubility in 
water.
21, 22 
Also N,N’-ethylenebisacrylamide was chosen as crosslinker due to its water 
solubility and high compatibility between components. Finally, to obtain soluble 
nanoparticles,   CM was fixed at 1%  w/w, since this value is below the gelation point, 
that corresponds to the limit at which the transition between macro- and microgelation 
occurs, calculated for a similar solvent and polymer composition of that used in this 
project.
20 
Before synthesis, the formation of functional monomer-template complex 
was achieved leaving the functional monomers and the template to interact in DMSO 
for 1h. The ratio between functional monomer and template, that in this case is the 
drug, was fixed at 1:1.2. The little excess of template with respect the functional 
monomer was used in the attempt to obtain a high number of specific binding sites, 
assuming a 1:1 monomer:template interaction and taking advantage also of the 
presence of the comonomer and the crosslinker in the pre-polymerization mixture able 
to create a polymeric matrix around the template molecule. After this time, the 
comonomer acrylamide (15% in mol), the crosslinker N,N’-ethylene bisacrylamide (70% 
in mol) and the radical initiator AIBN were added to the solution.  
The amount of radical initiator was fixed at 18% of the amount of the available double 
bonds in the pre-polymerization mixture, and was calculated from the following 
equation:  
 
 ( )  [ (  )   (  )    (  )]              
 
 
Where n(I), n(fm), n(bm) and n(cl) are respectively the number of mol of the initiator, 
the functional monomer, the co-monomer and the crosslinker. 
This high amount of radical initiator is necessary to obtain a good yield of 
polymerization, in fact previous polymerization experiments performed with 1%  AIBN 
showed a very low yield. The polymerization occurs on heating at 70°C for 4 days.  
The use of a high percentage of crosslinker is fundamental to impart the necessary 
rigidity to preserve the cavities shape and to impart mechanical stability to the MIP. 
However a crosslinker content above 90% leads to too rigid and less flexible polymer 
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limiting its swelling and therefore its binding capability. On the other hand, a content of 
crosslinker lower than 70% leads to high flexible polymers decreasing their binding 
selectivity.
23
  
After polymerization, a clear solution was obtained containing soluble nanoparticles in 
which the functional monomers are held in position by a highly crosslinked polymeric 
matrix. This method was applied for the synthesis of all MIPs for sunitinib, paclitaxel, 
SN38 and irinotecan with N-acryloyl tryptophan methyl ester, N-acryloyl-tyrosine 
methyl ester, 4-vinyl pyridine and 7-acryloyloxycoumarin (Table 3.1). For each 
functional monomer also a non-imprinted polymer (NIP) was synthesized as control 
polymer using the same polymerization procedure but without the presence of the 
template molecule. The yield of polymerization was calculated with the following 
equation: 
 
         
             
∑              
 
  
Polymer Drug Functional monomer 
Yield 
% 
0.5 - N-acryloyl-tyrosine-OMe 35 
0.6 - N-acryloyl-tryptophan-OMe 79 
0.7 - 7-acryloyloxycoumarin 92 
0.8 - 4-vinyl-pyridine 94 
1.5 Sunitinib N-acryloyl-tyrosine-OMe 63 
1.6 Sunitinib N-acryloyl-tryptophan-OMe 58 
1.7 Sunitinib 7-acryloyloxycoumarin 86 
1.8 Sunitinib 4-vinyl-pyridine 41 
2.5 SN38 N-acryloyl-tyrosine-OMe 61 
2.6 SN38 N-acryloyl-tryptophan-OMe 80 
2.7 SN38 7-acryloyoxylcoumarin 90 
2.8 SN38 4-vinyl-pyridine 27 
3.5 Paclitaxel N-acryloyl-tyrosine-OMe 41 
3.6 Paclitaxel N-acryloy-tryptophan-OMe 74 
3.7 Paclitaxel 7-acryloyloxycoumarin 76 
3.8 Paclitaxel 4-vinyl-pyridine 63 
4.5 Irinotecan N-acryloyl-tyrosine-OMe 68 
4.6 Irinotecan N-acryloy-tryptophan-OMe 77 
4.7 Irinotecan 7-acryloyloxycoumarin 82 
4.8 Irinotecan 4-vinyl-pyridine 45 
Table 3.1: polymer composition and yield 
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Removal of the template occurs by dialyzing the polymers first in methanol and then in 
water.  
The use of methanol increases the solubility of template molecules and leads to a 
polymer shrinkage that force the dissociation of the MIP-template complex. Finally, 
water allows to remove also unreacted functional monomers or by-products and to 
resume the better polymer conformation.
24
  
The polymers synthesized with irinotecan as template undergo a further washing step 
by dialysis first in 7:3 methanol:acetic acid mixture and after in water because of the 
difficulty to remove completely the template from the polymeric matrix.
25
 
 
1H-NMR Characterization of MIPs  
 
The success of polymerization was verified first by 
1
H-NMR spectroscopy dissolving 2 
mg of polymer in 800 µL of [D6]DMSO. Examples of the resulting spectra are reported in 
figures 8 and 9. The spectra exhibit an envelope of signals at high fields corresponding 
to the aliphatic protons of the polymer, in particular the signals between 1 and 2.5 ppm 
are associated to  and  protons to amide group, while broad signals between 2.5 and 
4 ppm are generated from the CH2-N groups. The protons of amide groups of the 
polymeric matrix and the aromatic protons of pyridine incorporated into the polymer 
generated a broad signal between 6 and 7 ppm.
26
  
 The NMR signal of the drug are not present in the spectrum of MIP 1.8 (Figure 3.8), 
indicating that the template molecule was completely removed from the polymer 
binding sites.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: 1H-NMR spectrum of MIP 1.8 
n
n
n
n
Amide and 
aromatic protons
Aliphatic
protons , 
to C=O
Aliphatic 
protons 
CH2-N  
Fluorescent MIPs 
 
 
78 
 
A similar spectrum was also obtained for MIP 2.6 (Figure 3.9). The characteristic two 
broad signals between 1 and 4 ppm correspond to aliphatic protons and those between 
7 and 8 ppm correspond to the amide groups of polymer; signals due to the aromatic 
protons of tryptophan are also observed. Both the MIP spectra showed a similar trend 
of signals because of the presence of an high percentage of the crosslinker (N,N’-
ethylenebisacrylamide, 70%) and of the acrylamide functional monomer (15%) in the 
polymeric matrix with respect the amount of functional monomer (15%). Therefore the 
main visible signals are due to the acrylamide-based polymeric matrix.  
 
 
                             Figure3.9: 1H-NMR spectrum of MIP 2.6 
 
Determination of Particles Size 
 
Analysis by NanoSight 
 
Preliminary studies on particles size were performed by NanoSight LM10. This 
instrument utilizes the properties of both light scattering and brownian motion to 
obtain the size distribution and concentration measurement of particles in liquid 
suspension. A laser beam passes through the sample chamber leading to a light 
scattering due to the presence of the polymeric particles in suspension. The light 
scattered from each particle is easily visualized via a 20x magnification microscope onto 
which a camera is mounted. The camera captures a video file of the particles moving 
under brownian motion. This video is analyzed by a software that follows the 
movement of many particles individually calculating the mean squared displacement 
Amide and 
aromatic
protons
Aliphatic
protons
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for each particle for as long as it is visible in the video. From these values, the diffusion 
coefficient (Dt) and the hydrodynamic radius (rh) were determined using the Stokes-
Einstein equation: 
    
   
     
 
 
Where the KB is the Boltzmann’s constant, T is the temperature and η is the viscosity. 
Since each and every visible particle is separately tracked, it is possible to generate 
particle size distribution profiles that reflect the actual number of particles seen in the 
video.
27
 
The particle sizes of water suspensions of MIPs and NIPs synthesized to capture 
sunitinib were first investigated using this technique. As shown in Figure 3.10a, all 
samples are characterized by a wide population of particles, with a fraction smaller 
than 100 nm and a major fraction of particles larger than 100 nm. However, after 
filtering the solution on 0.22 µm filter, only particles of about 100 nm size were visible 
(Figure 3.10b). While measuring the same sample after a long time, also the presence 
of particles of 300 nm and 490 nm was observed, suggesting the tendency of these 
particles to aggregate in water solution (Figure 3.10c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: NanoSight measurements of NIP 0.8 
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Polymer 
Concentration 
(mg/mL) 
Particle size (nm) 
After filtration 
1.6 0.125 105 
0.6 0.5 103 
1.8 2 100 
0.8 0.5 134 
1.5 0.125 155 
0.5 0.125 149 
1.7 1 89 
0.7 0.5 127 
 
Table 3.2: particle size of NIPs and MIPs for sunitinib, measured by NanoSight 
 
However, this technique is based on the light scattering of particles, therefore the 
bigger particles are more visible than the smaller ones because the amount of light 
scattered by big particles is higher than that produced by a small particle.
28
  
This reason, coupled with a low resolution of the instrument (10 nm), allows actually to 
detect only the presence of aggregates in the MIP samples. In fact probably these 
samples are characterized by a wide population of particles even lower than 100 nm 
size, but their scattering is not detectable due to the presence of larger aggregates.  
 Therefore all MIPs and NIPs were also analyzed by Dynamic Laser Light Scattering in 
DMSO.  
 
Dynamic Laser Light Scattering (DLLS) Measurements 
 
DLLS is an useful technique to measure the particle size from 0.3 nm to 10 micron  
diameter in a wide range of solvents. 
The instrument uses a laser beam to illuminate a particles suspension and measure 
their size by analyzing the intensity fluctuations in the light scattered during their 
brownian motion. 
If a small particle is illuminated by a light source such as a 
laser, the particle will scatter the light in all directions.  
In a sample containing thousands of particles, the incident 
laser beam produces the light scattering of particles leading 
to a speckle pattern in the screen, similar to that shown in 
Figure 3.11. As all the particles suspended in a liquid move 
constantly due to brownian motion, the speckle will also 
appear to move. The speckle pattern shows some bright 
Figure 3.11: example of a 
speckle pattern produced 
by light scattering.  
(From ref. 32) 
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and dark areas that are created by the constructive or destructive interaction between 
different waves propagated from the particles.
29
 If the waves arrive to the screen with 
the same phase, a constructive interference occurs and a bright patch is observed, 
while if the waves have different phases, a destructive interaction takes place giving 
dark areas in the speckle. 
As the particles move around in the sample, the constructive and destructive phase 
addition of the scattered light will cause the bright and dark areas to grow and diminish 
in intensity leading to a fluctuating speckle. The instrument measures the rate of the 
intensity fluctuation and uses this to calculate the size of the particles. This could be 
done thanks to a digital correlator, able to measure the degree of similarity between 
two signals over a period of time that is usually very short, from 1 to 10 milliseconds. 
The intensity of the light scattered from different particles becomes even more 
different during the time, leading to an exponential decrease of the correlation in 
function of the time. A plot similar to Figure 3.12 can be obtained for each particle.
30
  
 
 
Figure 3.12: example of decay of correlation function of particles with different size.(From ref.32) 
 
The brownian motion consists in the movement of particles due to the random collision 
with the molecules of the liquid that surrounds the particle. Therefore small particles 
move quickly, while large particles move slowly. This feature is very important for DLS 
measurements, in fact a small particle moving quickly will lead to a rapid fluctuation in 
the intensity of its speckle pattern and a rapid decreasing of its intensity correlation. 
Large particles moves slowly, and also the intensity fluctuation in the speckle and the 
rate of decay of the correlation function will be slow. 
As the rate of decay of the correlation function is related to particle size, the 
instrument software uses algorithms to obtain a particle size distribution from the 
decay rates of the correlation function measured from the sample.   
The size distribution by intensity shows the relative intensity of the scattered light in 
function of the particles size in nanometers. This size distribution by intensity could also 
be converted in distribution by volume using Mie theory. 
31
 
The particles size of all polymers synthesized in this project was measured by DLLS.  
Since previous experiments by NanoSight showed the tendency of these particles to 
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aggregate in water, the DLLS measurements were performed using 0.25 mg/mL 
particles suspensions in DMSO after sonication for 1h and filtration on 0.45 µm filter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.13a 
3.13b 
3.13c 
Chapter 3-Results and Discussion 
 
 
83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The size distribution by intensity showed for all samples the presence of two 
populations of particles of 10 nm and 100 nm, while in the size distribution by volume 
only one peak corresponding to particles of 10 nm size is visible.  
This behavior could be explained considering that large particles scattered the light 
more intensely than small particles, as explained by Rayleigh scattering equation where 
the intensity of a particle is related to the 6
th
 power of the diameter: 
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Where λ and I0 are respectively the wavelength and the intensity of the beam of light,    
is the scattering angle, R is the distance between the particle and the detector, n is the 
refractive index of the particle and d is the diameter of the particle.
32
 
Figure 3.13: a) size distribution by intensity of MIP 3.6; b) size distribution by volume of MIP 3.6; c) 
size distribution by volume of MIP 1.7; d) size distribution by volume of MIP 2.6; e) size distribution by 
volume of MIP 4.5 
3.13e 
3.13d 
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Therefore in a sample containing an equal number of particles of 5 nm and 50 nm, the 
peak corresponding to 50 nm size population will be 10
6
 higher than that of 5 nm size in 
the size distribution by intensity. In the size distribution by volume the peak 
corresponding to 50 nm size will be 10
3
 higher than that of 5 nm size because the 
distribution by volume is obtained from the distribution by intensity considering the 
volume of sphere (V): 
 
   
 
 
    
 
Were r is the radius of the sphere. 
The results obtained by measurements on MIPs and NIPs indicate the presence of a 
large population of 10 nm size, because both the size distribution by intensity and by 
volume showed a peak at 10 nm size. The presence of an highly intense signal at 100 
nm in the size distribution by intensity suggest the presence also of few particles of 100 
nm size corresponding to aggregates, as observed by NanoSight measurements.  
The polymer tendency to aggregate could be due to the presence of polar groups in the 
polymeric matrix that is basically made of ethylenebisacrylamide and acrylamide. The 
particle size for all MIPs and NIPs is shown in Table 3.3. 
 
Polymer 
Particle size 
(nm) 
 Polymer 
Particle size 
(nm) 
1.5 10.81  3.7 13.35 
1.6 11.12  3.8 12.90 
1.7 10.25  4.5 15.21 
1.8 10.39  4.6 11.46 
2.5 7.49  4.7 13.99 
2.6 14.94  4.8 10.53 
2.7 16.59  0.5 8.84 
2.8 13.30  0.6 13.43 
3.5 14.59  0.7 12.58 
3.6 16.90  0.8 9.17 
Table 3.3: particle size measured by DLLS 
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3.2 Recognition of the Targets 
In the following table the amount of target molecule and other drugs captured by each 
polymer and measured as described below are shown. 
Polymer Target 
Functional 
monomer 
Rebinding 
(QMIP) 
[nmol mg-1] 
Cross rebinding 
[nmol mg-1] 
Imprinting 
factor 
Sunitinib SN38 Paclitaxel 
1.5 1 5b 12 - 0 2 3 
1.6 1 6b 25 - 0 0 3 
1.7 1 7b 35 - 8 5 3 
1.8 1 8 6 - 8 0 6 
2.5 2 5b 46 22 - 4 1.7 
2.6 2 6b 47 25 - 0 1.5 
2.7 2 7b 45 38 - 0 2 
2.8 2 8 45 16 - 3 2 
3.5 3 5b 4 40 44 - 9
3.6 3 6b 3 40 5 - 6
3.7 3 7b 5 39 29 - 8
3.8 3 8  3 38 5 - 17
4.5 4 5b 10 11 44 2 7.1 
4.6 4 6b 6 41 48 3 2.6 
4.7 4 7b 15 39 48 0.9 0.7 
4.8 4 8 7 42 47 0.9 8.6 
Table 3.4: rebinding capabilities and selectivity of all MIPs synthesized for sunitinib, SN38 paclitaxel and 
irinotecan, measured after 1h of incubation. The imprinting factor was calculated at equilibrium. 
Rebinding Tests 
The molecularly imprinted polymers binding capability was investigated by rebinding 
tests. The test consists of the quantification during the time of the amount of free drug 
in a 1 mg/mL polymer water solution containing 50 µM initial drug concentration. After 
centrifugation to remove the polymeric nanoparticles, the unbonded drug 
concentration was quantified by an HPLC method. From the resulting data the polymer 
absorption capacity was calculated.
33
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The absorption capacity is the amount of drug captured by MIP or NIP per mg of 
polymer.  
It is calculated by the following equation: 
 
  
(     ) 
 
 
 
Where Q is the absorption capacity in nmol of captured drug per mg of polymer, while 
C0 and Cs are respectively the initial and the equilibrium concentrations of the target 
molecule in solution, V is the volume of the solution and W is the weight (mg) of the 
polymer.
34
 
All the molecularly imprinted polymers templated with SN38 showed a good binding 
affinity for the target, in fact they bind about 45-47 nmol/mg of the drug after several 
minutes of incubation and they reach saturation within one hour. The majority of MIPs 
showed also a good stability, and they retain the captured drug also after 24 hours of 
incubation. Only the MIP containing 4-vinylpyridine tends to release the drug after 8 
hours of incubation (Figure 3.14)). 
 
 
Figure 3.14: rebinding kinetics of SN38 with MIPs 2.5, 2.6, 2.7 and 2.8  
The polymers synthesized to capture sunitinib showed a lower amount of drug 
captured with respect that for SN38. However, a good binding capability was observed 
for MIP 1.7 that could bind 35 nmol/mg of drug after several minutes and reaches  
saturation after 12 hours binding 42 nmol/mg drug.  MIP 1.6 reaches saturation after 3 
hours capturing 27 nmol/mg drug, but after long time it tends to release some of 
captured sunitinib. A similar value of bound sunitinib was also obtained using MIP 1.5 
and MIP 1.8 that show a similar binding kinetics reaching the plateau after 3 hours of 
incubation (Figure 3.15). 
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Figure 3.15: rebinding kinetics of sunitinib with MIPs 1.5, 1.6, 1.7, 1.8  
 
Moreover, while the MIPs can bind and hold the drug for a long time,  NIPs have a 
lower binding affinity and tend to release the drug after 3 hours probably due to 
aggregation phenomena between the nanoparticles which lead to the expulsion of 
surface-interacting molecules (Figure 3.16)  
 
 
All the MIPs imprinted with paclitaxel showed a lower binding capability and a lower 
stability at long times with respect the other polymers. In particular, the MIP containing 
7-acryloyloxycoumarin and 4-vinylpyridine reached the maximum of captured drug 
within one hour, however after this time they tends to release the target molecule. This 
molecule is captured again after long times only by MIP 3.7. MIPs 3.6 and 3.5 show a 
slower binding kinetic reaching saturation after 2 hours and release the drug after long 
times. This behavior suggests that probably the majority of bound molecules are in 
proximity of the polymer surface and could be easily expelled due to aggregation 
Figure 3.16: rebinding kinetic of sunitinib with MIP and NIP containing 4-vinyl piridine 
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between polymer particles that could occur in water solutions. The amount of captured 
drug for these polymers never exceeded 10 nmol/mg (Figure 3.17). 
 
 
 
Rebinding tests were also performed with the polymers synthesized to capture 
irinotecan. In this case all the imprinted polymers reached the saturation after 1 hour 
of incubation and hold the drug even after long times. The amount of irinotecan 
captured at saturation is between 10 nmol/mg and 5 nmol/mg. All the non-imprinted 
polymers showed a lower binding capability with respect the MIPs, suggesting a good 
efficiency of the imprinting process and a good specificity for the target drug. The best 
MIP in terms of binding affinity and specificity is the polymer containing N-acryloyl-
tyrosine methyl ester as functional monomer (MIP 4.5) (Figure 3.18). 
 
 
 
 
 
Figure 3.17: rebinding kinetics of paclitaxel with MIPs 3.5, 3.6, 3.7 and 3.8 
Figure 3.18: rebinding kinetics of irinotecan with MIPs 4.5, 4.6, 4.8 and the respective NIPs in 
water 
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The binding capability of these polymers was investigated also in citrate buffer at pH=3 
because in these conditions all the irinotecan in solution is in its lactone form. The 
binding kinetics show that the binding affinity of MIP 4.6 is two times higher but the 
same amount of irinotecan was captured also by the non-imprinted polymer. Instead 
MIP 4.5 maintains its better performance over the NIP but its binding capability 
decreases in citrate buffer with respect to water (Figure 3.19). 
 
 
 
Cross-reactivity 
 
The selectivity of each MIP for its target molecule was also investigated by rebinding 
tests with other anticancer drugs. The tests were performed treating a 1 mg/mL water 
solution of MIP with a 50 µM drug and measuring, by HPLC, the remaining drug 
concentration in solution after different times.  
All the MIPs synthesised to capture sunitinib, SN38 and irinotecan are unable to bind 
paclitaxel. Their highly crosslinked polymeric matrix having binding sites for 
fundamentally planar molecules as sunitinib, SN38 or irinotecan, probably could not  
allow the access of a complex and non planar molecule as paclitaxel inside the polymer.  
On the contrary the crossreactivity between sunitinib, SN38 or sunitinib is higher.  
It is nevertheless possible to select several polymers having a good binding capability 
and a good selectivity. The best polymer for sunitinib is that containing coumarin as 
functional monomer (MIP 1.7), as it captures 35 nmol/mg of sunitinib after several 
minutes and its crossreactivity with SN38 and paclitaxel is 23% and 3% respectively 
(Figure 3.20). 
Figure 3.19: rebinding kinetics of irinotecan with MIP 4.5 and 4.6 and the corresponding NIPs in 
citrate buffer 
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Figure 3.20: rebinding kinetics of sunitinib, SN38 and paclitaxel with MIP 1.7 
 
  MIP 2.5 and MIP 2.6 for SN38 show the best performance, they bind 46-47 nmol of 
target molecule per mg of polymer without any release after 24 hours. Also when 
tested with other drugs they could bind 22-25 nmol/mg of sunitinib after one hour of 
incubation and less than 5 nmol/mg of paclitaxel (Figure 3.21). 
 
 
Figure 3.21: amount of SN38, sunitinib and paclitaxel bound by MIP 2.8, 2.6, 2.5 and 2.7 after 1 h 
of incubation 
 
As to irinotecan, the MIP containing N-acryloyl-tyrosine methyl ester as functional 
monomer (MIP 4.5) shows the best performance, it captures 9.8 nmol/mg of irinotecan 
within one hour. However, its selectivity is lower, in fact it binds 2.9 nmol/mg of 
paclitaxel and 10.9 nmol/mg of sunitinib within one hour, but after this time both the 
drugs are released from the polymer reaching 7.8 nmol/mg for sunitinib and 0.9 
nmol/mg for paclitaxel after 3 hours.  
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Imprinting Factor 
 
The efficiency of the imprinting process was evaluated by measuring the imprinting 
factor obtained from the rebinding experiments of MIPs and NIPs.  
The imprinting factor (IF) is calculated as the ratio of target drug amount bound to the 
imprinted polymer, to the amount of the same molecule captured by the non-
imprinted polymer: 
   
    
    
 
 
Where QMIP and QNIP are respectively the absorption capability of the imprinted and the 
not-imprinted polymer having the same monomer formulation. This normalization 
method removes binding due to non-specific interactions.
35
  
In this project the IF was preliminary calculated assuming that the number of functional 
monomers incorporated into the polymeric matrix of MIP and NIP is the same since the 
same polymer formulation was used with except for the presence of template molecule 
in MIP. 
The imprinting factors calculated for many of polymers in Table 3.4 are between 1 and 
3, this is consistent with the results of the NMR titrations with the monomers, where 
the scarce tendency to saturation indicates a relatively low affinity.
36
 Only MIP 3.5, 3.7, 
3.8, 4.5 and 4.8 showed higher values of IF. Therefore the imprinting process seems 
been more efficient with large template molecules, as irinotecan and paclitaxel, than 
with smaller molecules as sunitinib.  
 
Coumarin Content 
 
As the sunitinib MIPs containing coumarin resulted the most promising from the 
rebinding tests, we have further investigated their properties. The amount of coumarin 
incorporated into the polymeric matrix of MIP 1.7 and NIP 0.7 was quantified by UV-
visible spectroscopy.  
A calibration curve of 7-hydroxycoumarin in water was first obtained measuring the 
characteristic absorbance of coumarin at 324 nm (Figure 3.22).  
The UV spectrum of 60 µM and 120 µM water polymers solutions was measured and 
the absorbance intensity at 430 nm, corresponding to the maximum of absorbance, 
was used to quantify the functional monomer covalently bonded into the polymer by 
the calibration curve of 7-hydroxycoumarin (Table 3.5). 
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The amount of coumarin in the NIP is 548 pmol/µg, about twice the amount found in 
the MIP which contains 227 pmol/µg of functional monomer. 
This difference could be explained considering that the main difference between the 
MIP and NIP polymerization, is the presence of the template molecule in the 
polymerization mixture of the imprinted polymer. The template molecule could 
interfere in the polymerization process, by steric hindrance or by side reactions with 
the monomers, reducing the rate of polymerization with respect that of the non-
imprinted synthesis. 
This finding allows to recalculate the imprinting factor for MIP 1.7 according to 
the actual amount of coumarin per mass of polymers. In this way the corrected 
imprinted factor is 6. 
Fluorescence Properties of MIPs 
Fluorescence spectroscopy is a highly sensitive and rapid technique widely applied to 
study the interaction between a fluorescent molecule, called fluorophore, and a 
quencher able to decrease the fluorophore  fluorescence emission.  
In the absence of quencher, the fluorescent molecule after excitation at certain 
radiation, tends to rapidly return to the ground state by emission of a photon. The 
emission occurs at higher wavelengths than the excitation one. The emission rates of 
fluorescence are typically in the order of  10
8
 s
-1
, so that a typical fluorescence lifetime 
is near 10 ns. The lifetime (0) is the average time between excitation and  return to the 
ground state. 
Polymer 
(g/mL) 
Mean 
intensity 
Coumarin 
(mol/L) 
MIP 1.7 
60 
    0.18 1.44·10-5 
NIP 0.7 
60 
0.40 3.30·10-5 
MIP 1.7 
120 
0.31 2.56·10-5 
NIP  0.7 
120 
0.80 6.54·10-5 
Table 3.5: amount of coumarin in the 
polymer
Figure 3.22: calibration curve of 7-hydroxycoumarin in water 
Table 3.5: amount of coumarin in the 
polymer 
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The intensity of fluorescence emission could be decreased by a quenching mechanism 
that involves the interaction between the fluorophore and the quencher. Two different 
mechanisms could be distinguished: dynamic and static quenching.   
Dynamic quenching, called also collisional quenching, occurs when a fluorophore in its 
excited state is deactivated upon contact with the quencher that diffuses in solution. 
The dynamic quenching is described by the Stern Volmer equation: 
 
  
 
       [ ]      [ ] 
 
Where F0 and F are the fluorescence emission intensities in absence and in presence of 
the quencher respectively, kq is the bimolecular quenching constant, 0 is the lifetime 
of the fluorophore in the absence of quencher and [Q] is the quencher concentration. If 
the quenching is dynamic the Stern Volmer constant is indicated ad KD, and the values 
of bimolecular quenching constant are near 1·10
10
mol
-1
L
-1
s
-1
. Values of kq larger than 
the diffusion-controlled limit suggest that a static quenching occurs. In this case the 
Stern Volmer constant is indicated as KS.    
Static quenching consist of the interaction between the fluorescent molecule and the 
quencher leading to a non-fluorescent ground state complex.
37
 In static quenching the 
dependence of fluorescence intensity from the quencher concentration is derived 
considering the association constant of complex formation: 
   
                                                      F  +  Q              FQ 
 
   
[  ]
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 Where [F] is the concentration of the free fluorophore, [Q] is the concentration of free 
quencher and [FQ] is the concentration of complex and KS is the association constant. 
Since:  
   [ ]  [  ] 
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The Stern Volmer equation for static quenching becomes: 
 
  
 
     [ ] 
 
Where KS  is both the association and the Stern Volmer constant.
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The presence of tyrosine, tryptophan and coumarin in the polymeric matrix gives some 
fluorescent properties to the MIPs. Therefore the fluorescence technique was used to 
study the interaction of MIPs with their target molecules. The polymer binding ability at 
lower concentrations of drug was investigated by fluorescence titration of the polymer 
with increasing amounts of the drug. Fluorescence quenching was observed due to the 
interaction between the polymer and the drug. The quenching phenomenon was 
studied by the Stern-Volmer analysis, plotting the ratio of the fluorescence emission 
before and after addition of quencher, in function of the quencher concentration. 
 The Stern-Volmer plots obtained with all the fluorescent MIPs show a bimodal 
quenching behaviour, with a first, high slope, linear region occurring at low 
concentrations of drugs, and a further, low slope, linear region at higher drug 
concentrations. This behaviour suggests the presence of a non-homogeneous polymer 
containing binding sites with different affinity for the target molecule.
39
 
Conversely, the Stern–Volmer plots reporting the fluorescence quenching of the free 
functional monomers upon titration with the drugs show a single linear behaviour with 
a slope similar to that found in the second region of the polymers (Figure 3.23).   
3.23a 
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Figure 3.23: comparison between the Stern-Volmer plots of MIPs for SN38 and MIPs for 
sunitinib with analogues of the free functional monomers 
 
The efficiency of the drugs in quenching the MIPs emission was investigated by the 
Stern-Volmer equation, as shown below, that was separately applied on the two linear 
regions of the Stern-Volmer plots. 
 
                                                             
  
 
    
    [ ]    
 
Where F0 is the initial fluorescence intensity of the polymer, F is the fluorescence 
intensity in the presence of the drug, [Q] is the quencher concentration, and KappSV   is 
the apparent Stern-Volmer constant for the non-homogeneous MIP, that can be 
regarded as an apparent association constant between the population of fluorophores 
in the MIP and the quencher.
40 
The Stern–Volmer constants are reported in Table 6, with the bimolecular quenching 
constants kqapp calculated by the equation: 
 
  
    
   
   
 
 
 
where KSV is the Stern-Volmer constant and 0 is the lifetimes of fluorophores, which 
were assumed to be 4.3·10
-9 
s  for coumarin,
41
 3.6·10
-9
s for tyrosine and 3.1·10
-9 
s for 
tryptophan.
42,43 
In any case, including the low slope regions of the plots,  kqapp is larger than the value 
for the diffusion controlled quenching: 1·10
-10 
mol
-1
L
-1
s
-1
, therefore the fluorophore and 
3.23b 
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the quencher binds together leading to a static quenching. For this reason the observed 
quenching is to be considered as the consequence of a static interaction. 
The high Stern-Volmer constants measured (Table 3.6) at drug concentrations lower 
than 5 M for all polymers templated with sunitinib and for the polymers templated 
with SN38 and containing tyrosine and tryptophan, are most likely related to the 
presence of inner binding sites characterized by an higher apparent binding affinity. The 
amount of such sites appears as constant in the different MIPs, and probably related to 
the way chosen for their synthesis, namely to the molar ratio between the template, 
functional monomer, co-monomer and cross-linker. On the other side, lower affinity 
binding sites on the polymer surface may be associated to the behaviour of second 
region of the plot where the slope is similar to the Stern-Volmer constant obtained by 
the titration of the free functional monomers (Table 3.6). However, the increased slope 
of the Stern-Volmer plot of the polymer shows a good efficiency of the imprinting 
process that created binding sites complementary to the target molecule leading to an 
increased binding capability of the polymer than the corresponding functional 
monomer. 
Table 3.6: Stern-Volmer and quenching constants of MIPs and free functional monomers analogues. 
The constants below and (over) 5 µM drug concentration were obtained from titrations performed in 
water with MIP from 1.5 to 2.7. Titrations of paclitaxel were performed in DMSO. For MIP 3.5 and 3.6 
the constants refers to concentrations below and (over) 613 nM, while for the corresponding free 
molecules the values refers to concentrations below and (over) 9 µM. For MIP 3.7 the values refer to 
concentrations below and (over) 495 nM. 
MIP 
KSV
app 
[103Lmol-1] 
kq
app 
[1012Lmol-
1s-1] 
Molecule 
KSV
app 
[103Lmol-1] 
kq
app 
[1012Lmol-1s-1] 
1.5 37.6 (14.4) 10.4 (4) 
with 
sunitinib 
Boc-tyr 12.7 3.5 
1.6 25.2 (10.7) 8.1 (3.4) Boc-trp 12.2 3.9 
1.7 61.0 (15.6) 14.2 (3.6) 7-OH-coum 18.5 4.3 
2.5 26.1 (2.0) 7.2 (0.6) 
with  
SN38 
Boc-tyr 2.1 0.6 
2.6 20.9 (6.1) 6.7 (1.9) Boc-trp 5.6 1.8 
2.7 5.7 (2.1) 1.3 (0.5) 7-OH-coum 7.9 1.8 
3.5 4.3 (2.7) 1.2 (0.7) 
with  
paclitaxel 
Boc-tyr 3.7 (2.8) 1.0 (0.8) 
3.6 110 (1.0) 35.5 (0.3) Boc-trp 18.2 (1.7) 3.6 (0.3) 
3.7 50.4 (2.5) 11.7 (0.6) 7-OH-coum 0.2  0.4  
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The behaviour of MIP 1.7, containing coumarin and capable of rebinding sunitinb, is 
particularly interesting due to its emission of visible light whose quenching can be 
appreciated also by the naked-eye (Figure 3.24). Moreover this polymer showed a 
binding affinity higher than other MIPs, as indicated also by the high value of its Stern- 
Volmer constant, and the presence of specific sites since the slope of the NIP 0.7 Stern- 
Volmer plot is lower than that of MIP 1.7.
44
 Therefore MIP 1.7 was selected as a 
fluorescent sensor to set up a test in plasma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All the titrations with paclitaxel were performed in DMSO due to the insolubility of this 
drug in water. MIP 3.7 containing coumarin showed a high binding affinity at drug 
concentrations lower than 495 nM, while increasing the concentration the affinity 
decreases drastically. These values indicate that MIP 3.7 has few inner highly specific 
binding sites that are occupied at low drug concentrations, while increasing the amount 
of drug added also the less specific and external binding sites are occupied. Since both 
the quenching constants for the highly and less specific sites are higher than 10
10 
molL
-
1
s
-1
, static quenching occurs during all the titration. Finally, comparing the quenching 
and the SternVolmer constants of MIP 3.7 and those of free 7-hydroxycoumarin, it can 
be seen that the interaction with the free molecule is weak and occurs in part by a 
dynamic quenching. The incorporation of coumarin in the polymeric matrix increases 
drastically the quenching constant and the binding affinity due to the presence of 
specific binding sites in the MIP.  
Finally, comparing the polymers synthesized to capture paclitaxel,  MIP 3.6 showed the 
highest binding affinity at concentrations lower than 613 nM, and also a good 
specificity for paclitaxel since the slope of titration curves of both the non-imprinted 
MIP 1.7 with 
sunitinib 
MIP 1.7 
Sunitinib 
Figure 3.24: a) quenching of MIP 1.7 fluorescence upon addition of 50 M sunitinib, b) Stern 
Volmer plot of MIP 1.7, NIP 0.7 and 7-hydroxycoumarin 
a) b) 
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polymer and the free tryptophan is very low in comparison that of MIP 3.6. Therefore 
the imprinting process was very efficient for this polymer (Figure 3.25). 
 
 
Also the binding affinities of MIPs for irinotecan at low drug concentrations were first 
evaluated by the Stern Volmer analysis titrating MIPs 4.5 and 4.6 with increasing 
concentrations of irinotecan. As in the previous titrations, quenching of functional 
monomer fluorescence in the polymer was observed upon interaction with the drug. 
The calculated apparent Stern-Volmer and quenching constants indicate that for all 
polymers the interaction with the target leads to a static quenching. Moreover, the 
binding affinity of MIP 4.5 is twice that of the respective NIP 0.5 due to a good 
efficiency of the imprinting process (Figure 3.26a, Table 3.7). 
 The slopes of the Stern-Volmer plots of MIP 4.6 and NIP 0.6  corresponding to the 
apparent Stern-Volmer constant are conversely very similar, indicating that the number 
of specific binding sites in MIP 4.6 is very low (Figure 3.26b). 
 
 
 
 
 
 
 
 
Figure 3.25: a) Stern Volmer plot of MIP 3.6, the respective NIP and the free functional monomer 
analogue; b) fluorescence quenching of MIP3.6 upon interaction with paclitaxel 
a) b) 
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Polymer 
KSV
app 
[103Lmol-1] 
kq
app 
[1012Lmol-1s-1] 
MIP 4.5 10.4 2.9 
NIP 0.5 4.8 1.3 
MIP 4.6 18.2 5.9 
NIP 0.6 16.2 5.2 
Figure 3.26: On the left: Stern-Volmer plots of MIP 4.5, 4.6 and the respecive NIPs. On the right: a) 
fluorescence quenching of MIP 4.5 upon addition of irinotecan; b) fluorescence quenching of MIP 
4.6 upon addition of irinotecan 
3.26b 
Table 3.7: apparent Stern-Volmer and quenching constants of MIP 4.5 
and MIP 4.6 and the respective NIPs 
 
1 µM  
100 µM 
3.26a 
3.26b 
1 µM  
100 µM 
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The polymer containing coumarin was not analysed because the fluorescence emission 
band of coumarin is superimposed to that of irinotecan, therefore it is impossible to 
observe the quenching of coumarin fluorescence in the polymer during the titration 
with the drug. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.27: fluorescence emission spectra of irinotecan and 7-hydroxycoumarin 
 
The fluorescence quenching of MIP 4.5 and 4.6 upon interaction with irinotecan is quite 
high within the range of drug concentrations commonly found in real samples. 
However, the measurement of the tyrosine or tryptophan fluorescence quenching in 
the polymer exciting at 230 nm or 280 nm, is not possible in blood or plasma samples 
containing irinotecan, due to the presence of proteins or peptides containing tyrosine 
or tryptophan that emit at the same wavelengths of the polymer interfering in the drug 
quantification.  
 
 
3.3 Towards Fluorimetric Sensors:  
Two Proofs of Concept 
 
 
Sunitinib: a Proof of Concept in Plasma 
 
Since MIP 1.7 showed good binding capabilities and fluorescent properties, it was 
chosen as a potential fluorescent sensor to study its performance in quantifying 
sunitinib in plasma samples.  We have therefore designed a possible test to be carried 
out by simply diluting the plasma sample in DMSO, adding the fluorescent MIP probe 
and reading the resulting MIP emission, compared with that of a reference sample of 
plasma without sunitinib. This choice was due to the fact that the polymer has been 
synthesized in DMSO, while it releases the target when washed in alcohols as methanol 
-- 1 µM Irinotecan  
-- 1 µM 7-hydroxycoumarin 
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or ethanol. Such solvents are the typical denaturising agents commonly used in the 
treatment of plasma samples, while DMSO is rarely reported. The action of alcohols on 
human plasma is very different from that of DMSO, as alcohols lead to the denaturation 
and precipitation of most of the serum albumin, while DMSO leads to unfolding without 
precipitation.
45,46 
Serum albumin unfolding is nevertheless sufficient, in our hypothesis,  
to allow the release of the albumin-bound drugs.  
In this view, a calibration curve was obtained first titrating 60 g/mL MIP 1.7 with 
increasing amounts of sunitinib in a 4:1 DMSO : water mixture.  
The titration was repeated in triplicate experiments carried out on different polymer 
preparations in 4:1 DMSO : water mixture and repeated in different days. From these 
titrations an average calibration curve was obtained and used to quantify sunitinib in 
spiked samples in both a serum albumin solution in buffer and real human plasma 
(Figure 3.28). 
 
 
 
 
 
                                
 
 
 
 
 
Figure 3.28: distribution of the spiked samples on the calibration curve 
 
The precision of the calibration curve turned out to be very good, as the within-run 
variability (CV) is less than 9%, and the  average within-day variability is less than 5%.  
The lower limit of detection of sunitinib, defined as the lowest concentration of 
sunitinib leading to an emission of polymer fluorescence that can be statistically 
differentiated from the reference one (average emission under 3 from the initial 
emission), can be placed at 400 nM, as a consequence of the apparent Stern-Volmer 
constant and of the observed variability.  
Samples spiked with known quantities of sunitinib in both PBS and normal human 
plasma were treated with four volumes of DMSO to unfold proteins. Such treatment of 
the plasma sample lead to a slight white precipitate likely due to salts (as no 
absorbance at 280 nm was recorded after redissolving the precipitate in water).  After 
Fluorescent MIPs 
 
 
102 
 
centrifugation, MIP1.7 was added from a mother solution in DMSO, its emission was 
compared with that obtained from a not spiked plasma sample, and the sunitinib 
concentration was calculated from the calibration curve made in 4:1 DMSO : water 
mixture. The recovered concentrations of the drug in the spiked samples are reported 
in Table 3.8. 
 
Real sunitinib 
concentration  
(mol·L-1) 
Calculated sunitinib concentration (mol·L-1) 
In PBS with HSA  
50 mg·mL-1 
In plasma 
5·10-6 5.12·10-6 3.75·10-6 
2·10-5 1.47·10-5 - 
5·10-5 5.16·10-5 5.89·10-5 
8·10-5 6.92·10-5 - 
Table 3.8: recovered sunitinib concentration in spiked samples 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.29: correlation between the calculated sunitinib concentration and the real 
drug concentration of spiked samples in PBS with 50 mg/mL HSA (red) and in plasma 
(green) 
 
Despite the samples were quantified by a calibration curve performed in a different 
environment (DMSO : water mixture), the accuracy was encouraging, and the 
calculated concentrations correlate well with the theoretical ones in both PBS and 
plasma solutions. Therefore the robustness of the system upon changing the 
environment from DMSO : water to DMSO : PBS first, and then to DMSO : normal 
human plasma, is  good.  
The slope of the linear regression of such data is very close to the theoretical value of 1 
for both the plasma samples and the buffer-albumin ones. The good results obtained 
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with this proof of concept on MIP 1.7 open the way to the possibility to use a 
fluorescent MIP as sensor for monitoring drug concentration directly in plasma without 
the need of any treatment except the addition of DMSO. However, the system would 
require a careful optimization of the MIP affinity in order to reach a better sensitivity, 
with a selection of other functional co-monomers. The sensitivity of this non optimized 
test could be enough for the expected plasma concentrations of other tyrosine kinase 
inhibitors as imatinib, but in the case of sunitinib the system could be useful only to 
detect plasma levels of sunitinib exceeding the therapeutic range, and 
preconcentration of the samples would be required if one would use the test to obtain 
the whole pharmacokinetic curve in a patient. 
 
 
Signals from the Target: Irinotecan in Plasma 
 
A fluorescence sensor could be obtained exploiting the variation of fluorescence 
properties of the recognition element upon binding of the target, or the intrinsic 
fluorescence of the target molecule.  
Since irinotecan is a fluorescent molecule
47
 giving a high emission at 430 nm when 
excited at 360 nm, the development of sensors based on MIPs able to quench the 
irinotecan fluorescence was evaluated as first approach. The functional monomers 5b, 
6b and 7b are characterized by a lower fluorescence emission than irinotecan but are 
able to make hydrogen bonds and π-staking interactions with the drug, as observed by 
1
H-NMR titration experiments. As reported in section 3.2, it has been possible to detect 
the interaction of irinotecan with the tyrosine and tryptophan containing MIPs by 
titration of the monomer emission. Unfortunately this approach cannot be used in 
plasma samples, due to the presence of proteins and peptides themselves containing 
the same fluorophores. On the other side, coumarin emission is not useful with 
irinotecan, as it is a stronger emitter at close wavelengths.  
We have therefore tested the possibility to exploit the tyrosine and tryptophan MIPs as 
quenchers of the irinotecan emission. The MIP containing tyrosine methyl ester was 
selected as best polymer able to capture irinotecan with high specificity, as shown by 
Stern Volmer analysis. Moreover, a preliminary  fluorescence titration of the emission 
of 1 µM irinotecan with MIP 4.5 and MIP 4.6 in 3:1 DMSO:water mixture showed that 
MIP 4.5 is more efficient and gives the highest quenching of the irinotecan emission 
(Figure 3.30). 
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Figure 3.30: Fluorescence quenching of irinotecan upon addition of MIP 4.5 and 
MIP 4.6 in 3:1 DMSO:water mixture 
 
Further fluorescence titrations of 1 µM irinotecan with increasing amounts of MIP 4.5 
were  performed in both 3:1 methanol:plasma and 3:1 DMSO:plasma mixtures. DMSO 
was used to increase the polymer binding capability since the polymerization was 
performed in this solvent. Methanol was used because it is the common solvent 
adopted by clinicians to treat plasma samples before drug quantification. Despite these 
different environments, MIP 4.5 showed the same behaviour during both the titrations 
and the ability to quench the drug reached a plateau after 2 µg of MIP added. The 
titration in methanol:plasma mixture was also repeated with different concentrations 
of irinotecan to investigate the dynamic range of the system. The variation of the 
quenching response in function of drug concentration was observed from 4.25 µM to 
0.5 µM. The entity of quenching increases with the drug concentration because  the 
binding equilibrium is shifted towards the complex formation increasing the 
concentration of target molecule in solution. At low concentrations binding to the 
polymer is more difficult and the plateau occurs before 2 µg of polymer added. 
Moreover, above 0.5 µM drug the titration curves are overlapped, indicating that the 
lower limit of detection was reached (Figure 3.31). 
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Therefore a preliminary calibration curve was carry out treating, spiked samples 
containing different concentrations of irinotecan in 3:1 methanol:plasma mixture with 
2 µg of MIP 4.5. The fluorescence emission before and after addition of the polymer 
was measured exciting at 360 nm and measuring at 430 nm. The amount of polymer 
added was chosen in base of the previous titration curves (Figure 3.32), where after 2 
µg of MIP a plateau was reached. 
 
 
Figure 3.32: preliminary calibration curve of irinotecan with MIP 4.5 in 3:1 
methanol:plasma 
 
Even if the amount of quenching is not very high, a linear correlation was observed 
from 0.5 µM to 8 µM. Also this second proof of concept shows that MIPs are capable to 
work in plasma samples without significant decrease of their performance, even in the 
presence of methanol. 
Figure 3.31: a) titration curve of irinotecan with MIP 4.5 in methanol:plasma and DMSO:plasma mixture; b) 
titration curves of different concentrations of irinotecan with MIP 4.5 in 3:1 methanol:plasma 
a) b) 
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Signal from the Polymer: a Fluorescent MIP for Irinotecan 
The second approach in sensor development for irinotecan consists of the synthesis of 
a molecularly imprinted polymer containing an highly fluorescent functional monomer 
whose fluorescence emission is quenched upon interaction with the drug.  
To this aim we have identified a naftalimide-based functional monomer (16c) 
containing an amino group at the side chain able to make hydrogen bonds with 
irinotecan, and the aromatic system of naftalimide able to give an high emission 
fluorescence (Scheme 3.3). Analogues of this functional monomer are widely used in 
literature to obtain fluorescent polymers to be used in sensor development.
48
 The 
synthesis was performed following the procedure of Konstantinova and co-workers.
49
 
Scheme 3.3: synthesis of the fluorescent functional monomer: 2-allyl-6-((3-aminoethyl)amino)-
1H-benzo[de]isoquinoline-1,3(2H)-dione 
The molecularly imprinted polymer was synthesized with 30% of functional monomer 
and 70% of ethylene glycol dimethacrylate (EGDMA). The choice of this crosslinker is 
due to the attempt to increase the polymer solubility and stability in water, since it is 
widely used in literature to obtain soluble molecularly imprinted polymers.
50, 51 
The fluorescent properties of this polymer were evaluated by fluorescence titration of 
60 µg/mL polymer solution directly in 3:1 methanol:plasma mixture, with increasing 
amounts of irinotecan from 20 nM to 100 µM. The fluorescence emission of MIP was 
measured at 520 nm when excited at 448 nm. The Stren Volmer plot (Figure 3.33) 
corresponds to the mean of three independent titrations, the high variability of certain 
points is due to the low polymer stability and the tendency to aggregate in 
methanol:plasma mixture.    
As shown in Figure 3.33 the quenching of fluorescence is not very high and a residual 
polymer fluorescence remains even after reaching the equilibrium state that 
corresponds to the plateau observed in the Stern Volmer plot. At the plateau all the 
accessible polymer binding sites are occupied and  equilibrium between the free drug 
16 16b 16c 
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and the bound drug is established.  The polymer residual fluorescence could be due to 
the presence of some inner binding sites that are not accessible to the target molecule, 
or to the presence of an excess of functional monomer.  
Despite these problems, the MIP fluorescence changed upon interaction of very low 
drug concentrations, showing a linear response between 20 nM and 100 nM. 
 
 
 
 
 
 
 
The apparent Stern Volmer constant was calculated at low drug concentrations where 
the fluorescence quenching increase linearly with the amount of drug added. The 
obtained value is 406·10
3
 L·mol
-1
, indicating a good binding affinity of this MIP for 
irinotecan. Also the apparent quenching constant was calculated, using the lifetime of 
9-Butyl-4-butylamino-1,8-naphtalimide, an analogue molecule of the functional 
monomer used for MIP synthesis. The lifetime of this molecule in methanol is 8.3 ns,
52
 
therefore the obtained apparent quenching constant was 4.9·10
13
, indicating that the 
quenching is static.   
The obtained apparent Stern Volmer constant was very high with respect other MIPs 
previously synthesized. Moreover the fluorescence emission of naphtalimide occurs at 
higher wavelengths than both irinotecan and biomolecules that could be found in 
plasma, allowing the drug quantification in biological samples without any interference. 
 
 
Figure 3.33: fluorescence titration of MIP with increasing concentrations of irinotecan in 3:1 
methanol:plasma mixture. On the left: Stern Volmer Plot, on the right: quenching of polymer 
fluorescence emission upon addition of irinotecan. 
a) b) 
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4.1 Synthesis of a FRET-based MIP 
 
Principles of FRET 
 
In order to explore further possibilities to exploit MIP sensors, the Förster Resonance 
Energy Transfer (FRET) technique was employed to set up a competitive test for 
paclitaxel quantification. FRET is a photophysical phenomenon that involves the non-
radiative transfer of excitation energy from an excited fluorophore called donor, after 
absorption of a higher–energy photon, to a ground state acceptor brought in close 
proximity. The energy transfer occurs through space by a dipole-dipole interaction 
without emission of photons. Moreover, in this process the donor and acceptor ground 
states are energetically coupled. After FRET the acceptor molecule is in an excited state, 
and it could undergo to different mechanisms depending on its nature. If the acceptor 
is a quencher, as DABCYL, the molecule returns in the ground state by a non-radioactive 
deactivation, resulting to a quenching of fluorescence. While if the acceptor is a 
fluorescent molecule, it returns to the ground state by fluorescence emission at a 
wavelength that is red shifted with respect that of the donor.
1
 
 
 
 
Figure 4.1: a)  Jablonski diagram for FRET mechanism; b)  absorption (blue) and emission (red) 
spectra of EDANS and DABCYL FRET pair
2
 
 
The FRET efficiency depends on different factors:  
 The spectral overlap integral (I) defined as a quantitative measure of the 
donor-acceptor spectral overlap over all wavelengths, as indicated by the 
following equation:  
 
  ∫  ( )   ∫        ( )   
    ( )   
b)  
a)  
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Where PLD-corr is the normalized dimensionless spectrum of donor emission, εA 
is the acceptor absorption extinction coefficient and λ is the wavelength. 
To have a high FRET efficiency, the donor emission spectrum must significantly 
overlap the absorption spectrum of the acceptor. 
 
 The distance between FRET pairs, in fact the FRET efficiency (E) is inversely 
proportional to the sixth power of the distance between donor and acceptor 
molecules, as indicated by the following equation:  
 
  
  
 
  
    
 
 
Where r is the separation distance between donor and acceptor pair, while R0 
is the Förster distance corresponding to a rate of FRET (kDA) equalling the rate 
of radiative decay (kDA=1/D, where D is the excited state radioactive lifetime 
of the donor). In fact:  
    (
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And R0 is calculated from the following equation:  
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Where  p
2
 depends on the relative orientation of the donor and acceptor 
dipoles, NA is the Avogadro number, QD is the donor quantum yield and nD is 
the relative index of the medium. Typically R0 is between 20 and 100 Å. 
Therefore to have a FRET mechanism the distance between donor and 
acceptor must be between 1 nm and 10 nm.
3
 
 
 Dipole-dipole interactions: the FRET efficiency depends also on the relative 
orientation of the donor and acceptor dipoles. In particular this efficiency is 
high when the donor emission dipole moment is parallel to the acceptor 
adsorption dipole moment.
4
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Synthesis of an EDANS Functional Monomer 
 
5-((2-acryloylaminoethyl)amino)naphthalene-1-sulfonic acid (vinyl-EDANS, 10) was 
selected as best functional monomer to obtain a fluorescent molecularly imprinted 
polymer whose fluorescence is quenched due to interaction with 4-([4-
(Dimethylamino)phenyl]-azo)-benzoyl (DABCYL) by a Förster Resonance Energy Transfer 
(FRET) mechanism. Since DABCYL is also a red dye the obtained polymer will undergo to 
a change of both fluorescence intensity and color upon interaction with DABCYL. 
The incorporation of EDANS into the polymeric matrix of the MIP requires the presence 
of an acryloyl-group in the molecule, able to polymerize with acrylamide and the 
crosslinker N,N’-ethylenebisacrylamide. Therefore vinyl-EDANS (10) was synthesized by 
coupling between EDANS and N-hydroxysuccinimidoyl acrylate (9) in water.
5
 The 
reactant 9 was obtained by esterification of N-hydroxysuccinimmide with acryloyl 
chloride in dichloromethane with triethylamine.
6
   
 
 
 
Scheme 4.1: synthesis of vinyl-EDANS 
 
 
1H-NMR Titration Study of Vinyl-EDANS with Paclitaxel 
 
The study of interaction between the functional monomer and the drug was performed 
by 
1
H-NMR titration of paclitaxel with increasing concentrations of vinyl-EDANS. As 
shown in Figure 4.2, the main variations of paclitaxel chemical sifts occurs due to 
hydrogen bonding with its amide group. Lower shifts were also observed on the 
adjacent CH2’ and on protons of aromatic rings 2 and 3. Therefore the main 
interactions occur by both hydrogen bonds and π-staking involving the side chain of the 
Yield 68% 
Yield 86% 
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drug, probably because groups on the drug side chain are more accessible to vinyl-
EDANS with respect the bacatinic nucleus of paclitaxel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Synthesis of MIPs and NIPs Containing EDANS 
 
Molecularly imprinted polymers containing EDANS (15% in mol) as functional 
monomer, acrylamide (15% in mol) as co-monomer and N,N’-ethylenebisacrylamide 
(70% in mol) were synthesized for paclitaxel and for irinotecan by high dilution radical 
polymerization in DMSO with the same procedure previously described for other MIPs 
synthesis. CM was fixed at 1% w/w. The obtained yield is indicated in Table 4.1. 
 
 
Figure 4.2: 1H-NMR titration of paclitaxel with vinyl-EDANS: a) variation of protons chemical shifts; 
b) variation of the NH chemical shift 
 
Paclitaxel 
a) b) 
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Polymer Drug 
Yield 
% 
0.10 - 41% 
3.10 Paclitaxel 59% 
4.10 Irinotecan 48% 
 
Table 4.1: yield of polymers containing EDANS 
 
 
The size of the polymeric particles was analysed by Dynamic Laser Light Scattering. The 
analysis was performed in DMSO because it allows to solubilize these polymers, in fact 
it was also the porogen solvent used for their synthesis. The size distribution by volume 
of all MIPs and NIP shows particles of around 10 nm (Table 4.2), while the size 
distribution of intensity show also some particles of 100 nm even if the amount of 
these particles is very low since they are not visible in the size distribution by volume of 
NIP 0.10, while a small peak can be seen in the size distribution by volume of MIP 4.10 
and MIP 3.10. As in the previous polymers the bigger particles are probably aggregates 
of nanoparticles.  
 
 
Polymer 
Size 
(nm) 
0.10 11.32 
3.10 13.39 
4.10 12.35 
 
Table 4.2: particles size measured in DMSO 
considering the size distribution by volume 
 
 
Figure 4.3: size distribution by volume of MIP 4.10. Three replicates 
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         Figure 4.4: size distribution by intensity of MIP 4.10. Three replicates 
 
              Figure 4.5: size distribution by volume of NIP 0.10. Three replicates 
 
 
 
 
 
 
 
 
                    Figure 4.6: size distribution by intensity of NIP 0.10. Three replicates 
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Figure 4.7: size distribution by volume of MIP 3.10 
 
 
Figure 4.8: size distribution by intensity of MIP 3.10 
 
The MIP particles are a slightly bigger than NIPs, probably because paclitaxel and 
irinotecan are relative large molecules, and during the imprinting process large cavities 
are likely created in the MIP leading to an increase of their size with respect to the non-
imprinted polymer that contains only non-specific and superficial binding sites. 
 
Quantification of EDANS into the Polymer 
 
The amount of EDANS incorporated into the polymer was calculated by fluorescence 
spectroscopy. This is a useful technique because EDANS is the only fluorescent 
molecule in the polymer. Also since it is a high sensitive technique, it is possible to use 
low polymer concentrations and perform the test in PBS were the polymer is soluble 
only at low concentrations. A calibration curve of EDANS was obtained in PBS exciting 
at 335 nm end measuring the emission at 493 nm. Using this calibration curve, the 
amount of EDANS in 20 µg/mL, 40 µg/mL and 60 µg/mL MIP 3.10 and NIP 0.10 solutions 
in PBS (obtained from a batch solution in DMSO) was calculated. These polymers are in 
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fact soluble in PBS at low concentrations. This measurement was possible because 
EDANS is the only fluorescent molecule in the polymer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3: amount of EDANS calculated into the MIP and NIP 
 
The amount of EDANS found in MIP 3.10 is 60% than that in NIP. This result is also 
confirmed by UV measurements of MIP and NIP in DMSO: in fact in Figure 4.10 the 
absorbance of MIP 3.10 is higher than that of NIP 0.10.  
 
 
 
 
 
Polymer 
Polymer 
concentration 
(µg/mL) 
Florescence 
intensity 
Calculated 
EDANS 
concentration 
(mol/L) 
Mean 
[EDANS] 
(mol/L) in 1 
µg/mL of 
polymer 
ng of EDANS 
in 1 µg of 
polymer 
MIP 3.10 
20 65.46 8.96·10-7 
4.51·10-8 12.00 40 110.61 1.66·10-6 
60 186.25 2.93·10-6 
NIP 0.10 
20 98.09 1.45·10-6 
7.45·10-8 19.83 
40 180.33 2.83·10-6 
60 297.5 4.81·10-6 
y = 6E+07x + 12.324 
R² = 0.9984 
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Figure 4.9: calibration curve of EDANS in PBS 
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Figure 4.10: UV spectrum of 1 mg/mL MIP 3.10 and NIP 0.10 in DMSO 
 
Rebinding Tests of Polymers Containing EDANS 
 
The binding capability of MIP 3.10 and MIP 4.10 was investigated by rebinding tests and 
compared to the EDANS NIP. Tests with MIP 4.10 were performed in PBS to simulate pH 
and osmolality conditions similar to biological samples, and in citrate buffer to study 
the MIP binding capabilities when all irinotecan is in the closed lactone ring form. 
Conversely, the rebinding test with MIP 3.10 was performed only in PBS with 8% of 
DMSO. The employment of DMSO allows to dissolve paclitaxel in aqueous solutions. 
In Table 4.4 the amount of drug captured by polymers is reported taking into 
consideration that the MIPs have 40% of EDANS less than NIPs, as shown in the 
previous section. 
 
Solvent Polymer 
Drug captured 
(nmol/mg of polymer) 
Imprinting 
Factor 
PBS 
MIP 3.10 7.2 1.8 
MIP 4.10 6.0 1.1 
Citrate buffer MIP 4.10 3.5 2.2 
 
Table 4.4: amount of target captured by MIP 3.10 and MIP 4.10 in different solvents, 
after 30 min of incubation, when the equilibrium was reached. 
 
MIP 3.10 represents a good choice for the development of a FRET sensor, since it 
showed a higher binding capability than MIP 4.10 and also a good imprinting factor. 
Conversely the behaviour of MIP 4.10 is strongly dependent on the environment, in fact 
the polymer has a good binding specificity in acidic solutions but the number of 
captured molecules are half than that in PBS buffer.  
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4.2 Towards a FRET System 
 
 
The MIPs containing EDANS can be used for the development of a fluorescence and 
colorimetric test based on the competition between the free drug and a labelled 
analogue of the  drug covalently linked to DABCYL, for the binding into the polymer. 
Since DABCYL is a FRET quencher and a red dye, its interaction with EDANS will give 
both a quenching of polymer fluorescence and a red colour to the MIP. Therefore the 
drug concentration could be quantified by measuring variation of fluorescence and 
colour intensity of the polymer.  
 
Synthesis of DABCYL-Paclitaxel 
 
To develop a fluorescent and coloured test, the DABCYL dye was first covalently linked 
to paclitaxel to obtain a labelled drug.  
The modification was done on the hydroxyl group at position 7 (Scheme 4.2) of 
paclitaxel since it is little involved in the interaction with the functional monomers, as 
observed by previous 
1
H-NMR titrations. Moreover, a long spacer was added between 
paclitaxel and DABCYL to confer more flexibility to the labelled molecule and allow its 
binding inside the polymer. The spacer results from acylation of paclitaxel with succinic 
anhydride at hydroxyl 7, amidation of DABCYL at its carboxyl group, and convergent 
coupling of the two fragments. Several protection steps are required: paclitaxel 
contains three hydroxyl groups but only two are able to react with succinic anhydride, 
since hydroxyl 1 is a tertiary alcohol with high steric hindrance whose reactivity is very 
low. On the contrary, hydroxyl 2’ is a secondary alcohol placed on the easily accessible 
side chain of the drug, therefore the reaction with succinic anhydride will be favoured. 
The group is also involved in the interactions with the functional monomers and it is 
important to maintain this functionality. To this aim the 2’ hydroxyl was first protected 
with tert-butyl-dimethylsilyl chloride to avoid side reactions (yield 91%).
7
 After this 
protection, the 2’-tert-butyl-dimethylsilyl-paclitaxel-7-hemisuccinate (3c) was obtained 
by esterification of hydroxyl 7 of paclitaxel with succinic anhydride in DMF in the 
presence of dimethylaminopiridine (DMAP) that acts as nucleophilic catalyst (yield 
84%).
8
 The 
1
H-NMR spectrum of the resulting product 3c showed the presence of 
aliphatic protons of the succinic linker at 2.61 ppm, the disappearance of the hydroxyl 7 
proton signal at 2.45 ppm and the shift of  proton 7 from 4.42 ppm to 5.62 ppm due to 
deshielding effect of the succinic ester.
9
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The product was then coupled with DABCYL-cadaverine (12c). The intermediate 12c 
was obtained by a coupling reaction of hydroxysuccinimidyl-DABCYL (DABCYL-Osu) and 
Boc-cadaverine. The use of the commercially available reactant DABCYL-Osu allows to 
easily perform the coupling with Boc-cadaverine
10
 in DMF and with the presence of 
N,N-diisopropyl-ethylamine (DIEA) base. The yield of the reaction was 90%. The 
following deprotection of Boc with TFA gives the intermediate 12c (yield 93%).
11
  
 
 
 
 
 
Scheme 4.2: synthesis of 2’-tert-Butyl-Dimethylsilyl-Paclitaxel-7-hemisuccinate  (3c) 
Scheme 4.3: synthesis of DABCYL-cadaverine (12b) 
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The coupling between 3c and 12c was obtained in anhydrous acetonitrile at 0°C with 
triethylamine after addition of HOBt and EDC-Cl (yield 65%). The resulting orange 
product (3d) was deprotected with HF/Py (30% pyridine in 70% HF) anhydrous solution 
at 0°C in pyridine leading to the final product 3e
12
 (yield 80%; total yield 40%)(Scheme 
4.4).  
 
 
   
 
 
 
 
Scheme 4.4: coupling between 12c and 3c followed by removal of tert-butyldimethylsilyl group 
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Fluorescence Titrations of EDANS 
 
The fluorescence properties of EDANS upon interaction with paclitaxel and the 
modified drug were first investigated by fluorescence titrations. This preliminary test 
was performed to verify the ability of DABCYL-paclitaxel (3e) at quenching EDANS and 
ensure that the EDANS fluorescence is not  affected by paclitaxel interaction. A 3.9 µM 
EDANS solution in DMSO was titrated with increasing concentrations of paclitaxel or 
DABCYL-paclitaxel and the intensity at 455 nm, that corresponds to the maximum of 
emission peak, was measured after exciting at 335 nm. The EDANS molecule was used 
instead of vinyl-EDANS (10) because the vinyl-group could interfere on the fluorescence 
properties of EDANS.
13
  
 
 
The Stern Volmer plots obtained by the titration with 3e  and with the free paclitaxel 
show a linear behavior in 2 µM - 300 µM range. As expected, the ratio F0/F, that 
corresponds to EDANS quenching, increased rapidly upon interaction with 3e, leading 
to a high slope in the plot. This behavior is due to FRET mechanism occurring between 
EDANS and DABCYL covalently linked to paclitaxel (3e). Conversely, a low quenching of 
EDANS was observed upon interaction with paclitaxel. Since a linear behaviour was 
observed within all the range of concentrations, it was possible to calculate the 
apparent Stern Volmer constants from the slope of Stern Volmer plot (Figure 20), while 
the apparent quenching constants were calculated by the obtained KSV and the 
fluorescence lifetime of EDANS (12.7 ns)
14
. 
 
y = 772.96x + 1.0533 
y = 42284x + 0.8588 
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Figure 4.11: Stern Volmer plot obtained titrating EDANS with paclitaxel and with DABCYL-
paclitaxel in DMSO 
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Molecule 
KSV
app 
[103 L·mol-1] 
kq
app 
[1012 L·mol-1·s-1] 
Paclitaxel 0.77 0.06 
DABCYL-paclitaxel 42.28 3.33 
 
 
 
The  obtained values indicate also that a static quenching occurs with both paclitaxel 
and DABCYL-paclitaxel, in fact the quenching constants are higher than 1·10
10
. The 
fluorescence quenching led to DABCY-paclitaxel interaction is largely higher than that of 
the free paclitaxel, indicating a correlation between the intensity of the quenching and 
the mechanism of interaction, since DABCYL is a FRET quencher of EDANS. 
 
Fluorescence Titrations of Polymers  
 
The ability of DABCYL-paclitaxel to quenching the EDANS fluorescence in the polymeric 
matrix by FRET mechanism was investigated with both MIP 3.10 and the non-imprinted 
EDANS polymer. The experiment was performed titrating the polymers with increasing 
amounts of DABCYL-paclitaxel in DMSO and measuring the polymer emission intensity 
at 455 nm after exciting at 335 nm. The emission was recorded after 30 min for each 
addition, to allow the diffusion of the modified-drug into the polymeric matrix.  
As shown in the Stern Volmer plot of Figure 4.12 DABCY-paclitaxel was able to give a 
high quenching of MIP 3.10 fluorescence by a FRET mechanism, while the quenching 
with NIP 0.10 was considerably lower especially considering that the NIP has a higher 
number of EDANS molecules than MIP. 
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Figure 4.12: Stern Volmer plot of MIP and NIP emissions in DMSO with DABCYL-paclitaxel 
Table 4.5: apparent Stern Volmer and quenching 
constants for paclitaxel and DABCYL-paclitaxel 
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The apparent polymer binding affinities were investigated by Stern Volmer analysis 
considering a range of concentrations similar to the paclitaxel values found in real 
samples of plasma. These values correspond to the low range of the Stern Volmer plot, 
between 2 µM and 20 µM. The calculated apparent Stern Volmer constants and 
quenching constants in this range are higher than that obtained titrating the free 
EDANS with DABCYL-paclitaxel, as expected in the presence of binding sites. The 
calculated apparent quenching constants reveal a static quenching for both MIP and 
NIP even if the binding affinity of NIP is half than that of MIP. This reveals a higher 
specificity of MIP with respect to NIP and a good efficiency of the imprinting process. 
 
Polymer 
KSV
app 
[103 L·mol-1] 
kq
app 
[1012 L·mol-1·s-1] 
MIP 3.10 63.32 4.99 
NIP 0.10 37.20 2.93 
 
Table 4.6: apparent Stern Volmer and quenching constants of MIP and NIP 
 
 
Competitive Test with MIP 3.10 
 
The previous experiments showed a good capability of DABCYL-paclitaxel to quenching 
MIP 3.10 fluorescence and an increase quenching of MIP with respect NIP due to the 
imprinting process. Therefore the modified drug and MIP 3.10 can be used for the 
setup of a competitive test for paclitaxel quantification. 
To this aim, the first approach consists in the evaluation of the ability of paclitaxel to 
displace the modified drug from the polymer binding sites, restoring the polymer 
fluorescence. MIP 3.10 was first saturated with DABCYL-paclitaxel leading to a 
fluorescence quenching. The addition of increasing amount of free paclitaxel should 
displace the DABCYL-paclitaxel from the binding sites leading to an increase of 
fluorescence. The test was performed using 30 µM concentration of DABCYL-paclitaxel 
to saturate 240 µg/mL MIP and, after 30 min necessary to allow the total incorporation 
of the dye into the polymer, increasing concentrations of paclitaxel were added. The 
intensity of fluorescence emission was measured after 30 min to allow the system to 
reach the equilibrium. In Figure 4.13 the drastic quenching of fluorescence measured 
after addition of 30 µM modified drug is shown. However the MIP fluorescence is not 
restored upon addition of free paclitaxel.    
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Probably this behaviour is due to the creation of a strong complex between the 
modified drug and EDANS into the polymer, preventing the dye displacement by free 
paclitaxel. 
 
 
Reverse Competition Test with MIP 3.10 
 
Considering the negative results of the previous experiment a second approach to 
develop the competitive test was followed. This approach consists of a reverse 
competition test. 240 µg/mL MIP in DMSO was first incubated with 50 µM paclitaxel for 
30 min, and after titrated with increasing amounts of DABCYL-paclitaxel. The same 
experiment was repeated also in absence of free paclitaxel. Comparing the Stern 
Volmer plots of the two titrations, a decrease of the fluorescence quenching of MIP 
treated with paclitaxel was observed. Also the calculated apparent Stern Volmer and 
quenching constants indicated the tendency of MIP treated with paclitaxel to give a 
lower quenching of fluorescence upon addition of dye, with respect the untreated 
polymer (Table 4.7, Figure 4.14).  
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Figure 4.13: first attempt to set up a competitive test: DABCYL-paclitaxel (30µM) is not 
displaced by free paclitaxel 
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Table 4.7: apparent Stern Volmer and quenching constants obtained titrating 
MIP 3.10 with DABCYL-paclitaxel before and after treatment of 50 µM paclitaxel 
 
 
A high difference of quenching between the MIP with and without paclitaxel was 
observed after 200 µM dye added, therefore this value was chosen to set up a 
calibration curve using the reverse competition test. 
The calibration curve was obtained treating 240 µg/mL MIP solutions in DMSO with 
different concentrations of paclitaxel from 1 µM to 50 µM and adding 200 µM DABCYL-
paclitaxel to each solution after 30 min. The fluorescence emission of MIP was 
measured before and after the dye addition. In Figure 4.15 the ratio between the 
fluorescence before addition of DABCYL-paclitaxel (F0) and  after addition of dye (F) is 
plotted in function of the paclitaxel concentration in the analysed samples.   
 
 
 
Polymer 
KSV
app 
[103 L·mol-1] 
kq
app 
[1012 L·mol-1·s-1] 
MIP + 
paclitaxel 
18.92 1.49 
MIP 33.10 2.62 
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Figure 4.14: Stern Volmer plot obtained titrating MIP 3.10 with DABCYL-
paclitaxel, before and after treatment with 50 µM paclitaxel. 
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In the plot the fluorescence quenching of MIP decreases while increasing the paclitaxel 
concentration.  
Moreover, the variation of quenching in this curve is quite high between 1 µM and 30 
µM, and using this reverse competitive test it is possible to distinguish well between 
different paclitaxel concentrations within this range. The dynamic range of this curve is 
within the paclitaxel concentrations usually found in real samples, indicating that this 
reverse competitive test could be used to quantify paclitaxel in real plasma samples. 
However, this requires the capability of the system to perform also in plasma or 
methanol-plasma. 
To investigate this possibility preliminary tests were performed titrating MIP 3.10 with 
increasing concentrations of DABCYL-paclitaxel in 3:1 methanol:plasma. The dye 
capability to quench the EDANS fluorescence in the polymer was maintained also in this 
solvent (Figure 4.16). 
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Figure 4.15: calibration curve of paclitaxel obtained by the reverse competitive 
test in DMSO 
Figure 4.16: Fluorescence quenching of MIP 3.10 upon addition of DABCYL-paclitaxel 
in 3:1 methanol:plasma 
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The comparison of Stern Volmer plots corresponding to the MIP titrations with DABCYL-
paclitaxel in DMSO and in 3.1 methanol:plasma mixture show in both cases a good 
fluorescence quenching. The FRET system with MIP 3.10 and DABCYL-paclitaxel 
represent a valid starting point for the development of a FRET sensor to rapidly 
quantify paclitaxel in plasma samples. Analysis of spiked plasma samples is currently 
being performed in order to setup an analytical methodology. 
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5. Results and Discussion: 
 
A Colorimetric System  
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Part of this PhD project was focused on the development of a colorimetric sensor able 
to easily quantify irinotecan from plasma samples. This project was developed at 
Queen Mary University of London, in the research group of Prof. Marina Resmini during 
a six months secondment. In order to obtain a colorimetric sensor based on molecularly 
imprinted polymers, two different approaches can be followed if the target is not a 
strongly coloured molecule. The first approach consists of the employment of a 
coloured functional monomer in order to obtain a coloured polymer that has to change 
its colour upon interaction with the target. However, since the majority of dyes changes 
colour upon their protonation or de-protonation, the target molecule must be a strong 
acid or base. Otherwise, it is possible to develop a colorimetric test by a dye 
displacement technique, which is based on the competition between the drug and the 
dye for binding inside the polymer. This approach does not require a particularly 
property of the target, but only a higher affinity of the imprinted polymer for the 
analyte than for the dye. Colorimetric tests for analyte quantification based on a dye-
displacement technique have been already developed using molecularly imprinted 
polymers.
1
  
Since irinotecan is not a strongly coloured molecule, the dye displacement technique 
represents the easiest method to obtain a colorimetric test for the quantification of this 
drug. 
 
5.1 Finding the Best Functional Monomer:  
1H-NMR Titrations 
 
The development of a dye displacement test requires first the synthesis of a highly 
specific molecularly imprinted polymer for irinotecan. To this aim, different functional 
monomers were evaluated according to the interactions that they could make with the 
target molecule. 2-acrylamido-2-metylpropane sulfonic acid (AMPS, 17) (scheme 5.1) 
was chosen since it is a strong acid able to protonate free base irinotecan giving an ion 
pair, and also to make hydrogen bonds with the drug. Furthermore this functional 
monomer has been widely used to obtain highly soluble molecularly imprinted 
polymers exploited for the quantification of serotonin,
2
 biotin
3
 and D-phenylalanine.
4
 
The binding affinity of AMPS for irinotecan was also compared to that of 4-vinyl 
benzene sulfonate (4-VBS, 18) and of acrylic acid (19) for the same drug. Acrylic acid is a 
common functional monomer used for the synthesis of imprinted polymers and is able 
to make both hydrogen bonds and ion interactions with the target molecule, 4-vinyl 
benzene sulfonate can make ion interactions with the protonated piperidine moiety of 
protonated irinotecan and π-staking interactions with the drug aromatic rings. 4-vinyl 
benzene sulfonate has been widely used for the synthesis of ion exchange membranes
5
 
or nanoparticles
6
. 
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In order to find the functional monomer able to best interact with irinotecan, 
1
H-NMR 
titrations of protonated drug with increasing amounts of functional monomers were 
performed in different solvents. The force of interactions, in fact, could be dependent 
on the solvent in which the titration is performed. 
In Table 5.1 the variations of chemical shift of each proton of protonated irinotecan 
that best interact with the functional monomers are reported. As expected, 4-VBS 
makes π-staking interactions with the aromatic rings of irinotecan, protons 7, 8 and 10, 
giving a small variation of chemical shift, larger shifts were observed due the 
interaction with the piperidine group of the drug, mostly  with the NH and the adjacent 
protons 20 and 22. Conversely, acrylic acid made only hydrogen bonds with the 
irinotecan NH group and protons 24, 28 of the piperidine group. 
The variation of chemical shifts due to the creation of hydrogen bonds between the 
two molecules is also favoured in non-polar solvents, like deuterated acetone, DMF and 
chloroform, as observed from the entity of shifts obtained from the titrations with 4-
VBS and with acrylic acid in different solvents.  
The interaction of irinotecan with AMPS was stronger than with other functional 
monomers. In fact a high variation of chemical shift was observed for protons of the 
piperidine group and the NH group, and also for protons 8 and 10 probably due to 
hydrophobic interactions or hydrogen bonds with the near carbamate group of the 
drug. 
 
 
 
 
 
  
 
 
2-Acrylamido-2-
methylpropane sulfonic acid  
(AMPS, 17) 
4-vinyl-benzene sulfonate sodium 
salt  (4-VBS, 18) 
Acrylic acid 
(19) 
Scheme 5.1: functional monomers 
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Functional 
monomer 
Solvent 
 H of di-piperidine group after
5eq of functional monomer added 
  H of aromatic rings after 5eq 
of functional monomer added 
H 24/26 H20/22 H23/19 NH H8 7 H10 
4-VBS 
DMSO-d6 0 0.0336 0 0.3017 0.00165 0.00345 0.00055 
MeOD 0 0 0.03785 0.0105 0.03015 0.0136 
Acetone+  
40% DMF-d7 
0.0453 0.0242 0.0142 
D2O 0 0        0 0.0236 0.0172 
DMF-d7 0 0.0434 0 0 0.0028 0.0028 0.0028 
acrylic 
acid 
DMSO-d6 0 0 0 0 0 0 0 
MeOD 0.0059 0        0 0.0008 0.0013 0.00085 
CDCl3 +  
6% AcCN-d3 
0.0177 0 0 0.2146 0.01025 
AMPS DMSO-d6 0.0114 0.03885 0.0191 0.7032 0 0.0017 0.0037 
Table 5.1: variation of proton chemical shifts of irinotecan due to the addition of 5 equivalents of 
AMPS in different solvents 
Figure 5.1: a) variation of protons chemical shifts of irinotecan-HCl upon interaction with AMPS; b) shifts 
of NH of irinotecan in DMSO-d6 
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To further improve the interactions between the functional monomers and the drug, 
the titrations were repeated also with free base irinotecan. Irinotecan hydrochloride 
was first neutralized by NaOH and extracted in DCM to obtain free base irinotecan with 
a good yield (91%). The product was titrated with increasing amounts of acrylic acid and 
of AMPSA. In both the titrations the variation of protons chemical shifts of the 
piperidine group became larger with respect than with protonated irinotecan.  
Moreover, the titration curves obtained from the shifts of these protons upon addition 
of AMPS, reach the plateau after only 1 equivalent added, indicating that a strong 
interaction occurs. This interaction consists of the proton transfer from the sulfonic 
acid group of AMPS to the piperidine group of free base irinotecan, in fact the 
appearance of the NH signal of irinotecan salt was also observed during the titration. 
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Figure 5.2:a) variation of proton chemical shift of free base irinotecan upon interaction with AMPS; 
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Functional 
monomer 
Solvent 
 H of di-piperidine group after 
 5eq of functional monomer added 
 H of aromatic rings after 5eq 
of functional monomer added 
 H 24/26  H20/22  H23/19 H8 H7 H10 
acrylic acid 
CDCl
3
 
0.5367 0.23685 0.0542 0.0085 0.0164 0.0083 
CD
2
Cl
2
 
0.5758 0.3333 0.108 0.0239 0.0105 
AMPS DMSO-d6 
0.1768 0.11055 0.01565 0.0214 0.0084 
Table 5.2: variation of proton chemical shifts of free base irinotecan upon interaction with 5 
equivalents of AMPS 
Therefore AMPS was chosen to obtain a highly selective molecularly imprinted polymer 
for irinotecan. Moreover, since AMPS is a strong acid with a pKa of 1.9,
7,8
 it could 
protonate the aniline yellow dye (pKa of 2.28)
9
 giving a change of colour from yellow to 
red. The interaction between aniline yellow and sulfonate salts is already reported in 
literature.
10
 So a molecularly imprinted polymer containing AMPS and the aniline 
yellow dye could be used to set up a colorimetric test where the amount of drug 
captured by the polymer is quantified observing the colour of the sample.  
 
5.2 Synthesis of Molecularly Imprinted Polymers for 
Irinotecan 
Molecularly imprinted polymers containing different amounts of AMPS, acrylamide or 
N-isopropylacrylamide as co-monomer and N,N’-methylenebisacrylamide as crosslinker
were synthesized in DMSO. The use of N-isopropylacrylamide allows to increase the
polymer solubility in water
11, 12
 even if it is already improved with respect the previous
polymers thanks to AMPS functional monomer. The choice of the amount of AIBN was
Scheme 5.2: aniline yellow dye: change of colour from yellow to red in acidic conditions 
pH < 2.28 
pKa = 2.28 4-aminoazobenzene (Aniline yellow)
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fundamental to obtain a good yield of polymerization. As first approach polymers were 
synthesized using only 1% of radical initiator, however very low yields were observed in 
particular for the imprinted polymers. Therefore  the amount of AIBN was increased to 
5% leading to a good yield of polymerization for both MIPs and NIPs. Finally the CM was 
fixed at 0.5% in weight respect to the weight of DMSO to obtain soluble nanoparticles 
and avoid aggregation. 
In table 5.3 the composition and yield of MIPs and NIPs containing AMPS is shown. 
Polymer 
Irinotecan 
[mg] 
Functional 
monomer 
Co-
monomer 
Cross-
linker 
AIBN Solvent of dialysis Yield 
0.0 - - Acrylamide 30% 
MBA 
70% 
1% H2O+HCl pH=2 95% 
0.15a - 
AMPS  
10% 
Acrylamide 20% 
MBA 
70% 
1% 
1) MeOH: AcCOOH 
2) H2O 
43% 
0.15b - 
AMPS  
5% 
Acrylamide 25% 
MBA 
70% 
1% 
1) MeOH: AcCOOH 
2) H2O 
95% 
0.15c - 
AMPS  
10% 
Acrylamide 20% 
MBA 
70% 
5% 
1) MeOH AcCOOH 
2) H2O+HCl pH=2 
88% 
0.15d - 
AMPS  
5% 
Acrylamide 25% 
MBA 
70% 
5% 1) MeOH AcCOOH 
2) H2O+HCl pH=2 
61% 
0.15e - 
AMPS  
10% 
NIPAM 
20% 
MBA 
70% 
5% 
1) MeOH AcCOOH 
2) H2O+HCl pH=2 
91% 
4.15a 16.2 
AMPS  
10% 
Acrylamide 
20% 
MBA 
70% 
1% 
1) MeOH: AcCOOH 
2) H2O 
18% 
4.15b 7.4 
AMPS  
5% 
Acrylamide 
25% 
MBA 
70% 
1% 
1) MeOH:AcCOOH 
2) H2O 
1% 
4.15c 15.0 
AMPS  
10% 
Acrylamide 
20% 
MBA 
70% 
5% 
1) MeOH AcCOOH 
2) H2O+HCl pH=2 
75% 
4.15d 13.2 
AMPS  
5% 
Acrylamide 
25% 
MBA 
70% 
5% 
1) MeOH AcCOOH 
2) H2O+HCl pH=2 
50% 
4.15e 15.0 
AMPS  
10% 
NIPAM 
20% 
MBA 
70% 
5% 
1) MeOH AcCOOH 
2) H2O+HCl pH=2 
89% 
Table 5.3: polymer composition and yield 
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After synthesis, the polymerization mixture was dialyzed to remove both side products 
and the template molecule.  First polymers were dialyzed in methanol:acetic acid 
mixture that is necessary to remove irinotecan from the polymeric matrix, and then in 
water. However the sulfonic acid group dissociates at neutral pH in water. Therefore, 
since the retention of the acidic functionality in the polymer is necessary to perform 
the colorimetric test, the polymer was further dialyzed in acidic water. The pH of water 
was kept at 2 because this is the lower pH supported by the dialysis membrane; at this 
pH the sulfonate groups of the polymer are protonated, since their pKa increases with 
respect the free functional monomer.
13
 In fact the polymeric matrix around the sulfonic 
groups decreases the polarity of their environment leading to an increase of the 
sulfonic acid pKa.   
The removal of irinotecan from the polymeric matrix was difficult since highly specific 
binding sites were created. First attempts were performed dialyzing only with methanol 
and after in water but the majority of template remained inside the polymer. Therefore 
different mixtures of methanol:acetic acid or methanol:TFA were tested on MIP 4.15a. 
After synthesis, 2.3 mL of the polymerization mixture in DMSO were dialyzed only in 
water as reference,  the remaining solution was divided in four samples. The first one 
was 50% diluted with a 7:3 methanol:acetic acid mixture, stirred overnight and then 
dialyzed in water with 10% of 7:3 methanol:acetic acid mixture (washing n°1). The 
second sample was directly dialyzed in 7:3 methanol:acetic acid mixture changing the 
mixture twice (washing n°2). The third sample was  dialyzed in 7:3 methanol:TFA 
mixture (washing n°3) and finally the last one  was dialyzed in 6:4 methanol:acetic acid 
mixture changing the mixture twice (washing n°4). After each washing step, all samples 
were dialyzed in water and freeze-dried. The obtained MIPs were analysed by UV-
visible spectroscopy and compared to the MIP dialyzed only in water. The UV 
absorbance of MIP solutions in DMSO was measured at 363 nm, the irinotecan 
characteristic absorption. The amount of drug still inside the polymer was calculated 
from the measured absorption using a calibration curve of irinotecan in DMSO.  
As shown in Figure 5.3 the best removal of template was achieved with 6:4 
methanol:acetic acid mixture. Therefore this mixture was used to wash all imprinted 
polymers until complete removal of the drug. 
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Figure 5.3: comparison between the UV spectra of 0.125 mg/mL MIP 4.15a 
solutions in DMSO after different washing steps. 
5.3 MIP Characterization 
Dynamic Laser Light Scattering 
The particle size of the polymers dissolved in water solutions were measured by DLLS. 
All the solutions showed the presence of a majority of particles of about 10 nm size, 
and a low number of bigger particles that probably corresponds to aggregates of 
nanoparticles. The polymer solubility was increased with respect the polymers 
previously synthesized, thanks to the use of AMPS functional monomer, nevertheless 
the  tendency to aggregate occurs also in these polymers.  
Some measurements were also performed with polymers in DMSO in the attempt to 
decrease the number of aggregates. However, also in this case some aggregates were 
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Table 5.4: amount of irinotecan in the MIP, 
calculated by the calibration curve 
y = 20187x + 0.003 
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Figure 5.4: calibration curve of free base irinotecan in DMSO 
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observed while the dimensions of the majority of particles were around 10 nm as 
observed in water.  
Finally, the presence of irinotecan in the polymerization mixture of MIP affects also the 
particle size, in fact the majority of imprinted polymers are smaller than the respective 
non imprinted polymer. 
5.5a 
5.5b 
5.5c 
5.5d
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Table 5.5:polymer size obtained from the size distribution by volume, in 
water and in DMSO 
Z-potential
The zeta potential of nanoparticles was measured to verify the incorporation of the 
sulfonic acid groups inside the polymeric matrix. In fact these groups dissociate in water 
giving negative charges in the polymer.  
When a charged particle moves in solution there is a thin layer of counter ions, called 
Stern layer,
14
 that is close to the particle and moves with it, while increasing the 
distance from the particle, the charges are less firmly attached to the surface and does 
not move with the particle, leading to a diffuse layer. The zeta potential is the potential 
measured at the boundary between the Stern layer and the diffuse layer.
15
 This 
boundary is called slipping plane. In practice, the zeta potential is calculated form the 
Solvent Polymer 
Size 
(nm) 
water 
4.15d 10.19 
0.15d 15.57 
4.15c 7.53 
0.15c 15.14 
4.15e 6.21 
0.15e 12.84 
DMSO 
0.15c 14.48 
4.15e 10.21 
0.15e 12.10 
5.5e
Figure 5.5: measurements by DLLS: a) size distribution by intensity of NIP 0.15c, b) size distribution by 
volume of NIP 0.15c, c) size distribution by volume of MIP 4.15c, d) size distribution by volume of MIP 
4.15e, e) size distribution by volume of NIP 0.15e 
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Henry equation after measuring the electrophoretic motility that corresponds to the 
measure of particles velocity during their movement towards the electrode of opposite 
charge.  This velocity was obtained measuring the fluctuating intensity of light scattered 
by the particles during their movement to the electrode of opposite charge. The rate of 
the fluctuations is proportional to the particles velocity. The Henry equation is: 
 
   
        
  
 
 
Where z is zeta potential, UE is the electrophoretic motility, ε is the dielectric constant 
and η is the viscosity and f(Ka) is the Henry function.
16 
The zeta potential is usually measured to verify also the stability of particles 
suspension, in fact values more positive than +30 mV or more negative than -30 mV are 
associated to stable suspensions. If the particles have intermediate values between -30 
mV and +30 mV of zeta potential, there is no enough force to allow the repulsion of 
particles having the same charge, therefore they tend to aggregate.17  
 The zeta potential of all MIPs and NIPs synthesized is negative and the values between 
-24 mV and -17 mV indicate that the polymer suspensions are not highly stables. This 
result is consistent with the presence of aggregates observed by DLLS measurements. 
 
  
Polymer mV  
4.15d -21.40 
0.15d -20.85 
4.15c -19.97 
0.15c -24.45 
4.15e -17.35 
0.15e -17.4 
Table 5.6: zeta potential 
of polymers in water 
 
 
 
IR Spectroscopy of Polymers 
 
The incorporation of AMPS in the polymeric matrix was also evaluated by IR 
spectroscopy, and the characteristic bands corresponding to the asymmetric stretching 
of S=O bond between 1180 cm-1 and 1200 cm-1 and the band at 1038 cm-1 of symmetric 
stretching of S=O was observed in all polymers. 18, 19, 20 
 
Figure5.6: zeta potential of NIP 0.15e in water 
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5.4 Recognition of Irinotecan 
 
 
The polymer binding capability was investigated by rebinding tests with MIP 4.15e and 
NIP 0.15e in different solvents. In particular the MIP performance was first evaluated in 
water since we aimed to use this polymer for irinotecan quantification in plasma.  
1.5 mL of 50 µM irinotecan solution were treated with 1.5 mg of MIP and after different 
times the amount of captured drug was measured by a HPLC method. Since at neutral 
pH the sulfonic acid groups in the polymer are in their anion form and irinotecan 
hydrochloride is used in this test to allow drug solubility, a ion pair can be created 
inside the polymer binding site. As shown in Figure 5.8, MIP 4.15e reaches the 
equilibrium within one hour capturing 8 nmol/mg of irinotecan and is able to hold the 
drug during the time. The amount of drug captured by NIP 0.15e is near to zero, 
therefore an imprinting factor of 22 was calculated, assuming that the number of 
binding sites of the MIP is the same of NIP. This value is higher than that obtained from 
MIPs previously synthesized and suggest a good efficiency of the imprinting process.  
 
 
 
1038 cm-1 : 
symmetric 
stretching of S=O 
1180-1200 cm-1 : 
asymetric stretching 
of S=O 
Figure 5.7: IR spectrum of NIP 0.15c 
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The rebinding test was also performed in citrate buffer at pH=3 to study the polymer 
binding capability when all irinotecan is in the protonated form with the closed lactone 
ring. The amount of drug captured by both MIP 4.15e and NIP 4.15e in this solvent is 
very low and near to zero.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These results were also compared to the recovery of irinotecan free base in 
acetonitrile, using the same polymer and irinotecan concentrations of previous tests. 
The binding kinetics of MIP 4.15e is similar to that of NIP 0.15e capturing 30 nmol per 
mg of polymer after 5 h when the equilibrium is reached. The rebinding capability in 
acetonitrile is over 3 times higher than in water, in fact MIP 4.15e was synthesized 
using irinotecan free base as template molecule. Also in these conditions the sulfonic 
acid group of AMPS in the polymer can protonate irinotecan free base giving a strong 
interaction. The similar behavior observed for both MIP and NIP may be due to the MIP 
tendency to aggregate in acetonitrile, decreasing the number of accessible binding sites 
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Figure 5.8: rebinding kinetics of protonated irinotecan with MIP 4.15e and NIP 0.15e in water 
 
Figure 5.9: rebinding kinetics of protonated irinotecan with MIP 4.15e and NIP 0.15e in 
citrate buffer 
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to irinotecan. To verify this hypothesis the test was repeated decreasing the polymer 
concentration at 0.5 mg/mL to avoid aggregation and increasing the drug concentration 
to 100 µM to facilitate the rebinding process. In these conditions the imprinted 
polymer reaches the plateau after 3h and captures 100 nmol of drug per mg of 
polymer, NIP 0.15e captures only 40 nmol after 3h, so the imprinting factor  is greatly 
increased. Since a high irinotecan rebinding and a good selectivity was guaranteed 
using these polymer and drug concentrations, they could be taken in consideration for 
the development of a preliminary colorimetric test in acetonitrile.  
 
 
  
 
Cross Reactivity Tests  
 
Since MIP 4.15e showed a high specificity in water, cross reactivity tests were also 
performed in this solvent. The tests consist in the quantification of the drug captured 
by 1.5 mg of MIP 4.15e suspended in 1.5 mL of 50 µM water solution of sunitinib or 
paclitaxel. 
As shown in Figure 5.11, MIP 4.15e has a good selectivity, since the amount drug 
captured is very low with respect to the amount of protonated irinotecan captured.  
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Figure 5.10: a) rebinding kinetics of irinotecan free base in acetonitrile with 1 mg/mL MIP 4.15e and 
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The good binding specificity and selectivity of MIP 4.15e observed in water make this 
polymer potentially useful for the drug quantification in plasma samples. 
 
 
5.5 Towards a Colorimetric Test 
 
Choice of the Best Solvent 
 
In order to develop the colorimetric test for irinotecan quantification, the interaction 
between the aniline yellow dye and AMPS functional monomer was first investigated in 
different solvents.  Aniline yellow dye (20 µM) was titrated with increasing amounts of 
AMPS in different solvents to find the solvent in which the proton transfer from the 
sulfonic acid to the dye is best visible, giving a change of colour. In fact the neutral form 
of this dye is yellow,  its protonated form is red.
21,
 
22
 
As shown in Figure 5.12, the change of colour of aniline yellow dye from yellow to red 
corresponds to the decrease of intensity of its absorption peak at 370 nm and the 
simultaneous appearance of the peak at 500 nm. However, this change occurs only in 
non-polar solvents as DCM and acetonitrile, while in all polar solvents like water, 
methanol and DMSO the dye remains yellow even after 10 equivalent of acid added. 
This behaviour could be explained considering that the pKa of aniline yellow is 2.8, 
therefore the dye is protonated by AMPS but the protonated aniline yellow 
immediately transfers its proton to water. Therefore the resulting colour of the solution 
is yellow. Probably the proton exchange from aniline yellow to solvents molecules 
occurs also in other polar solvents like methanol and DMSO where a low amount of 
Figure 5.11: selectivity test of MIP 4.15e with paclitaxel and sunitinib in water 
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water is usually present. Conversely, in acetonitrile and in DCM the proton transfer 
occurs only between the sulfonic acid group and the dye, giving an immediate 
response. 
 
Figure 5.12: Titrations of 20 µM aniline yellow with AMPS from 0.5 to 10 or 20 eq in different solvents. 
The best colour variation was observed in acetonitrile where all the dye was protonated 
after 10 equivalents of AMPS added. Moreover, the extinction coefficient of both 
neutral and protonated form of dye is higher in acetonitrile than in other solvents, 
allowing to work with low concentrations, in fact the change of colour is well visible 
both by UV-vis spectroscopy and by the necked eye with 10 µM dye (Figure 
5.13).Therefore acetonitrile was chosen as the best solvent to set up the colorimetric 
systems. 
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Since the final aim is the irinotecan quantification in plasma samples, but is impossible 
to perform the colorimetric test in water environment, we exploited also the possibility 
to perform the test diluting plasma or aqueous irinotecan samples in acetonitrile. This 
approach requires first to find of the maximum quantity of water that the test could 
support when performed in acetonitrile.  
To this aim 20 µM aniline yellow solution in acetonitrile was first titrated with 
increasing concentrations of AMPS until the complete saturation of dye. The titration 
was followed by UV visible spectroscopy. After 24 equivalents of AMPS added, only the 
red peak is visible. Starting from this condition, small amounts of water were added, 
from 0.5% to 10% volume.  
The UV spectrum showed a large decrease of the peak at 500 nm and an increase of the 
peak at 400 nm after 2% of water added.  
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yellow 
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Figure 5.13: top: UV-visible titration of aniline yellow 10 µM in AcCN with increasing 
concentrations of AMPS from 0.5 eq to 10 eq; bottom: pictures of the obtained solutions. 
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Figure 5.14: titration with water of 20 µM aniline yellow solution containing 24 equivalents of 
AMPS in acetonitrile 
 
This experiment proved that the colorimetric test does not support the presence of 
water even in minimum quantities. Therefore a new strategy is necessary to quantify 
irinotecan from plasma samples using the colorimetric test in acetonitrile. A possible 
solution may be the addition of a sample treatment step before performing the 
colorimetric test. The step consists of drying small amounts of blood or plasma samples 
at room temperature and recover irinotecan in. To this aim cartridges able to treat and 
dry small amounts of patients’ blood or plasma are already commercialized.
23,24,25 
 
Treatment of Plasma Samples 
 
To evaluate this sample treatment step aimed to recover irinotecan in acetonitrile, a 
first attempt was preformed drying 5 µL of plasma spiked with  different concentrations 
of  irinotecan in the 250 nM – 750 M range (corresponding to the expected amounts 
in real samples), and recovering the drug in 1 mL of acetonitrile, after sonication. 
However the amount of drug captured was very low maybe because the majority of 
irinotecan is still bounded to plasma proteins. Therefore the experiment was repeated 
treating with methanol plasma samples containing irinotecan, in order to unfold and 
remove proteins. The resulting 3:1 methanol:plasma solution was dried at room 
temperature and dissolved in the same volume of acetonitrile. After sonication, the 
amount of irinotecan recovered from dried plasma was quantified by HPLC.  
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Even if this is a very preliminary experiment, its result is encouraging and a reasonable 
trend in recovery accuracy is observed. Further work aimed at optimizing the system 
and coupling the sample preparation with the colorimetric test is currently going on in 
cooperation with the industrial partner. 
 
The colorimetric test that we aimed to set up can be based on two different 
approaches. The first consists of the drug quantification by measuring the dye 
displacement from the polymer binding sites upon interaction with irinotecan. This 
approach exploits the increased binding affinity of MIP for irinotecan than that for the 
dye. The second approach consists first of the treatment of the sample containing 
irinotecan with a polymer suspension in acetonitrile and after of the measurement of 
the sample colour due to addition of aniline yellow dye. In this way the dye colour in 
the sample is dependent on the amount of drug captured by the polymer. In the 
absence of drug all the polymer binding sites, containing AMPS, are able to protonate 
aniline yellow leading to a red colour. If the entire polymer is saturated with irinotecan, 
all the sulfonic acid groups will interacts with the drug, therefore aniline yellow will be 
not protonated.    
 
UV-titration of MIP 4.15c  
 
Following the first approach the irinotecan ability to displace the dye from the polymer 
binding sites was evaluated by UV-visible titration. The experiment was performed 
treating MIP 4.15c with 40 µM aniline yellow and measuring the UV spectrum before 
and after addition of increasing concentrations of irinotecan free base in acetonitrile.  
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Figure 5.15: recovery of irinotecan from dried plasma after 
treatment with methanol 
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In this case an intense red colour is observed at the starting point due to the interaction 
between MIP and aniline yellow, the colour intensity decreases increasing the drug 
concentration. In Figure 5.16 the absorbance intensity of the sample at 500 nm is 
plotted in function of the drug concentration added to the sample. The obtained curve 
is linear in the 100 µM- 600 µM range. 
The observed decrease in the absorbance intensity of peak at 500 nm and consequent 
change of colour from red to yellow is due to the displacement of the dye from the 
polymer binding sites due to the binding of irinotecan. The test also verified a good 
affinity of MIP 4.15c  for irinotecan. 
Qualitative Colorimetric Test with MIP 4.15d 
In order to set up the colorimetric test also the second approach was evaluated. To this 
aim a first qualitative experiment was performed treating 1 mL of 400 µM free base 
irinotecan solution in acetonitrile with 2 mg of MIP 4.15d and adding , after 10 min,  
aniline yellow to a 40 µM final concentration. The colour of the sample was compared 
to that of a polymer solution containing the same concentrations of MIP and aniline 
yellow but without the drug. As shown in Figure 5.17 the sample containing irinotecan 
remained yellow since all the polymer binding sites are occupied by the drug, while the 
sample untreated with the drug, has a more red colour. This colour increases its 
intensity during the time, since MIP 4.15d is composed only by 5% of AMPS and it is not 
completely soluble in acetonitrile, therefore the accessibility of the dye inside the 
binding sites can be difficult leading to a low kinetic. However, after overnight 
incubation, the colour of the sample without irinotecan is completely red, and that of 
the sample saturated with the drug is still yellow.   
y = -449.32x + 0.3059 
R² = 0.9561 
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Figure 5.16: titration of MIP 4.15c treated with aniline yellow, with increasing amounts of 
irinotecan free base in acetonitrile 
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Encouraged by these positive results we focused on the development of a quantitative 
test by UV-visible spectroscopy. 
Choice of Aniline Yellow Concentration 
In order to set up a quantitative test, MIP 4.15e (0.25 mg/mL in acetonitrile) was first 
titrated with different concentrations of aniline yellow dye to find the dye 
concentration necessary to saturate all the polymer binding sites. MIP 4.15e was 
chosen aiming at increasing and speed up the colorimetric response, since this polymer 
is synthesized with a double amount of AMPS with respect to MIP 4.15d, and with N-
isopropyl acrylamide as co-monomer. 
During the titration, the intensity of the peak at 500 nm increases since, increasing the 
dye concentration, aniline yellow is forced to bind inside the polymer. However, at high 
dye concentrations the absorbance peak at 400 nm produced by the unreacted 
molecules becomes large and partially superimpose the peak at 500 nm. Therefore a 
correction was made subtracting the absorbance intensity of different concentrations 
of aniline yellow without polymer measured at 500 nm, to the values obtained during 
the titration. The resulting curve reached the plateau after 200 µM dye. 
d
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Figure 5.17: first colorimetric test in acetonitrile using 2 mg/mL MIP 4.15d, 400 
µM free base irinotecan and 40 µM aniline yellow 
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5.6 Colorimetric Test 
With 0.25 mg/mL MIP 4.15e 
The first colorimetric test was performed adding to a 0.25 mg/mL of polymer 
suspension in acetonitrile different concentrations of free base irinotecan. After 5 min, 
200 µM aniline yellow was added. After recording the UV spectrum, the absorbance 
intensity at 520 nm was corrected subtracting the residual absorbance of the free dye, 
and plotted in function of the irinotecan concentration in the sample. The resulting 
curve showed a linear response from 2 µM to 20 µM drug. 
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Figure 5.19: a) colorimetric test with 0.25 mg/mL MIP 4.15e; b) calibration curve obtained 
from the test  
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In order to increase the intensity of the signal at the starting point and increase the 
sensitivity, the polymer concentration was increased first to 0.4 mg/mL and after to 0.5 
mg/mL. The colorimetric test performed with 0.5 mg/mL polymer suspension and  400 
µM aniline yellow showed a visible change of color from red to yellow increasing the 
irinotecan concentration from 3.6 µM to 112 µM. Moreover, a calibration curve was 
obtained plotting the absorbance at 520 nm of the sample, normalized with the 
absorbance at 520 nm of the sample without irinotecan, in function of the drug 
concentration. The dynamic range of this curve is 3.6 µM-75 µM  
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Figure 5.20 : a) colorimetric test with 0.5 mg/mL MIP 4.15e; b) calibration curve obtained 
from the test  
Figure 5.21: colorimetric test: color variation of samples containing different 
concentrations of irinotecan 
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This colorimetric test with 0.5 mg/mL MIP 4.15e represent a potentially good system to 
quantify irinotecan in real samples, since the drug concentrations usually found in 
patient samples are within the dynamic range of this curve. Therefore this test could be 
used for the development of a point of care device similar to that used for glycaemia 
analysis
26,27
 or pregnancy test
28
, to be used directly by patients for a rapid and easy 
irinotecan quantification. 
From the engineering point of view this requires the development of a portable device 
able to measure the UV absorbance of the sample at 520 nm. To this aim, collaboration 
with the Center of Excellence for Biosensors, Instrumentation and Process Control 
(COBIK) is still in progress.  
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6.1 Instrumentation 
 
Thin layer chromatographies (TLC) were conducted on Merck plastic sheets pre-coated 
with 0.25 mm silica gel 60F-254. TLC plates were examined under UV light or were 
stained with aqueous permanganate solution or iodine vapors. 
Flash chromatography purifications were carry out with Merck silica gel 60 (230-240 
Mesh). 
Melting points were measured on a Büchi SMP-20 apparatus. 
Nuclear magnetic resonance (NMR): 500 MHz 
1
H-NMR and 125 MHz 
13
C-NMR spectra 
were obtained on a Varian 500 spectrometer. All the 
1
H-NMR titrations were 
performed with the Varian 500 spectrometer except for that with AMPS, acrylic acid 
and 4-vinylbenzenesulfonate that were recorded with a Bruker 400 MHz spectrometer. 
The characterization of neutral irinotecan was obtained with a Bruker AV600 
spectrometer. 
Mass spectrometry measurements (MS): electrospray ionization (ESI) spectra were 
collected on a Esquire 400 (Bruker Daltonics) spectrometer. 
Infrared spectra (IR) were recorded on a Perkin-Elmer Avatar 320 FT-IR spectrometer 
on thin films samples over sodium chloride, while IR spectra of polymers were 
performed with a Perkin Elmer Spectrum 65 FT-IR spectrometer. 
High performance liquid chromatography (HPLC) analysis were run on an Agilent series 
1100 liquid chromatograph equipped with Agilent 1100 series variable wavelength 
detector and a Phenomenex reverse phase Luna C18 column. 
Fluorescence measurements were performed with a CARY Eclipse (Varian) 
spectrometer. 
UV-visible spectra were recorded on a UV-1800 spectrometer (Shimadzu) and on a 
CARY-100 UV-visible spectrometer (Varian). 
Particles size were measured first by a NanoSight Ltd LM10 instruments, and after by 
Dynamic Laser Light Scattering (DLLS) on Zetasizer nano-S (Malvern) instrument that 
was used also to measure the z-potential. 
 
6.2 Materials 
 
Chemicals and solvents were purchased from Sigma Aldrich, deuterated solvents from 
Aldrich and Cambridge Isotope Laboratories. Anhydrous dichloromethane was obtained 
drying the solvent over CaCl2 overnight and distillation, while anhydrous pyridine and 
THF were purchased by Sigma Aldrich. When anhydrous conditions were required, 
reaction flasks were flame-dried and placed under a flux of argon.  
Crimp cap Weaton vials used for the polymer synthesis were purchased from Sigma 
Aldrich. 
Spectra/Por3 dialysis membrane MWCO 3500 Da was purchased from Spectrumlabs. 
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Pure drugs: Iriontecan-HCl, Paclitaxel, Sunitinib and SN38 were purchased from 
Bepharm. 
The citrate buffer  pH=3 used for the rebinding tests was obtained  by addition of 18 mL 
of 0.1 M trisodium citrate to 82 mL of 0.1 M citric acid.  
 
 
6.3 Fluorescent MIPs: n. 1.5 - 4.8 
 
Synthesis of Functional Monomers 
 
Methyl 2-acrylamido-3-(4’-hydroxyphenyl)propanoate  
(N-acryloyl L-tyrosine methyl ester; 5b ) 
 
 
 
2.0 g (10.2 mmol) of L-tyrosine methyl ester were dissolved in 150 mL of anhydrous 
DCM and 4.5 mL (32.4 mmol) of triethylamine. After cooling at 0°C, a solution of 
acryloyl chloride (1 mL, 12.3 mmol, 1.2) in 50 mL of DCM was added dropwise and the 
reaction mixture was stirred overnight under anhydrous atmosphere. The solvent was 
removed in vacuum and the crude product was purified by silica gel column 
chromatography (elution with DCM:ethyl acetate from 1:1 to 2.5:7.5) leading to white 
crystals of the product (1.2 g, yield 47%).  
MS-ESI (m/z): 272.0 [M+Na]
+
  
1
H NMR (500 MHz, CDCl3, 25 °C, ppm)  = 3.05 (dd, 
2
J = 14 Hz, 
3
J = 9 Hz, 1H, CH2-3 pro-
R), 3.12 (dd, 
2
J = 14 Hz, 
3
J = 6 Hz, 1H, CH2-3 pro-S), 3.75 (s, 3H, COO-CH3), 4.94 (m, 1H, 
CH-2), 4.68 (dd, 
3
J trans = 10 Hz, 
3
J cis = 1.2 Hz, 1H, CH-c), 5.93 (s, 1H, NH), 6.10 (bb, OH), 
6.09 (dd, 
2
J = 17 Hz, 
3
Jtrans = 10 Hz, 1H, CH2-b), 6.29 (dd, 
2
Jtrans = 17 Hz,
 3
Jcis = 1.2 Hz, 1H, 
CH2-a), 6.73 (d, 
3
J = 8.5 Hz, 2H, CH-2’, 6’), 6.94 (d, 
3
J = 8.5 Hz, 2H, CH-3’, 5’).  
13
C NMR (500 MHz, CDCl3, 25 °C, ppm)  = 37.27 (1C, CH2-3), 52.62 (1C, COO-CH3), 53.49 
(1C, CH-2), 115.69 (2C, CH-2’, 6’), 127.41 (1C, CH-c), 127.70 (1C, CH2-a, b), 130.30 (1C, C-
4’), 130.51 (2C, CH-3’, 5’), 152.32 (C, C-1’), 165.30 (1C, CO-NH), 172.27 (1C, COO-CH3).  
IR (cm
-1
): 1662
 
(C=O), 1721 (C=O), 3318 (N-H). 
mp: 125.6 – 129°C. 
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(S)-methyl 2-acrylamido-3-(1’H-indol-3’-yl)propanoate  
(N-acryloyl L-tryptophan methyl ester 6b) 
 
 
 
 
0.5 g (1.96 mmol) of L-tryptophan methyl ester were dissolved in 10 mL of anhydrous 
DCM and 0.67 mL (4.8 mmol) of triethylamine. After cooling at 0 °C, a solution of 
acryloyl chloride (0.2 mL, 2.3 mmol) in 5 mL of DCM was added dropwise and the 
reaction mixture was stirred overnight under anhydrous atmosphere. The solvent was 
removed in vacuum and the crude product was purified by silica gel column 
chromatography (elution with DCM:ethyl acetate from 8:2 to 5:5) leading to white 
crystals of the product (0.4 g, yield 81%).  
MS-ESI (m/z): 295 [M+Na]
+
 
1
H-NMR (500 MHz, [D6]DMSO, 25 °C, ppm) δ = 3.07 (dd, 
2
J = 14.6 Hz, 
3
J = 8.5 Hz, 1H, 
CH2-3 pro-R), 3.18 (dd, 
2
J = 14.6 Hz, 
3
J = 5 Hz, 1H, CH2-3 pro-S), 3.59 (s, 3H, COO-CH3), 
4.60 (m, 1H, CH-2), 5.60 (dd, 
3
Jcis = 2 Hz, 
3
Jtrans = 10 Hz, 1H, CH-c), 6.07 (dd, 
2
J = 17.11 Hz, 
3
Jcis = 2 Hz, 1H, CH-a), 6.29 (dd, 
2
J = 17.11 Hz,  
3
Jtrans = 10 Hz, 1H, CH-b), 6.98 (td, 
3
Jortho = 
8 Hz, 
4
Jmeta = 1 Hz, 1H, CH-6’), 7.06 (td, 
4
Jmeta = 1 Hz, 
3
Jortho = 4 Hz, 1H, CH-4’), 7.13 (d, 
3
J = 
2 Hz, 1H, CH-2’), 7.33 (d, 
3
Jortho = 8 Hz, 1H, CH-5’), 7.49 (d, 
3
Jortho = 8 Hz, 1H, CH-7’), 8.54 
(d, 
3
J = 8 Hz, 1H, NH amide), 10.85 (s, 1H, NH indole). 
13
C-NMR (500 MHz, [D6]DMSO, 25 °C, ppm) δ = 27.79 (1C, CH2-3), 52.55 (1C, COO-CH3), 
53.21 (1C, CH-2), 110.14 (1C, C-3’), 111.41 (1C, CH-5’), 118.76 (1C, CH-7’), 119.89 (1C, 
CH-4’), 122.41 (1C, CH-2’), 122.90 (1C, CH-6’), 127.29 (1C, CH2-a,b), 127.82 (1C, C-3’a), 
130.56 (1C, CH-c), 136.33 (1C, C-7a), 165.13 (1C, CO-NH), 172.38 (1C, COO-CH3).  
IR (cm
-1
): 1662 (C=O amide), 1737 (C=O ester), 3296 (N-H). 
mp: 49-49.5 °C. 
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2-oxo-2H-chromen-7-yl acrylate  
 (7-acryloyloxycoumarin; 7b) 
 
 
 
0.5 g (3.1 mmol) of 7-hydroxy-coumarin were dissolved in 10 mL of anhydrous DCM and 
1.26 mL (9.1 mmol) of triethylamine. After cooling at 0 °C, a solution of acryloyl chloride 
(0.4 mL, 4.6 mmol) in 7 mL of DCM was added dropwise and the reaction mixture was 
stirred overnight under anhydrous atmosphere. After addition of a saturated solution 
of sodium chloride, a red precipitate was removed by filtration and the remaining 
solution was washed 3 times with a saturated solution of sodium chloride. The organic 
phase was evaporated in vacuum leading to an orange product that was purified by 
silica column chromatography (elution with DCM:petroleum ether:ethyl acetate 2:1:1) 
to yield the pure product as  white crystals (0.6 g, yield 90%).  
MS-ESI (m/z): 238.9 [M+Na]
+
 
1
H-NMR (500 MHz, CDCl3, 25 °C, ppm)  = 6.08 (dd, 
3
Jtrans = 10.5 Hz, 
3
Jcis = 1 Hz, 1H, CH-
c), 6.33 (dd, 
2
J= 17 Hz,
 3
Jtrans = 10.5 Hz, 1H, CH2-b), 6.40 (d, 
3
Jortho = 9.6 Hz, 1H, CH-4), 6.65 
(dd, 
2
J = 17 Hz, 
3
Jcis = 1 Hz, 1H, CH2-a), 7.10 (dd, 
3
Jortho = 8.4 Hz, 
4
Jmeta = 2 Hz, 1H, CH-6), 
7.17 (d, 
4
Jmeta = 2 Hz, 1H, CH-8), 7.50 (d, 
3
Jortho = 8.4 Hz, 1H, CH-5), 7.70 (d, 
3
Jortho = 9.6 Hz, 
1H, CH-3).  
13
C-NMR (500 MHz, CDCl3, 25 °C, ppm)  = 110.57 (1C, CH-8), 116.27 (1C, CH-4), 116.86 
(1C, C-4a), 118.49 (1C, CH-6), 127.44 (1C, CH-c), 128.70 (1C, CH-5), 133.82 (1C, CH2-a, 
b), 142.96 (1C, CH-3), 153.23 (1C, C-7), 154.85 (1C, C-8a), 160.45 (C=O), 163.90 (C=O). 
IR (cm
-1
) : 1734 (2 C=O). 
mp: 136.9-137.5 °C. 
 
1H NMR Titrations 
 
The interaction between the functional monomers and the template molecule were 
investigated by titrating the drug with the functional monomers 5b, 6b, 7b and 4-vinyl 
pyridine (8). In particular, a 7 mM solution of SN38 in [D6]DMSO was titrated with 
increasing amounts of the functional monomer to obtain final concentrations ranging 
from 3.5 mM to 98 mM. A 5 mM solution of paclitaxel in [D6]DMSO was titrated with 
increasing amounts of functional monomers to obtain final concentrations ranging from 
2.5 mM to 70 mM, and a 6.7 mM sunitinib solution in [D6]DMSO was titrated with the 
functional monomers from 3.35 mM to 93.7 mM. Finally, irinotecan-HCl 5.3 mM (3.0 
mg, 4.4 µmol in 840 µL) in [D6]DMSO was titrated with increasing concentrations of 
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functional monomer from 2.6 mM to 74.2 mM. The 
1
H NMR spectrum was recorded 
after every addition. 
 
Recrystallization of AIBN 
 
2.0 g of AIBN were placed in a round-bottomed flask equipped with a stirring bar and a 
condenser. The vacuum and a flow of argon was alternated in the system for 10 times, 
to avoid any trace of oxygen. AIBN was dissolved in 5mL of ethanol and the 
temperature was increased slowly to 50-55 °C. At this temperature 2 mL of ethanol 
were added to solubilize the product. The flask was then left to reach room 
temperature to allow the crystallization.  
 
 
Synthesis of Molecularly Imprinted Polymers  1.5 – 4.8 
 
1 eq of functional monomer and 1.2 eq of the drug were dissolved in a total amount of 
DMSO corresponding to the 99% in weight of total functional monomers and 
crosslinker. After stirring in anhydrous conditions for 40 minutes, the solution was 
transferred in a crimp cap Wheaton vial and 70% (in mol) of N,N’-
ethylenebisacrylamide, 18% (in mol, calculated on the amount of the available double 
bonds) of recrystallized AIBN and 15% (in mol, 1eq) of acrylamide were added. The vial 
was left first under vacuum and then was flushed with argon (3 times for 10 minutes). 
Radical polymerization was achieved heating the vial up to 70°C for 4 days.  Each 
polymer was synthesised either in presence of the template molecule, leading to MIP 
particles, or without the template, leading to NIP. The resulting clear solutions were 
dialyzed against methanol for 2 days and against water for other 2 days, changing the 
solvent 3 times a day. Finally the solution was freeze-dried leading to a fluffy polymer.  
Since a low amount of drug remains entrapped in certain MIPs, they were further 
washed by suspending 2 mg of polymer in 1 mL of methanol; after shaking for 5 min, 
the mixture was centrifuged at 13000 rpm for 10 min. After removal of the 
supernatant, the MIP was resuspended in methanol and the washing step was repeated 
again until the drug was no longer detected  in the supernatant. Finally the MIP was 
dissolved in water and freeze-dried. 
The composition of the polymerization mixtures for each polymer is reported in the 
following table. 
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Polymer 
Drug 
[mg] 
Functional monomer 
[mg] 
Co-
monomer 
[mg] 
N,N-ethylene 
Bisacrylamide 
[mg] 
AIBN 
[mg] 
DMSO 
[mL] 
Yield 
% 
0.5 - 
N-acryloyl-tyrosine-
OMe 
12 
Acrylamide 
3.4 
37.7 16.1 4.8 35 
0.6 - 
N-acryloyl-tryptophan-
OMe 
13.1 
Acrylamide 
3.4 
37.7 16.1 4.9 79 
0.7 - 
7-acryloyloxycoumarin 
10.4 
Acrylamide 
3.4 
37.7 16.1 4.6 92 
0.8 - 
4-vinyl-pyridine 
3.5 
Acrylamide 
2.4 
26 11.1 2.9 94 
1.5 
Sunitinib 
23 
N-acryloyl-tyrosine-
OMe 
12 
Acrylamide 
3.4 
37.7 16.1 4.8 63 
1.6 
Sunitinib 
23 
N-acryloyl-tryptophan-
OMe 
13.1 
Acrylamide 
3.4 
37.7 16.1 4.9 58 
1.7 
Sunitinib 
23 
7-acryloyloxycoumarin 
10.4 
Acrylamide 
3.4 
37.7 16.1 4.6 86 
1.8 
Sunitinib 
23 
4-vinyl-pyridine 
5.0 
Acrylamide 
3.4 
37.7 16.1 4.1 41 
2.5 
SN38 
23 
N-acryloyl-tyrosine-
OMe 
12.2 
Acrylamide 
3.5 
38.3 16.3 4.8 61 
2.6 
SN38 
23 
N-acryloyl-tryptophan-
OMe 
13.3 
Acrylamide 
3.5 
38.3 16.3 4.9 80 
2.7 
SN38 
23 
7-acryloyoxylcoumarin 
10.6 
Acrylamide 
3.5 
38.3 16.3 4.7 90 
2.8 
SN38 
23 
4-vinyl-pyridine 
5.1 
Acrylamide 
3.5 
38.3 16.3 4.2 27 
3.5 
Paclitaxel 
32.9 
N-acryloyl-tyrosine-
OMe 
8.0 
Acrylamide 
2.3 
25.2 10.7 3.2 41 
3.6 
Paclitaxel 
37.6 
N-acryloy-tryptophan-
OMe 
10.0 
Acrylamide 
2.6 
28.8 12.3 3.7 74 
3.7 
Paclitaxel 
23.5 
7-acryloyloxycoumarin 
5.0 
Acrylamide 
1.6 
9 4.5 1 76 
3.8 
Paclitaxel 
34.1 
4-vinyl-pyridine 
3.5 
Acrylamide 
2.4 
26 11.1 2.9 63 
4.5 
Irinotecan 
40.6 
N-acryloyl-tyrosine-
OMe 
12.5 
Acrylamide 
3.5 
39.2 16.7 5.78 68 
4.6 
Irinotecan 
40.6 
N-acryloy-tryptophan-
OMe 
13.6 
Acrylamide 
3.5 
39.2 16.7 5.07 77 
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4.7 
Irinotecan 
40.6 
7-acryloyloxycoumarin 
10.8 
Acrylamide 
3.5 
39.2 16.7 4.8 82 
4.8 
Irinotecan 
40.6 
4-vinyl-pyridine 
5.3 
Acrylamide 
3.5 
39.2 16.7 4.3 45 
 
 
Washing of MIPs 4.5 – 4.8 
 
10 mg of MIP 4.5, 4.6, 4.7 and 4.8 were dissolved in 4 mL of a 7:3 methanol:acetic acid 
mixture and dialyzed first against  the same mixture (2 changes), then against methanol 
only (3 changes) and finally against water (5 changes). After freeze-drying, clean fluffy 
MIPs were obtained.  
 
Nanosight 
 
The non-imprinted polymers 0.5 – 0.8 and the molecularly imprinted 1.5 -1.8 
synthesized for sunitinib were dissolved in water at concentrations ranging from 2 
mg·mL
-1
 to 0.125 mg·mL
-1
 and filtered on 0.22 m filter before the analysis. 
 
Dynamic Laser Light Scattering 
 
All MIPs and NIPs were dissolved in DMSO to obtain a 0.25 mg·mL
-1
 concentration and 
the solution was placed into an ultrasonic bath for 1 h. After filtration on 0.45 µm filter, 
the size distribution by intensity and by volume was recorded in triplicate on a Malvern 
Zetasizer instrument using a 1 mL quartz cuvette  with light path of 1 cm.  
 
Coumarin Content in MIP 1.7 and NIP 0.7 
 
The concentration of coumarin in its polymers was calculated by UV-visible 
spectroscopy.  
The absorbance intensity at 324 nm in the UV-visible spectrum of 60 g/mL and 120 
g/mL polymer water solution, after sonication for 20 min, was measured for the MIP 
synthesized for sunitinib and for the respective NIP (350 L in a quartz cuvette of 1 mL). 
The obtained values were used to calculate the coumarin concentration from a 
calibration curve of coumarin in water. In order to create such curve, the absorbance 
intensity at 324 nm of increasing solutions of 7-hydroxycoumarin from 1 M to 100 M 
in water, was recorded. 
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Rebinding Tests 
 
The rebinding kinetics of the drugs to MIPs were investigated dissolving 1.5 mg of the 
polymer in 1.5 mL of a 50 M drug solution in water. The mixtures were incubated at 
25°C under continuous stirring and 200 L aliquots of the solution were taken after 
different times (from 10 min to 12 h) and enriched with 5 L of a 1 mM quinolinone or 
caffeic acid solution as external standard. This new solution was centrifuged (10000 
rpm for 6 min) to remove the polymer, and the supernatant, containing an unknown 
amount of the drug and 25 M external standard, was analysed by HPLC to quantify the 
drug concentration. The ratio between the area of the drug peak and the reference 
peak in the chromatogram of the sample treated with the polymer was compared with 
that of a reference sample containing only the drug, untreated with the polymer, to 
calculate the amount of drug captured by the polymer.
1
  
 
 
Cross-reactivity Studies 
 
The polymer selectivity was investigated by the same rebinding test by HPLC, however 
in this case the MIPs templated with sunitinib were treated with a 50 M solution of 
SN38 or paclitaxel, while the MIPs for SN38 were treated with 50 M sunitinib or 
paclitaxel, moreover the MIPs synthesised to capture paclitaxel, were treated with 
SN38 or sunitinib. Finally the MIPs synthesized to capture irinotecan were treated with 
50 M sunitinib or paclitaxel or SN38. 
 
Fluorescence Titration of MIPs 1.5 – 4.8 
 
The binding capability of MIPs were also analysed by fluorescence titration of a 60 
g/mL solution of the polymer in water with a small amount of DMSO as shown below, 
with increasing concentrations of the drug. The fluorescence emission of the polymers 
containing tyrosine was analysed at 303 nm, when they are excited at 274 nm, while all 
polymers  containing tryptophan were excited at 280 nm and the emission at 340 nm 
was observed. Finally the fluorescence emission of all polymers containing coumarin 
were analysed at 456 nm when the polymer is excited at 327 nm with exception of the 
polymer templated with paclitaxel whose fluorescence emission of coumarin  was at 
393 nm because of the change of solvent (DMSO). All the  polymers templated with 
sunitinib were dissolved in water with 3% of DMSO and titrated with the drug from 0.5 
M to 88.8 M. Also the polymers templated with SN38 were dissolved in water with 
3% of DMSO with the exception of the polymer containing tryptophan that was 
dissolved in water with 15% of DMSO because of its low solubility. During the titration, 
increasing concentrations of SN38 were added from 0.5 M to 165 M. Finally, all the 
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polymers templated with paclitaxel were dissolved in DMSO and titrated with 
increasing amounts of paclitaxel from 0.1 M to 1 mM in DMSO because of the 
insolubility of paclitaxel in water. 
During all the titrations the excitation and emission slits were set to 10 nm, and the 
emission was averaged over 1s, with the exception of the polymer 2.6 that was 
analysed with 5 nm excitation slit; while the polymers 1.7 and 2.7 were analysed with 
both the slits at 5 nm. 
The presence of low amounts of DMSO as co-solvent during the titrations was also 
evaluated measuring the polymer emission after increasing additions of DMSO. The 
fluorescence emission is not affected by DMSO.    
 
Fluorescence Titration of Fluorophores 
 
Titration of Boc-tyrosine 
 
The fluorescence of Boc-tyrosine was measured at an excitation wavelength of 274 nm 
and emission wavelength of 303 nm, slit set at 10 nm, average time of 1s. About the 
titration with SN38, to a 2.1 M solution of Boc-tyrosine in water with 3% of DMSO, 
different amounts of SN38 from 0.5 M to 165 M were added. While for the titration 
with sunitinib, increasing amounts of the drug, from 0.5 M to 88 M, were added to a 
3.2 M solution of Boc-tyrosine in water with 3% of DMSO. 
Finally the titration with paclitaxel was performed in DMSO by the addition of the drug 
from 0.1 M to 1 mM, to a 25.5 M solution of Boc-tyrosine in DMSO. In this case the 
fluorescence emission at 303 nm was observed with the emission slit set at 5 nm. 
 
Titration of Boc-tryptophan 
 
in all the titrations of Boc-tryptophan the fluorescence was measured at an excitation 
wavelength of 280 nm and at an emission wavelength of 340 nm. The titration with 
sunitinib (from 0.5 M to 88 M) was performed with a 510 nM solution of Boc-
tryptophan in water with 3% of DMSO. The fluorescence was measured with slits set at 
10 nm, average time of 1s. In the titration with SN38 (from 0.5 M to 165 M), a 1.5 
M solution of Boc-tryptophan in water with 15% of DMSO was used and the 
fluorescence was measured with excitation slit set at 5 nm and average time of 1s. 
Finally a 3 M solution of Boc-tryptophan in DMSO was also titrated with paclitaxel 
(from 0.1 M to 1 mM) with excitation slit set at 5 nm, average time of 1s. 
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Titration of 7-hydroxy-coumarin 
 
Sunitinib: to 400 L of a of 5 M aqueous solution 7-hydroxy-coumarin, increasing 
amounts of sunitinib were added (from 0.5 M to 73 M) and the quenching of 
fluorescence was measured at an excitation wavelength of 327 nm, emission at 456 
nm, excitation slit 2.5 nm, average time of 1s. SN38: 350 L of a 1 M solution of 7-
hydroxy-cumarin in water with 3% of DMSO were titrated with SN38 from 0.5 M to 
212 M. The solution was excited at 327 nm and the fluorescence emission at 456 nm 
was observed with slits set at 5 nm, average time of 1s. Paclitaxel: 400 L of 1 M 7-
hydroxy-coumarin in DMSO was titrated with paclitaxel (from 0.1 M to 1 mM) and the 
fluorescence quenching was measured at 393 nm exciting at 327 nm with silts of 10 
nm. 
 
Fluorescence Properties of MIP 4.7 
 
The fluorescence properties of MIP 4.7 and of the corresponding NIP were investigated 
by fluorescence spectroscopy exciting the polymer at 327 nm and measuring the 
emission from 350 nm to 600 nm with excitation and emission slits of 5 nm. Using these 
conditions fluorescence spectra were recorded for 60 µg/mL MIP and NIP solutions in 
4:1DMSO:water, obtained by dilution of the 1 mg/mL in DMSO. The emission spectra of 
the polymers were compared to that of 1 µM 7-hydroxycoumarin solutions in DMSO, in 
water and in 4:1DMSO:water, obtained by dilution from the 7.4 mM mother solution in 
DMSO (1.2 mg, 7.4 µmol in 1 mL), and to that of 1 µM irinotecan solution in DMSO 
(batch solution: 4 mM, 1.7 mg, 2.5 µmol in 625 µL of DMSO). 
 
Fluorescence Titrations of MIPs 4.5 and 4.6 
 
The quenching of fluorescence of the MIPs and NIPs synthesized to capture irinotecan 
and containing tyrosine-OMe and tryptophan-OMe was investigated by fluorescence 
titrations with the drug. 
1 mg of polymer was dissolved in 1 mL of DMSO. After sonication for 30 min, a 60 
µg/mL polymer solution was obtained in 4:1 DMSO:water by dilution from the 1 mg/mL 
mother solution. The  solution was titrated with increasing amounts of irinotecan from 
1 µM to 100 µM using a 4 mM (1.7 mg, 2.5 µmol, in 625 µL of DMSO:water 4:1) 
irinotecan batch solution. 
In  the titration of the polymers containing tyrosine-OMe, the emission intensity at 318 
nm when the polymer was excited at 274 nm was measured setting the  excitation and 
emission slits respectively at 10 and 20 nm. The fluorescence emission of the polymers 
containing tryptophan-OMe was measured at 350 nm exciting at 280 nm with 
excitation and emission slits of 10 nm.  
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The polymers containing  tryptophan-OMe were also titrated in citrate buffer at pH=3. 
In this case the 1 mg/mL polymer solution in DMSO was diluted to the 60 µg/mL in 
citrate buffer and increasing amounts of irinotecan from 1 µM to 100 µM were added 
in the cuvette from the 4 mM drug solution in citrate buffer (1.7 mg, 2.5 µmol, in 625 
µL of citrate buffer). The titration was performed exciting at 280 nm and measuring the 
emission at 357 nm with excitation and emission slits set respectively at 15 nm and 20 
nm. 
 
Fluorescence Titration of Irinotecan with MIPs 
 
400 µL of 1 µM irinotecan in 3:1 DMSO:water (obtained by dilution from the 400 µM 
mother solution in DMSO) were titrated with MIP 4.6 and with MIP 4.5 from 0 µg to 4 
µg final amount in the cuvette using the 10 µg/mL, 50 µg/mL, 250 µg/mL MIP solutions 
in 3:1 DMSO:water and 1 mg/mL polymer solutions in DMSO. The fluorescence 
emission of irinotecan at 430 nm exciting at 360 nm was measured before and after the 
addition of polymer using excitation and emission slits of 5 nm. 
The 10 µg/mL, 50 µg/mL, 250 µg/mL MIP 4.5 solutions in 3:1 DMSO:water and 1 mg/mL 
polymer solutions in DMSO were also used to titrate 400 µL of 0.25 µM, 0.5 µM, 1 µM 
and 4.25 µM irinotecan in treated 3:1 methanol:plasma. The methanol:plasma 
solutions were obtained by addition of three volumes of methanol to one volume of 
plasma, and  3 centrifugation runs  for 10 min at 13000 rpm at 4 °C. The 0.25 µM, 0.5 
µM, 1 µM and 4.25 µM irinotecan solutions were obtained by dilution in treated 3:1 
methanol:plasma of the 2.95 mM mother drug solution (2 mg of irinotecan, 2.95 µmol 
in 1 mL of water). The excitation and emission wavelength were respectively 360 nm 
and 430 nm while the excitation and emission slits were 5 nm for the 0.5 µM and 1 µM 
irinotecan titrations, 5 nm and 10 nm for the 0.25 µM drug titration and 5 nm and 2.5 
nm for the 4.25 µM irinotecan titration. 
 
Calibration Curve with MIP 4.5 
 
MIP 4.5 was used to create a calibration curve by fluorescence spectroscopy to quantify 
irinotecan from samples of plasma after treatment with three volumes of methanol and 
centrifugation at 13000 rpm for 10 min at 4 °C to remove proteins. 2 µg of MIP 4.5 
(obtained from a 1 mg/mL batch polymer solution in 3:1 DMSO:water) were added to 
samples containing different concentrations of irinotecan from 0.5 µM to 8 µM in 3:1 
methanol:plasma (irinotecan batch solution 3.1 mM in water: 2.1 mg, 3.1 µmol in 1 
mL). The fluorescence emission of irinotecan was measured at 430 nm before and 30 
min after the addition of polymer, exciting at 360 nm with excitation and emission slits 
of 5 nm for 0.5 µM, 1 µM, 2 µM and 1.5 µM drug, while excitation slit of 5 nm and 
emission slit of 2.5 nm were used for 3 µM, 4 µM and 8 µM drug concentrations. 
Fluorescence emission spectra were also recorded between 370 nm and 600 nm. 
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Validation Test of MIP 1.7 
 
1 mg/mL solution of MIP 1.7 in DMSO was diluted to a final  60 g/mL concentration  in 
4:1 DMSO:water. In order to obtain the calibration curve, 400 L of the 60 g/mL MIP 
solution were titrated with increasing amounts of sunitinib (from 1 M to 154 M) with 
a 4 mM and a 400 M sunitinib mother solution in 4:1 DMSO:water. 
The spiked samples at 5 M, 50 M and 80 M sunitinib were made diluting the 4 mM 
or the 400 M sunitinib solution in PBS with 50 mg/mL HSA or in plasma. After the 
addition of 4 volumes of DMSO and the MIP (the final polymer concentration was 60 
g/mL), the fluorescence emission was measured at 456 nm after excitation at 327 nm 
with excitation and emission slits of  5 nm. 
 
A fluorescent Polymer for Irinotecan 
 
Synthesis of 2-allyl-6-bromo-1H-benzo[de]isoquinoline-1,3(2H)-dione (16b) 
 
 
 
 
312 mg (1.13 mmol, 1 eq) of 6-bromobenzo[de]isochromene-1,3-dione (16) were 
dissolved in 7 mL of ethanol and the resulting solution was heated up to 55 °C under 
continuous stirring; at this temperature 89 µL of allyl amine (68 mg, 1.19 mmol, 1 eq) 
were added. The mixture was refluxed for four hours and the reaction was monitored 
by TLC using a 1:1 dichloromethane:ethyl acetate mixture as mobile phase. After 
cooling at room temperature, the solid was filtered, washed with ethanol and dried 
under vacuum. 239 mg (yield 67%) of light brown powder were obtained.  
ESI-MS (m/z): 338.4 and 340.3 [M+Na]
+
, 355.2 and 357.2 [M+K]
+
 
1
H-NMR (δ, ppm, 500 MHz, CDCl3): 4.79 (d, 
3
J= 6 Hz, 2H, CH2-d), 5.21 (dd, 
3
Jcis= 10.2 Hz, 
1H, 
4
J= 1.2 Hz, CH2-1b ), 5.32 (dd, 
4
J= 1.4 Hz, 1H, 
3
Jtrans= 17.2 Hz, CH2-1a ), 5.98 (m, 1H, 
CH-c), 7.85 (t, 
3
Jorto= 7.4 Hz, 
3
Jorto= 7.4 Hz, 1H, CH-8), 8.04 (d, 1H, 
3
Jorto= 8 Hz, CH-5), 8.42 
(d, 
3
Jorto= 8 Hz, 1H, CH-4), 8.57 (d, 
3
Jorto= 8.5 Hz, 1H, CH-7), 8.66 (d, 
3
Jorto = 7.3 Hz, 1H, CH-
9) 
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13C-NMR (δ, ppm, 500 MHz, CDCl3): 42.68 (1C, CH2-d), 117.97 (1C, CH2-ab), 122.30 e 
123.17 (2C, C-6a, 10), 128.25 (1C, CH-8), 129.21, 130.55 (2C, C-4a, 9a), 130.83 (1C, C-6), 
131.28 (1C, CH-4), 131.50 (1C, CH-5), 132.07 (1C, CH-c), 132.32 (1C, CH-9), 133.54 (1C, 
CH-7), 163.47, 163.49 (2C, C-1, 3) 
 
 
Synthesis of 2-allyl-6-((3-aminoethyl)amino)-1H-benzo[de]isoquinoline-1,3(2H)-dione 
(16c) 
 
A mixture of 645 mg of (16b) (2.04 mmol, 1 eq), 1.63 mL of ethylene diamine (1.47 g, 
d=0.90 g/mL, 24.5 mmol, 12 eq) and 40 mL of ethanol was heated under reflux. The 
reaction was monitored by TLC using a 1:1 dichloromethane:ethyl acetate mixture as 
mobile phase. After 20, 23, 42 and 46 hours, further three equivalents of ethylene 
diamine were added. 66 hours were required to fully complete the reaction. After this 
time the solvent was removed under reduced pressure to obtain a red oil. 60 mL of 
water were added to the oil and the mixture was cooled overnight at 4 °C. The resulting 
solid was filtered, washed with cool water and dried at 60 °C for two days. 553 mg of 
pure 16c were obtained as red solid (yield 92%).  
ESI-MS (m/z): 296.4 [M+H]+ 
1H-NMR (δ, ppm, 500 MHz, CDCl3): 3.18 (s, 2H, CH2-13),  3.41 (d, 
3J= 4 Hz, 2H, CH2-12), 
4.79 (d, 3J= 4Hz, 2H, CH2-d), 5.18 (d, 
3Jcis= 10 Hz, 1H, CH2-b), 5.29 (d, 
3Jtrans= 17 Hz, 1H, 
CH2-a), 6.00 (m, 1H, CH-c), 6.19 (bbd, 1H, NH-11), 6.705 (d, 3Jorto= 8.4 Hz, 1H, CH-5), 
7.62 (t, 3Jorto= 7.6 Hz, 1H, CH-8), 8.18 (d, 
3Jorto= 8.3 Hz, 1H, CH-7), 8.46 (d, 
3Jorto= 8.2 Hz, 
1H, CH-4), 8.59 (d, 1H, 3Jorto= 7.1 Hz, CH-9) 
13C-NMR (δ, ppm, 500 MHz, CDCl3): 40.30 (1C, CH2-13), 42.31 (1C, CH2-d), 44.99 (1C, 
CH2-12), 104.62 (1C, CH-5),  110.29 (1C, C-6a), 117.12 (1C, CH2-ab), 120.65 (1C, C-10), 
123.16 (1C, C-4a/9a), 124.85 (1C, CH-8), 126.49 (1C, CH-7), 130.06 (1C, C-4a/9a), 131.42 
(1C, CH-9), 132.87 (1C, CH-c), 134.81 (1C, CH-4), 149.93 (1C, C-6), 164.03, 164.61 (2C, C-
1, 3) 
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Synthesis of MIP 
 
30 mg of functional monomer 16c (100 µmol, 30% in mol) were dissolved in 6.9 mL of 
DMSO with 41 mg of irinotecan hydrochloride (60 µmol) and stirred for 40 min. After 
this time, ethylene glycol dimethacrylate (EGDMA) (44 µL, 233 µmol, 70% in mol) and 
AIBN (17 mg, 102 µmol) were added. The monomer concentration CM was fixed at 1% 
in weight respect to the weight of DMSO. The mixture was transferred in a crimp cap 
Wheaton vial that was first left under vacuum and after flushed with argon alternatively 
for 4 times. The polymerization occurs heating at 70°C for 4 days. The resulting clear 
solution was dialyzed fist in 7:3 methanol:acetic acid mixture and after in water milliQ. 
After freeze-drying a yellow fluffy polymer was obtained (58.3 mg, yield 77%)(MIP 
4.16). A non imprinted polymer was synthesized having the same composition but 
synthesised in the absence of irinotecan in the polymerization mixture (32.2 mg, yield 
42%). 
 
Fluorescence Titration of MIP 4.16    
 
1 mg of MIP 4.16 was dissolved in 1 mL of DMSO and the resulting solution was diluted 
in 3:1 methanol:plasma to the 60 µg/mL solution. 400 µL of the 60 µg/mL MIP solution 
were titrated with increasing concentrations of irinotecan from 20 nM to 100 µM, using  
a mother irinotecan solution in 3:1 methanol:water mixture (3.2 mg, 4.7 µmol in 1.2 
mL). The emission intensity of polymer at 525 nm was measured when excited at 448 
nm, using excitation slit of 10 nm and emission slit of 5 nm. 
 
 
6.4 A FRET-based MIP 
 
Synthesis of the Functional Monomer 
 
2,5-dioxopyrrolidin-1-yl acrylate    
(N-acryloxysuccinimide; 9) 
 
 
 
1.0 g (8.7 mmol) of N-hydroxysuccinimide was dissolved in 13 mL of DCM and 1.2 mL 
(9.0 mmol) of triethylamine. After cooling at 0 °C, 0.75 mL (9.2 mmol) of acryloyl 
chloride were added dropwise into the solution. The mixture was stirred for 20 min at 0 
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°C and for 1 h at room temperature. The salt created during the reaction as side 
product was removed by filtration, while the solution was washed twice with 8 mL of 
cold water and 8 mL of cold brine. The organic phase was dried with anhydrous sodium 
sulphate and concentrated by vacuum to a 1 mL volume. The concentrated solution 
was cooled at 0 °C, diluted with 2.5 mL of 6:1 hexane:ethyl acetate mixture and stirred 
for 20 min. The white precipitate was collected by filtration and dried under vacuum 
(0.95 g, yield 68 %). 
MS-ESI (m/z): 192 [M+Na]
+ 
1
H-NMR (500 MHz, CDCl3, 25 °C, ppm)  = 2.85 (s, 4H, CH2-3, 4), 6.17 (d, 
3
J=11 Hz, 1H, 
CH-a), 6.32 (dd, 1H, 
3
J=11 Hz, 
3
J=18 Hz, CH-c), 6.70 (d, 
3
J=18 Hz, 1H, CH-b). 
13
C-NMR (500 MHz, CDCl3, 25 °C, ppm)  = 25.83 (2C, CH2-3, 4), 122.94 (1C, CH-c), 
136.11 (1C, CH2-a, b), 160.96 (2C, C-2, 5), 168.87 (1C, CH2=CH-C=O-N). 
 
 
5-((2-acryloylaminoethyl)amino)naphthalene-1-sulfonic acid 
(vinyl-EDANS; 10) 
 
 
 
EDANS (50 mg, 0.18 mmol), sodium hydrogen carbonate (420 mg, 5.0 mmol) and N-
hydroxy succinimidoyl acrylate (38 mg, 0.22 mmol) were dissolved in 25 mL of water. 
The mixture was left at room temperature under stirring for 24 h. After this time 25 mL 
of acetone were added, the resulting precipitates were removed by filtration and the 
solvents were removed under vacuum. The resulting crude was purified by  flash 
chromatography (6:4 DCM:methanol) to obtain 52 mg of a dark yellow solid (yield 86 
%). 
MS-ESI (m/z): 319 [M-H]
- 
1
H-NMR (500 MHz, [D6]DMSO, 25 °C, ppm)  = 3.22 (t, 
3
J=6 Hz, 2H, CH2-1’), 3.49 (t, 
3
J=6 
Hz, 2H, CH2-2’), 5.60 (dd, 
3
Jcis=10 Hz, 
2
J=2 Hz, 1H, CH2-a), 5.75 (s, 1H, SO3H), 6.13 (dd, 
3
Jtrans=17 Hz, 
2
J=2 Hz, 1H, CH2-b), 6.20 (t, 
3
J=5 Hz, 1H, Ar-NH), 6.25 (dd, 
3
Jtrans=17 Hz, 
3
Jcis=10 Hz, CH-c), 6.56 (d, 
3
J=8 Hz, 1H, CH-2), 7.25 (dd, 
3
J=8 Hz, 1H, CH-3), 7.31 (dd, 
3
J=7 
Hz, 
3
J=8 Hz, 1H, CH-7), 7.91 (d, 
3
J=6 Hz, 1H, CH-6), 8.09 (d, 1H, 
3
J=8 Hz, CH-4), 8.10 (d, 
1H, 
3
J=8 Hz, CH-8), 8.45 (t, 
3
J=5 Hz, 1H, NH-CO). 
13
C-NMR (500 MHz, [D6]DMSO, 25 °C, ppm)  = 38.12 (1C, CH2-2’), 43.51 (1C, CH2-1’), 
102.40 (1C, CH-2), 115.66 (1C, CH-8), 122.10 (1C, CH-7), 122.60 (1C, CH-4), 124.14 (1C, 
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CH-6), 125.18 (1C, CH2-a, b), 126.03 (1C, CH-3), 129.41 (C, C-4a), 131.6 (1C, CH-c), 
131.76 (1C, C-5), 135.09 (1C, C-8a), 164.79 (1C, C=O). 
IR (cm
-1
): 1620 (N-H), 1654 (C=O), 2916.4 (C-H). 
 
 
Paclitaxel Modification with the DABCYL dye 
 
Tert-butyl 5-aminopentylcarbamate   
(Boc-cadaverine; 11) 
 
 
 
3.0 g (5.3 eq, 29.4 mmol) of 1,5-diaminopentane were dissolved in 40 mL of DCM. 
Maintaining the temperature at 0°C, a solution of di-tert-butyl dicarbonate  in 
dichloromethane (1eq, 5.5 mmol, 1.2 g in 20 mL) was added drop by drop. The solution 
was stirred for 1 h at 0°C and for 1 h at room temperature. The byproduct generated 
during the reaction in the form of a yellow powder was removed by filtration, while the 
remaining solution was evaporated under reduced pressure to obtain a yellow oil. The 
product was dissolved in 20 mL of ethyl acetate and washed with saturated sodium 
bicarbonate and brine. After drying on anhydrous sodium sulphate, the filtered solution 
was dried under reduced pressure to obtain a yellow oil (1.04 g, yield 94%). 
MS-ESI (m/z): 203.1 [M+H]
+
 
1
H-NMR (500 MHz, CDCl3, 25 °C, ppm): δ= 1.30-1.36 (m, 2H, CH2- 3), 1.44 (s, 11H, NH2 
and OC(CH3)3), 1.46-1.49 (m, 2H, CH2- 4), 1.49-1.56 (m, 2H, CH2- 2), 2.68 (t, J
3
=7 Hz, 2H, 
CH2-5), 3.10 (m, 2H, CH2- 1), 4.56 (s, 1H, NH). 
13
C-NMR (500 MHz, CDCl3, 25 °C, ppm): δ= 24.20 (1C, CH2- 3), 28.56 (3C, CH3, OC(CH3)3), 
30.07 (1C, CH2- 2), 33.42 (1C, CH2- 4), 40.54 (1C, CH2- 1), 42.16 (1C, CH2-5), 79.18 (1C, 
OC(CH3)3), 156.16 (1C, C=O). 
IR (cm
-1
): 3335 (N-H), 1697 (C=O).  
 
 
 
 
 
 
 
 
 
 
1 
2 4 
3 5 
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(E)-tert-butyl (5-(4-((4-(dimethylamino)phenyl)diazenyl)benzamido)pentyl)carbamate     
(DABCYL-Boc-cadaverine; 12b)  
 
 
 
To 50 mg (1 eq, 0.14 mmol) of DABCYL-Osu dissolved in 3.2 mL of DMF, a solution of 33 
mg (1.2 eq, 0.2 mmol) of tert-butyl 5-aminopentylcarbamate  in 500 µL of DMF was 
added. After addition of 28.2 µL (1.2 eq, 0.2 mmol) of DIEA the solution was kept 
overnight at room temperature. The progress of the reaction was followed by TLC using 
8:2 DCM:MeOH as mobile phase. After this time DCM was added and the organic phase 
was washed with water and with brine. The organic layer was dried and evaporated to 
obtain the product as a red solid (yield 90%). 
MS-ESI (m/z): 476 [M+Na]
+
  
1
H-NMR (500 MHz, CDCl3, 25 °C, ppm): δ= 1.42 (s, 9H, OC(CH3)3), 1.43 (m, 2H, CH2- 3), 
1.54 (m, 2H,CH2-2), 1.66 (m, 2H, CH2-4), 3.11 (s, 6H, N(CH3)2 ), 3.13 (m, 2H, CH2-1), 3.47 
(t, 
3
J=6 Hz, 2H, CH2-5), 4.59 (s, 1H, NHCOOC(CH3)3 ), 6.28 (s, 1H, NHCOAr), 6.77 (d, 
3
J=9 
Hz, 2H, CH-11, 13), 7.85 (m, 4H, CH-6, 7, 8, 9), 7.91 (d, 
3
J=9 Hz, 2H, CH-10, 12). 
13
C-NMR (500 MHz, CDCl3, 25 °C, ppm): δ=23.72 (1C, CH2-3), 28.49 (3C, C(CH3)3), 29.05 
(1C, CH2-4), 29.56 (1C, CH2- 2), 40.03 (1C, CH2-5), 40.21 (1C, CH2-1), 40.5 (2C, CH3, 
N(CH3)2), 111.58 (2C, CH-11, 13), 122.07 (2C, CH-10, 12), 127.84 (4C, CH-6,7,8,9). 
IR (cm
-1
)= 1629.3 (C=O), 1686.7 (C=O), 2931 (C-H), 3315.9 (N-H amides). 
 
 
(E)-N-(5-aminopentyl)-4-((4-(dimethylamino)phenyl)diazenyl)benzamide 
(DABCYL-cadaverine; 12c) 
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20 mg of compound 12b were dissolved in 5 mL of a 20% solution of TFA in DCM and 
the mixture was kept at room temperature overnight. After removal of the solvent,  the 
resulting crude was dissolved in DCM and washed with saturated sodium hydrogen 
carbonate and dried with Na2SO4 anhydrous. Finally, the solvent was removed to give 
the compound 12c as an orange solid (93%).   
MS-ESI (m/z): 354 [M+H]
+
 
1
H-NMR (500 MHz, CD3OD, 25°C, ppm): δ= 1.49 (m, 2H, CH2-3), 1.72 (m, 4H, CH2-2, 4), 
2.94 (t, 
3
J=7 Hz, 2H, CH2-1), 3.12 (s, 6H, CH3-14, 15), 3.43 (t, 
3
J=7 Hz, 2H, CH2-5), 6.86 (d, 
3
J=9, 2H, CH-11, 13), 7.88 (m, 6H, CH-6, 7, 8, 9, 10, 12). 
13
C-NMR (500 MHz, CD3OD, 25°C, ppm): δ= 23.74 (1C, CH2-3), 28.53 (1C, CH2-4), 28.94 
(1C, CH2-2), 38.89 (2C, CH3-14, 15), 39.37 (1C, CH2-5), 40.23 (1C, CH2-1), 111.32 (2C, CH-
11, 13), 121.61 (2C, CH-7, 9), 125.18 (2C, CH-10, 12), 128.02 (2C, CH-6, 8), 135.2 (1C, C-
C=O), 141.07 (1C, N(CH3)2-Ar-C-N=N), 145.23 (1C, N(CH3)2-C-Ar), 155.57 (1C, N=N-C-Ar-
C=O), 168.74 (1C, C=O). 
IR (cm
-1
)= 1626.7 (C=O), 2920.5 (C-H), 3416.2 (N-H). 
 
 
2’-tert-Butyl-Dimethylsilyl-Paclitaxel (3b) 
 
 
 
 
570 mg (3.8 mmol) of tert-Butyl-dimethylsilyl chloride and 520 mg (7.6 mmol) of 
imidazole were dissolved in 1 mL of anhydrous DMF. 500 µL of the resulting light blue 
solution were added to 100 mg (0.1 mmol) of paclitaxel. The pale yellow solution was 
stirred under a flux of argon for 1h. The reaction was followed by TLC with 1:1 ethyl 
acetate:hexane as mobile phase. Finally 2 mL of DCM were added to the solution and 
the organic phase was washed with brine and  dried. The solvent was removed under 
reduced pressure to obtain 106 mg of a white powder (yield 91%). 
MS-ESI (m/z): 990 [M+Na]
+ 
1
H-NMR (500 MHz, CDCl3, 25 °C, ppm): δ= -0.29 (s, 3H, CH3Si), -0.01 (s, 3H, CH3Si), 0.8 (s, 
9H, (CH3)3CSi), 1.13 (s, 3H, CH3-16), 1.24 (s, 3H, CH3-17), 1.61 (s, OH-C1), 1.69 (s, 3H, 
CH3-19), 1.88 (m, 1H, CH-6b), 1.90 (s, 3H, CH3-18), 2.13 (m, 1H, CH-14a), 2.23 (s, 3H, 
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CH3(CO)C-10), 2.40 (m, 1H, CH-14b), 2.57 (m, 1H, CH-6a), 2.63 (s, 3H, CH3(CO)C-4), 3.82 
(d, 
3
J=7 Hz, 1H, CH-3), 4.22 (d, 
2
J=9 Hz, 1H, CH-20a), 4.33 (d,
 2
J=9 Hz, 1H, CH-20b), 4.44 
(dd, 
3
J=10 Hz, 
4
J=7 Hz, 1H, CH-7), 4.66 (d, 
4
J=2 Hz, 1H, CH-2’), 4.98 (dd, 
3
J=10 Hz, 
4
J= 2 
Hz, 1H, CH-5), 5.71 (m, 2H, CH-3’, CH-2), 6.29 (m, 2H, CH-10, CH-13), 7.04 (d, 
3
J=9 Hz, 
1H, NH), 7.30 (m, 1H, CHp-Ph2), 7.32 (m, 2H, CHm-Ph3), 7.40 (m, 4H, CHm-Ph2, CHm-
Ph1), 7.5 (m, 1H, CHp-Ph3), 7.52 (m, 2H, CHo-Ph2), 7.60 m, 1H, CHp-Ph1), 7.74 (m, 2H, 
CHo-Ph3), 8.14 (m, 2H, CHo-Ph1) 
13
C-NMR (500 MHz, CDCl3, 25 °C, ppm): δ= -5.12 (1C, CH3Si),  -5.90 (1C, CH3Si), 9.73 (1C, 
CH3-19), 15.18 (1C, CH3-18), 20.68 (1C, CH3(CO)C-10), 22.42 (1C, CH3-16), 23.22 (1C, 
CH3(CO)C-4), 25.69 (3C, (CH3)3CSi), 26.89 (1C, CH3-17), 35.75 (1C, CH2-14), 35.92 (1C, 
CH2-6), 45.65 (1C, CH-3), 55.71 (1C, CH-3’), 71.38 (1C, CH-13), 72.16 (1C, CH-7), 75.05 
(1C, CH-2), 75.49 (1C, CH-2’), 75.78 (1C, CH-10), 76.70 (1C, CH-20), 84.58 (1C, CH-5), 
126.60 (2C, CHm-Ph3), 127.09 (2C, CHo-Ph3), 128.19 (1C, CHp-Ph2), 128.89 (2C, CHm-
Ph2), 128.91 (2C, CHm-Ph1), 130.40 (2C, CHo-Ph1), 131.87 (1C, CHp-Ph3), 133.76 (1C, 
CHp-Ph1). 
IR (cm
-1
): 1243.2 (C-O), 1653 (C=O), 1724.4 (C=O), 2955.7 (C-H), 2977.6 (C-H), 3442.6 (O-
H), 3501 (O-H). 
 
 
2’-tert-Butyl-Dimethylsilyl-Paclitaxel-7-hemisuccinate  (3c) 
 
 
 
 
13 mg (1.23 eq, 0.127 mmol) of succinic anhydride, 100 mg (1eq, 0.103 mmol) of 2’-
tertbuthyl-dimethylsilyl-paclitaxel and 126 mg (10 eq, 1.032 mmol) of DMAP were 
dissolved in 4 mL of anhydrous toluene under an argon atmosphere. The mixture was 
kept at 90°C for two days. 
 The reaction was followed by TLC using a 9:1 DCM:MeOH mixture.  
After cooling to room temperature, 10 mL of 0.2% hydrochloric acid were added. The 
solution was extracted with DCM, the organic phase was dried and evaporated to give 
93 mg of pure product (yield 84%). 
MS-ESI (m/z): 1090 [M+Na]
+ 
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1
H-NMR (500 MHz, CDCl3, 25 °C, ppm): δ= -0.30 (s, 3H, CH3Si), -0.03 (s, 3H, CH3Si), 0.80 
(s, 9H, (CH3)3CSi), 1.16 (s, 3H, CH3-16), 1.24 (s, 3H, CH3-17), 1.76 (br, 1H, OH-C1), 1.82 (s, 
3H, CH3-19), 1.85 (m, 1H, CH-6b), 1.97 (s, 3H, CH3-18), 2.15 (s, 3H, CH3(COO)C-10), 2.18 
(m, 1H, CH-14b), 2.41 (m, 1H,CH-14a), 2.57 (s, 3H, CH3(COO)C-4), 2.62 (m, 4H, CH2-α, β), 
2.67 (m, 1H, CH-6a), 3.96 (d, 
3
J=7 Hz, 1H, CH-3), 4.21 (d, 
2
J=9 Hz, 1H, CH-20a), 4.34 (d, 
2
J=9 Hz, 1H, CH-20b), 4.67 (d, 
4
J=2 Hz, 1H, CH-2’), 4.98 (d, 
3
J=9 Hz, 1H, CH-5), 5.62 (dd,
 
3
J=10 Hz, 
4
J=7 Hz, 1H, CH-7), 5.69 (d, 
3
J=6 Hz, 1H, CH-2), 5.72 (dd,
3
J=8 Hz, 
4
J=2 Hz, 1H, 
CH-3’), 6.27 (m, 2H, CH-10,13), 7.32 (m, 1H, CHp-Ph2), 7.43 (m, 4H, CHm-Ph2, CHm-Ph3), 
7.54 (m, 5H, CHm-Ph1, CHo-Ph2, CHp-Ph3), 7.60 (m, 1H, CHp-Ph1), 7.75 (m, 2H, CHo-Ph3), 
8.14 (m, 2H, CHo-Ph1) 
13
C-NMR (500 MHz, CDCl3, 25 °C, ppm): δ= -5.87 (1C, CH3Si), 10.69 (1C, CH3-19), 14.80 
(1C, CH3-18), 20.82 (1C, CH3(COO)C-10), 21.27 (1C, CH3-16), 23.10 (1C, CH3(COO)C-4), 
25.48 (3C, (CH3)3CSi), 26.39 (1C, CH3-17), 29.01 (1C, CH2-α), 29.69 (1C, CH2- β), 33.12 
(1C, CH2-6), 35.52 (1C, CH2-14), 46.78 (1C, CH-3), 55.68 (1C, CH-3’), 71.21 (1C, CH-13), 
71.56 (1C, CH-7), 74.43 (1C, CH-2), 74.96 (1C, CH-2’), 75.33 (1C, CH-10), 76.29 81C, CH-
20), 84.08 (1C, CH-5), 126.32 (2C, CHm-Ph3), 127.15 (2C, CHo-Ph3), 128.11 (1C, CHp-Ph2), 
128.90 (6C, CHo-Ph2, CHm-Ph2, CHm-Ph1), 130.36 (2C, CHo-Ph1), 131.96 (1C, CHp-Ph3), 
133.87 (1C, CHp-Ph1). 
IR (cm
-1
): 1242.3 (C-O), 1653.2 (C=O), 1734 (C=O), 2951.5 (C-H), 3447.1 (O-H). 
 
 
2’-tert-Butyl-Dimethylsilyl-Paclitaxel-7-[3-(5-(4-(4 (dimethylamino) styryl) benzamido) 
pentylcarbamoyl)] propanoate  (3d) 
 
 
 
20 mg (1 eq, 18.7 µmol) of compound 3c were dissolved in 1.5 mL of anhydrous 
acetonitrile and 0.5 mL of triethylamine were added. After cooling at 0°C, 3.8 mg (1.5 
eq, 28.1 µmol) of HOBt and 8.0 mg (2.7 eq, 51.5 µmol) of EDC-Cl were added and the 
solution was stirred at 0°C for 30 min. 
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After this time, 9 mg (1.4 eq, 26.2 µmol) of compound 12c in 4 mL of acetonitrile were 
added and the mixture was stirred for 30 min at 0°C and for 4 days at room 
temperature.  
5 mL of DCM were added and the organic phase was washed first with 5 mL of 0.1% 
sodium hydroxide and then twice with 5 mL of brine. Evaporation of the solvent gave 
an orange oil. The crude was purified by flash-chromatography with a 9:1 DCM – 
methanol mobile phase on silica. 17 mg of compound 3d (65%) were obtained. 
MS-ESI (m/z): 1426 [M+Na]
+ 
1
H-NMR (500 MHz, CDCl3, 25 °C, ppm): δ= -0.3 (s, 3H, CH3Si), 0.02 (s, 3H, CH3Si), 0.80 (s, 
9H, (CH3)3CSi), 1.16 (s, 3H, CH3-16), 1.25 (s, 3H, CH3-17), 1.43 (m, 2H, CH2-28), 1.56 (m, 
2H, CH2-27), 1.66 (m, 2H, CH2-29), 1.67 (s, 3H, CH3-19), 1.81 (s, 3H, CH3-18), 1.88 (m, 1H, 
CH2-6a/b), 2.42 (m, 2H, CH2-14), 2.56 (m, 3H, CH3(COO)C-4), 2.62 (m, 1H, CH2-6a/b), 
2.66 (m, 4H, CH2-22, 23), 3.10 (s, 6H, N(CH3)2), 3.31 (m, 2H, CH2-26), 3.48 (m, 2H, CH2-
30), 3.96 (m, 1H, CH-3), 4.20 (d, 
2
J=9 Hz, 1H, CH2-20b), 4.33 (d, 
2
J=9 Hz, 1H, CH2-20a), 
4.69 (d, 
4
J=2 Hz, 1H, CH-2’), 4.96 (t, 
3
J=9 Hz, 1H, CH-5), 5.61 (m, 1H, CH-7), 5.70 (m, 2H, 
CH-3’, CH-2), 5.91 (t, 
3
J=6 Hz, 1H, NH-25), 6.25 (m, 2H, CH-10, CH-13), 6.43 (m, 1H, NH-
31), 6.74 (m, 2H, CH- 42, 43), 7.07 (d, 
3
J=8 Hz, NH-CO-Ph1), 7.32 (m, 2H, CHp-Ph2), 7.41 
(m, 4H, CHm-Ph2, CHm-Ph3), 7.51 (m, 5H, CHp-Ph3, CHo-Ph2, CHm-Ph1), 7.61 (m, 1H, CHp-
Ph1), 7.75 (m, 2H, CHo-Ph3), 7.87 (m, 6H, CH-34, 35, 36, 37, 40, 41), 8.11 (m, 2H, CHo-
Ph1). 
13
C-NMR (500 MHz, CDCl3, 25 °C, ppm): δ= -5.67 (1C, CH3Si), -5.087 (1C, CH3Si), 11.06 
(1C, CH3-18), 21.64 (1C, CH3-16), 23.06 (1C, CH3(COO)C-4), 23.57 (1C, CH3-19), 24.07 (1C, 
CH2-28), 25.68 (3C, (CH3)3CSi), 28.09 (1C, CH-6a/b), 29.26 (1C, CH2-29),29.57 (1C, CH3-
17), 29.90 (1C, CH2-27), 30.03 (1C, CH2-22, 23), 31.19 (1C, CH2-14), 33.46 (1C, CH-6a/b), 
39.27 (1C, CH2-26), 40.13 (1C, CH2-30), 40.49 (3C, N(CH3)2), 43.52 (1C, C-15), 47.21 (1C, 
CH-3), 55.91 (1C, CH-3’), 71.5 (1C, CH-10), 71.98 (1C, CH-7), 74.9 (1C, CH-2), 75.44 (1C, 
CH-2’), 75.62 (1C, CH-13), 76.69 (1C, CH2-20), 84.24 (1C, CH-5), 111.95 (1C, CH-42, 43), 
122.5 (2C, CH-36, 37), 123.1 (3C, CHp-Ph3, CHo-Ph2), 125.67 (2C, CH-40, 41), 126.72 (1C, 
CHp-Ph2), 127.3 (1C, CHo-Ph3), 128.11 (2C, CH-34, 35), 129.06 (4C, CHm-Ph2, CHm-Ph3), 
129.30 (1C, CHm-Ph1), 130.57 (2C, CHo-Ph1), 132.69 (1C, C-11), 133.9 (1C, CHp-Ph1), 
134.31 (1C, C-Ph3), 134.81 (1C, C-Ph2), 134.95 (1C, C-Ph1), 135.37 (1C, C-33), 138.51 
(1C, CH-12), 152.86 (1C, C-44), 155.28 (1C, C-38), 167.1 (1C, C=O-Ph3), 167.25 (1C, C=O-
Ph1), 167.6 (1C, C-32), 170.04 (1C, COO-C-10), 170.49 (COO-C-4), 172.11 (1C, C-21), 
172.23 (1C, C-24), 172.34 (1C, C-1’), 203.9 (1C, C-9). 
IR (cm
-1
): 1621.2 (C=O), 1725.7 (C=O), 2924.9 (C-H), 2956.2 (C-H), 3347.4 (O-H, N-H). 
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Paclitaxel-7-[3-(5-(4-(4(dimethylamino)styryl)benzamido)pentylcarbamoyl)] 
propanoate    
(DABCYL-paclitaxel; 3e) 
 
 
10 mg (7.12 µmol) of compound 3d  were dissolved in 2 mL of anhydrous pyridine. 
After cooling at 0°C, 12 drops of HF/Py were added and the mixture was stirred for 15 
min at 0°C and for 22 h at room temperature. 10 mL of DCM were added in solution 
and the organic phase was washed twice with 2% HCl  and dried with MgSO4. After 
filtration, the solvent was evaporated to obtain 7 mg of a dark red solid (yield 80%). 
MS-ESI (m/z): 1311 [M+Na]
+
, 1323 [M+Cl]
-
 
1
H-NMR (500 MHz, [D6]DMSO, 25 °C, ppm): δ= 0.98 (s, 3H, CH3-17), 1.04 (s, 3H, CH3-16), 
1.41 (m, 1H, CH2-6b), 1.46 (m, 2H, CH2-28), 1.51 (m, 4H, CH2-27, 29), 1.65 (s, 3H CH3-19), 
1.74 (s, 3H, CH3-18), 1.77 (m, 1H, CH2-14b), 1.88 (m, 1H, CH2-14a), 2.11 (s, 3H, 
CH3(COO)C-10), 2.23 (s, 3H, CH3(COO)C-4), 2.3 (m, 1H, CH2-6a), 2.38 (m, 4H, CH2-22, 
23), 3.07 (s, 6H, CH3-45, 46), 3.49 (m, 4H, CH2-26, 30), 3.70 (d, 
2
J=7 Hz, 1H, CH-3), 4.04 
(s, 2H, CH2-20), 4.59 (d, 
3
J=8 Hz, 1H, CH-2’), 4.70 (s, 1H, OH), 4.96 (d, 
3
J=9 Hz, CH-5), 5.41 
(m, 3H, CH-3’, CH-2, CH-7), 5.89 (t, 
3
J=9 Hz, 1H, CH-13), 6.04 (s, 1H, CH-10), 6.84 (m, 2H, 
CH-42, 43), 7.22 (m, 1H, CHp-Ph2), 7.40 (m, 4H, CHm-Ph2, CHo-Ph2), 7.49 (m, 2H, CHm-
Ph3), 7.55 (m, 1H, CHp-Ph3), 7.63 (m, 2H, CHm-Ph1), 7.71 (m, 1H, CHp-Ph1), 7.80 (m, 4H, 
CH-36, 37, 40, 41), 7.86 (m, 2H, CHo-Ph3), 7.96 (m, 4H, CHo-Ph1, CH-34, 35), 8.52 (m, 
1H, NH-25), 8.93 (d, 
3
J=9 Hz, 1H, NH-31). 
13
C-NMR (500 MHz, [D6]DMSO, 25 °C, ppm): δ= 10.11 (1C, CH3-19), 12.76 (1C, CH3-17), 
13.39 (1C, CH3-18), 20.16 (1C, CH3(COO)C-10), 22.32 (1C, CH3(COO)C-4), 24.03 (1C, CH2-
27), 25.78 (1C, CH3-16), 28.32 (1C, CH2-29), 28.44 (1C, CH2-28), 29.15 (1C, CH2-6), 28.77 
(2C, CH2-22, 23), 32.80 (2C, CH2-30), 39.53 (2C, CH3-45, 46), 45.57 (1C, CH-3), 55.96 (1C, 
CH-7), 69.11 (1C, CH-13), 70.48 (1C, CH-2), 73.27 (1C, CH-2’), 73.68 (1C, CH-3’), 74.37 
(1C, CH-10), 74.68 (1C, CH2-20), 82.37 (1C, CH-5), 111.11 (2C, CH-42, 43), 121.22 (2C, 
CH-41, 42), 124.75 (2C, CH-36, 37), 126.04 (2C, CHo-Ph3), 127.54 (4C, CHm-Ph2, CHo-
Ph2), 127.92 (2C, CHm-Ph3), 128.04 (2C, CH-34, 35), 128.29 (1C, CHp-Ph1), 128.42 (2C, 
CHm-Ph1), 128.70 (1C, CHp-Ph2), 129.20 (2C, CHo-Ph1), 131.08 (1C, CHp-Ph3), 132.69 
(1C, C-11), 134.31 (1C, C-Ph3), 134.81 (1C, C-Ph2), 134.95 (1C, C-Ph1), 135.37 (1C, C-33), 
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138.51 (1C, CH-12), 152.86 (1C, C-44), 155.28 (1C, C-38), 167.1 (1C, C=O-Ph3), 167.25 
(1C, C=O-Ph1), 167.6 (1C, C-32), 170.04 (1C, COO-C-10), 170.49 (COO-C-4), 172.11 (1C, 
C-21), 172.23 (1C, C-24), 172.34 (1C, C-1’), 203.9 (1C, C-9). 
IR (cm
-1
): 1620.9 (C=O), 1735.7 (C=O), 2924 (C-H), 2956 (C-H), 3347.8 (O-H, N-H). 
   
1H-NMR Titration  
 
The interactions between vinyl-EDANS and the template molecule (paclitaxel or 
irinotecan), were investigated by 
1
H-NMR titrations of the drug with increasing 
amounts of functional monomer.  
Paclitaxel (4 mg, 4.69 µmol) was dissolved in 840 µL of [D6]DMSO to obtain a final 5.58 
mM concentration. To the solution different concentrations of vinyl-EDANS were added 
from 2.79 mM to 78.12 mM and the 
1
H-NMR spectrum  was recorded before and after 
every addition. 
The same experiment was performed with 7 mM irinotecan (4 mg, 5.90 µmol in 840 µL 
of [D6]DMSO) and increasing amounts of vinyl-EDANS from 3.5 mM to 98 mM. 
 
Synthesis of MIPs and NIP 3.10 – 4.10 
 
1 equivalent of vinyl-EDANS was dissolved in a total amount of DMSO equal to the 99% 
in weight of total functional monomers and crosslinker with 1.2 eq of drug. After 
stirring in anhydrous conditions for 40 minutes, the solution was transferred in a crimp 
cap Wheaton vial and 70% (in mol) of N,N’-ethylenebisacrylamide,  15% (in mol, 1eq) of 
acrylamide and 18% (in mol, calculated on the amount of the available double bonds) 
of recrystallized AIBN and were added. The vial was left first under vacuum and then 
was flushed with argon (3 times for 10 minutes). After heating at 70°C for 4 days, the 
resulting clear solution was dialyzed against methanol for 2 days and against water for 
other 2 days, changing the solvent 3 times a day. As reference also a non-imprinted 
polymer was synthesized. This polymer has the same composition of MIPs but was 
synthesized without the template molecule.  
After dialysis the polymer solutions were freeze-dried and the MIPs were further 
washed shaking them in methanol  and removing the supernatant by centrifugation 
(13000 rpm for 10 min). Polymers were finally dissolved in water and freeze-dried. The 
composition of the polymerization mixtures for each polymer is reported in the 
following table: 
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Polymer 
Drug 
[mg] 
Functional 
monomer 
[mg] 
Co-
monomer 
[mg] 
N,N-ethylene 
Bisacrylamide 
[mg] 
AIBN 
[mg] 
DMSO 
[mL] 
Yield 
[mg] 
% 
0.10 - 
EDANS 
12.5 
Acrylamide 
2.8 
30.6 13.1 4.1 41% 
3.10 
paclitaxel 
40 
EDANS 
12.5 
Acrylamide 
2.8 
30.6 13.1 4.1 59% 
4.10 
Irinotecan 
40 
EDANS 
15.7 
Acrylamide 
3.5 
38.6 16.5 5.2 48% 
 
 
DLLS 
 
1 mg of polymer was dissolved in 4 mL of DMSO and the mixture was left into an 
ultrasonic bath for 1 h. The resulting solution was filtered on 0.45 µm filter and used for 
DLLS analysis. 
 
Rebinding Tests  
 
1.5 mg of polymer was suspended in 1.5 mL of PBS or citrate buffer at pH=3 with 50 µM 
drug. After different times between 5 min and 5 hours, 200 µL of the supernatant were 
collected and the solution was centrifuged at 13000 rpm for 10 min to completely 
remove the polymer. The obtained supernatant was analyzed by HPLC as reported in 
ref
1
.  The same HPLC methods were applied to create calibration curves of paclitaxel 
and of irinotecan from 0 µM to 100 µM in PBS where each drug concentration was 
measured in 5 replicates. From the obtained calibration curves the the amount of drug 
captured by the polymer was quantified. 
 
Quantification of EDANS into the Polymer 
 
1 mg of MIP 3.10 and NIP 0.10 were dissolved in 1 mL of DMSO and the solution was 
diluted to  20 µg/mL, 40 µg/mL and 60 µg/mL in PBS. The fluorescence emission of the 
resulting solutions was measured at 493 nm with an excitation wavelength of 335 nm 
and both excitation and emission slits of 5 nm.  
The EDANS concentration in the polymer solutions was obtained from a calibration 
curve of EDANS from 0 µM to 7 µM in PBS (all concentrations were made in triplicates), 
using excitation and emission wavelengths of 335 nm and 493 nm and slits of 5 nm.  
Moreover, the absorbance of EDANS into the imprinted and non-imprinted polymer 
was compared by UV-visible spectroscopy using 1 mg/mL polymer solutions in DMSO. 
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Fluorescence Titrations of EDANS  
 
3.9 µM EDANS  obtained by dilution from the 3.7 mM mother solution (1 mg of EDANS, 
3.7 µmol, in 1 mL of DMSO) was titrated by addition of increasing concentrations of 
paclitaxel from 0 µM to 300 µM using the 5 mM, 400 µM and 100 µM paclitaxel 
solutions in DMSO.  
The titration of 3.9 µM EDANS was also performed with DABCYL-paclitaxel (from 0 to 
300 µM) in DMSO using a 500 µM and a 4 mM (1.7 mg, 1.32 µmol in 329.5 µL of DMSO) 
batch solution of modified drug. For both the titrations the emission intensity at 455 
nm was measured when EDANS was excited at 335 nm using excitation and emission 
slits respectively of 5 nm and 10 nm. 
 
Fluorescence Titration of MIP 3.10 and NIP 0.10  
 
1 mg of polymer was dissolved in 1 mL of DMSO and diluted with the same solvent to a 
final 240 µg/mL concentration. This solution was titrated with increasing 
concentrations of DABCYL-paclitaxel from 0 µM to 200 µM using a 1 mM and 500 µM 
modified drug solution in DMSO obtained by dilution of the 4 mM (1.7 mg, 1.3 µmol in 
329.5 µL of DMSO). The emission intensity was measured after 30 min from every 
addition of DABCYL-paclitaxel to promote the interaction between the polymer and the 
modified drug. 
The polymer emission was recorded at 455 nm exciting at 335 nm with excitation and 
emission slits of 5 nm and 10 nm. The titration was performed with both the imprinted 
and the non-imprinted polymer. 
 
Competition Test with MIP 3.10 
 
 MIP 3.10 was used to set up a competition test between the free paclitaxel and 
DABCYL-paclitaxel for the binding with the polymer. The MIP saturation step  was 
performed by the addition of 3 µL of a 4 mM DABCYL-paclitaxel mother solution in 
DMSO to 400 µL of a 240 µg/mL MIP solution in DMSO (obtained by dilution of the 1 
mg/mL batch solution in DMSO) to obtain a polymer solution containing 30 µM 
modified drug. The fluorescence emission of EDANS was measured at 455 nm exciting 
at 335 nm with excitation slit of 5 nm and emission slit of 10 nm, before and after the 
addition of DABCYL-paclitaxel and after waiting for 30 min. 
After saturation, increasing concentrations of free paclitaxel from 0 µM to 500 µM 
were added using a 1 mM (obtained diluting the 4 mM) and 4 mM (1.71 mg, 2 µmol in 
500 µL of DMSO) drug solutions. The titration was performed exciting at 335 nm and 
measuring the emission at 455 nm with excitation and emission slits respectively of 5 
nm and 10 nm, after waiting for 30 min. 
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Reverse Competition Test with MIP 3.10 
 
Investigating the Best DABCYL-paclitaxel Concentration 
 
1 mg of MIP was dissolved in 1 mL of DMSO. Two samples containing 240 µg/mL MIP in 
DMSO were obtained from this solution by dilution. One of these samples was used as 
the reference of the test, while 42.7 µL of 1.17 µM paclitaxel in DMSO were added to 
the second sample to obtain a 50 µM drug concentration. 
The fluorescence emission of these samples with and without the addition of DABCYL-
paclitaxel from 0 µM to 200 µM (using 1 mM and 4 mM DABCYL-paclitaxel solutions in 
DMSO) was measured after 30 min of interaction, exciting at 335 nm and measuring at 
455 nm with excitation slit of 5 nm and emission slit of 7 nm.  
 
Creation of a Calibration Curve 
 
Different samples containing 240 µg/mL MIP and increasing concentrations of free 
paclitaxel from 0 µM to 50 µM were prepared in DMSO. After measuring its 
fluorescence intensity at 455 nm exciting at 335 nm with excitation and emission slits 
respectively of 5 nm and 7 nm, 200 µM DABCYL-paclitaxel was added to these samples 
and their fluorescence emission was measured again after 30 min.  
 
 
6.5 A Colorimetric System 
 
 
1H-NMR Titrations  
 
Irinotecan-HCl 
 
3 mg (4.43 µmol) of irinotecan-HCl were dissolved in 750 µL of deuterated solvent, and 
different equivalents of functional monomer, from 0.5 eq to 5 eq were added. The 
1
H-
NMR spectrum of the drug was compared to that recorded after each addition of 
functional monomer.  
The drug was titrated with sodium 4-vinylbenzenesulfonate in [D6]DMSO, CD3OD, 
(CD3)2CO with 40% DMF-d7, D2O and DMF-d7, while with acrylic acid in [D6]DMSO, 
CD3OD and in CDCl3 with 6% AcCN-d3. Finally the titration was performed also with 2-
acrylamido-2-ethyl-1-propane sulfonic acid (AMPS) in [D6]DMSO. 
The 400 MHz spectrometer was used for all the titrations.  
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Free Base Irinotecan 
 
(S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-
pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate   
irinotecan free base, 4a) 
 
 
 
 
 
 
 
40 mg (1 eq, 59 µmol) of irinotecan hydrochloride were dissolved in 8 mL of water. 
After addition of 48.4 µL of 1.28 M NaOH (1.05 eq, 61.9 µmol), the  irinotecan free base 
was extracted with DCM. Anhydrous  sodium sulfate was added to the organic phase 
and after filtration, the solvent was removed under reduced pressure to obtain a yellow 
solid (31.4 mg, 91%). 
1
H-NMR (600 MHz, CDCl3, 25 °C, ppm): δ= 1.03 (t, 
3
J=7, 3H, CH3-15), 1.40 (t, 
3
J= 8 Hz, 3H, 
CH3-17), 1.48 (m, 2H, CH2-26), 1.64 (m, 6H, CH2-25, 27; CH2-20ax, 22ax), 1.87 (m, 2H, CH2-
14), 1.96 (m, 2H, CH2-20eq, 22eq), 2.59 (m, 5H, CH2-24, 28; CH-21), 2.90 (t, 
3
J= 12 Hz, 1H, 
CH2-19ax), 3.07 (t, 
3
J= 12 Hz, 1H, CH2-23ax), 3.15 (q, 
3
J= 7 Hz, 2H, CH2-16), 3.79 (s, 1H, 
OH), 4.34 (d, 
3
J= 12 Hz, 1H, CH2-19eq), 4.44 ( d, 
3
J= 12, 1H, CH2-23eq), 5.25 (s, 2H, CH2-
12), 5.30 (d, 
2
J= 15 Hz, 1H, CH2-1a), 5.75 (d, 
2
J= 15 Hz, 1H, CH2-1b), 7.58 (dd, 
3
J= 9 Hz, 
2
J= 
3 Hz, 1H, CH-8), 7.63 (s, 2H, CH-5), 7.83 (d, 
4
J= 2 Hz, 1H, CH-10), 8.21 (d, 
3
J= 9 Hz, 1H, 
CH-7). 
13
C-NMR (600 MHz, CDCl3, 25 °C, ppm): δ=7.89 (1C, CH3-15), 14.11 (1C, CH3-17), 24.92 
(1C, CH2-26), 26.25 (4C, CH2-25, 27; CH2-20, 22), 31.34 (1C, CH2-14), 50.27 (3C, CH2-24, 
28), 62.36 (1C, CH-21), 44.09 (1C, CH2-19), 44.43 (1C, CH2-23), 22.90 (1C, CH2-16), 49.51 
(1C, CH2-12), 66.11 (1C, CH2-1), 125.76 (CH-8), 97.56 (1C, CH-5), 114.50 (1C, CH-10), 
132.44 (1C, CH-7), 118.53 (1C, C-13a), 127.31 (1C, C-10a), 127.7 (1C, 11a), 145.26 (1C, 
5a), 147.15 (1C, C-11), 147.34 (1C, C-7a), 150.34 (1C, C-4a), 150.54 (1C, C-6a), 151.66 
(1C, C-9), 153.26 (1C, C-18), 157.75 (1C, C-13), 174.08 (1C, C-3). 
IR (cm
-1
): 1594.6 (C-C aromatics), 1653.2 (C=C), 1717.4 (C=O), 2932.3 (C-H), 3388.4 (O-
H). 
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1
H-NMR Titration of Irinotecan Free Base  
3 mg (5.1 µmol) of irinotecan free base were dissolved in 600 µL of deuterated solvent. 
The 
1
H-NMR spectrum was recorded before and after the addition of increasing 
amounts of functional monomer. The titration was performed in CDCl3 and in CD2Cl2 
with acrylic acid and in [D6]DMSO with 2-acrylamido-2-ethyl-1-propane sulfonic acid.  
 
Synthesis of MIP 4.15 
 
1 eq of  irinotecan free base and 1 eq (10% or 5% in mol) of AMPS were dissolved in 2 
mL of DMSO and stirred for 1 h to allow the interaction between the template and the 
functional monomer. After this time, the solution was placed in a crimp cap Weathon 
vial and the co-monomer acrylamide or N-isopropyl acrylamide (NIPAM) (20% or 25% in 
mol), the crosslinker methylene-bisacrylamide (MBA) (70% in mol), and the radical 
initiator AIBN (5% in mol calculated on the amount of available double bonds) dissolved 
in DMSO were added in solution. The monomer concentration CM was fixed at 0.5% in 
weight respect to the weight of DMSO. After flushing the mixture with argon and 
making vacuum alternatively for 4 times to remove oxygen, the polymerization was 
achieved by heating at 70°C for 4 days. 
A non imprinted polymer was synthesized having the same composition of MIP but 
synthesized in the absence of irinotecan in the polymerization mixture. 
The resulting clear solutions were dialyzed first against 6:4 methanol: acetic acid (three 
changes for two days) and after against milliQ water containing HCl (final pH=2) for 
three days changing the solvent twice a day. The dialyzed solutions were freeze-dried 
to obtain a white fluffy polymer. 
The composition of each polymer is reported in the following table:  
 
 
Polymer 
Irinotecan 
[mg] 
Functional 
monomer 
[mg] 
Co-
monomer 
[mg] 
Cross-
linker 
[mg] 
AIBN 
[mg] 
DMSO 
[mL] 
Solvent of dialysis 
Yield 
[mg] 
0.0 - - 
Acrylamide 
30% 
5 
MBA  
70% 
25.3 
1% 
0.6  
5.5 H2O+HCl pH=2 
28.8 
 (95%) 
0.15a - 
AMPS 10% 
5.7 
Acrylamide 
20% 
3.9 
MBA  
70% 
29.8 
1% 
0.8 
7.1 
1) MeOH: AcCOOH 
2) H2O 
16.8 
(43%) 
0.15b - 
AMPS 5% 
2.6 
Acrylamide 
25% 
4.5 
MBA  
70% 
27.8 
1% 
0.8 
6.2 
1) MeOH: AcCOOH 
2) H2O 
32.7 
(95%) 
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0.15c - 
AMPS 10% 
5.3 
Acrylamide 
20% 
3.6 
MBA 
70% 
27.5 
5% 
3.6 
6.6 
1) MeOH: AcCOOH 
2) H2O +HCl pH=2 
32.1 
(88%) 
0.15d - 
AMPS 5%  
4.7 
Acrylamide 
25% 
8 
MBA  
70% 
48.6 
5% 
6.4 
11.1 
1) MeOH: AcCOOH 
2) H2O+HCl pH=2 
37.4 
(61%) 
0.15e - 
AMPS 10% 
5.3 
NIPAM 
20% 
5.8 
MBA  
70% 
27.5 
5% 
3.5 
7.0 
1) MeOH: AcCOOH 
2) H2O+HCl pH=2 
35.2 
(91%) 
4.15a 16.2 
AMPS 10% 
5.7 
Acrylamid
e 20% 
3.9 
MBA 
70% 
29.8 
1% 
0.8 
7.1 
1) MeOH: AcCOOH 
2) H2O 
7.0 
(18%) 
4.15b 7.4 
AMPS 5% 
2.6 
Acrylamid
e 25% 
4.5 
MBA 
70% 
27.8 
1% 
0.8 
6.2 
 1) MeOH:AcCOOH 
2) H2O 
0.4 
 (1%) 
4.15c 15.0 
AMPS 10% 
5.3 
Acrylamid
e 20% 
3.6 
MBA 
70% 
27.5 
5% 
3.6 
6.6 
1) MeOH AcCOOH 
2) H2O+HCl pH=2 
27.1 
(75%) 
4.15d 13.2 
AMPS 5% 
4.7 
Acrylamid
e 25% 
8.0 
MBA 
70% 
48.6 
5% 
6.4 
11.1 
1) MeOH AcCOOH 
2) H2O+HCl pH=2 
31.0 
(50%) 
4.15e 15.0 
AMPS 10% 
5.3 
NIPAM 
20% 
5.8 
MBA  
70% 
27.5 
5% 
3.5 
7.0 
1) MeOH AcCOOH 
2) H2O+HCl pH=2 
34.2 
 (89%) 
 
Template Removal 
After polymerization of MIP 4.15a, 2.3 mL of the MIP solution in DMSO were dialyzed  
against water only, while to  the remaining MIP solution (4.8 mL) the same volume of 
7:3 MeOH:acetic acid was added and the resulting mixture was stirred overnight. The 
polymer was dialyzed first against water with 10% of 7:3 methanol:acetic acid and then 
against  Millipore water only.  
The polymer was further dialyzed in different mixtures of 7:3 or 6:4 methanol:acetic 
acid or in 7:3 methanol:TFA, and finally dialyzed against MilliQ water.  
After each washing process the polymer was freeze-dried and the amount of irinotecan 
entrapped in the polymer was quantified from a calibration curve of irinotecan free 
base. The calibration curve was obtained measuring the UV-visible absorbance of 
different concentrations of drug in DMSO, from 10 µM to 50 µM, starting from the 1.9 
mM irinotecan free base batch solution in DMSO. The intensity of the characteristic 
peak of irinotecan at 363 nm was plotted in function of drug concentration. 
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1 mg of the washed MIP was dissolved in 1 mL of DMSO to obtain the 1 mg/mL batch 
solution that was further diluted to the 0.125 mg/mL and the 0.612 mg/mL solutions in 
DMSO that were measured by UV-visible spectroscopy.  
 
DLLS 
 
The particle size of NIPs and MIPs were measured by Dynamic Laser Light Scattering 
using a Malvern Zetasizer instrument. 0.5 mg of polymer were dissolved in 2 mL of 
water and left into an ultrasonic bath for 1 h. The solution was filtered on a 0.45 µm 
filter, placed in a 1 mL plastic cuvette  with a 1 cm optical path  and analyzed in 
triplicate. The size distributions by intensity and by volume were recorded. 
Some polymers were also measured in a DMSO solution after sonication and filtration. 
In this case a 1 mL quartz cuvette of was used with a 1 cm optical path . 
 
Z-potential 
 
All the MIPs and NIPs containing AMPS as functional monomer were analyzed by z-
potential to verify the presence of charges on the polymer surface. 0.5 mg of polymer 
was dissolved in 2 mL of water and the solution was placed into an ultrasonic bath for 1 
h. After filtration on 0.45 µm filter, the solution was analyzed in triplicate. 
 
Solid State IR  
 
 NIPs 0.15c, 0.15d and 0.15e were analyzed by IR-spectroscopy to verify the presence of 
the sulfonic acid incorporated into the polymeric matrix. The IR spectrum of NIP 
containing AMPS was compared with the spectrum of a control NIP 0.0 containing only 
acrylamide and MBA . 
IR of NIP 0.15c:  3283 cm
-1
: stretching NH of acrylamide and of AMPS, stretching OH of 
SO3H; 1648 cm
-1
: stretching of C=O of acrylamide and of amide group of AMPS; 1528 
cm
-1
: bending of NH of amide groups; 1449 cm
-1
: bending of C-N bond of amide groups; 
1115 cm
-1 
and 1205 cm
-1
: C-C stretching of polymer, 1021 cm
-1
: symmetric stretching of 
S=O group 
IR of NIP 0.15d: 3284 cm
-1
: stretching NH of acrylamide and of AMPSA, stretching OH of 
SO3H; 1643.7 cm
-1
: stretching of C=O of acrylamide and of amide group of AMPS; 1520 
cm
-1
: bending of NH of amide groups; 1452 cm
-1
: bending of C-N bond of amide groups; 
1201.9 cm
-1
: asymmetric stretching of S=O and C-C stretching of polymer; 1113 cm
-1
: C-
C stretching of polymer; 1038 cm
-1
: symmetric stretching of S=O group. 
IR of NIP 0.15e: 3288 cm
-1
: stretching NH of acrylamide and of AMPSA, stretching OH of 
SO3H; 1643 cm
-1
: stretching of C=O of acrylamide and of amide group of AMPS; 1522 
cm
-1
: bending of NH of amide groups; 1456 cm
-1
: bending of C-N bond of amide groups; 
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1203 cm
-1
: asymmetric stretching of S=O and C-C stretching of polymer; 1111.6 cm
-1
: C-
C stretching of polymer; 1038 cm
-1
: symmetric stretching of S=O group. 
IR of NIP 0.0: 3283 cm
-1
: stretching NH of acrylamide; 1641.8 cm
-1
: stretching of C=O of 
acrylamide; 1521.9 cm
-1
: bending of NH of amide groups; 1449 cm
-1
: bending of C-N 
bond of amide groups; 1205 cm
-1
 and 1111.6 cm
-1
: C-C stretching of polymer. 
 
Rebinding Test with MIP 4.15e and NIP 0.15e 
 
Rebinding of Irinotecan Free Base in Acetonitrile 
 
1.5 mg of MIP 4.15e or NIP 0.15e were suspended in 1.5 mL of a 50 µM solution of 
irinotecan free base in acetonitrile, obtained by dilution of the 1.7 mM mother solution 
(1 mg, 1.7 µmol in 1 mL of AcCN). After different times from 5 min to 7 h, 200 µL of the 
supernatant were collected and centrifuged at 13000 rpm for 10 min. 50 µL of the 
resulting solution were injected into the HPLC for the drug quantification.
1
  
 
Rebinding of Protonated Irinotecan in Citrate Buffer 
 
1.5 mg of MIP 4.15e or NIP 0.15e were dissolved in 1.5 mL of a 50 µM irinotecan 
solution in citrate buffer at pH=3 obtained by dilution of the 1.5 mM mother solution (1 
mg, 1.47 µmol in 1 mL of citrate buffer). After different times from 5 min to 12 h, 200 
µL of the polymer mixture were centrifuged at 13000 rpm for 10 min and 50 µL of the 
obtained supernatant were analyzed by HPLC.
1
  
 
Rebinding of Protonated Irinotecan in Water 
 
1.5 mg of MIP 4.15e or NIP 0.15e were dissolved in 1.5 mL of a 50 µM irinotecan 
solution in water, obtained diluting the 4 mM mother solution (2.7 mg, 4 µmol in 1 mL 
of water). After different times from 5 min to 12 h, 200 µL of the polymer mixture were 
centrifuged at 13000 rpm for 10 min and 50 µL of the obtained supernatant were 
analyzed by HPLC
1
.  
 
Cross Reactivity Tests of MIP 4.15e and NIP 0.15e 
 
1.5 mg of polymer were suspended in 1.5 mL of 50 µM acqueous solutions of paclitaxel, 
sunitinib of SN38. After different times 200 µL of the supernatant were collected and 5 
µL of internal standard (1 mM quinolinone in AcCN for SN38 and paclitaxel, and 1 mM 
caffeic acid in 1:1 water:acetonitrile for sunitinib) were added. After centrifugation at 
13000 rpm for 10 min, 50 µL of the supernatant were analyzed by HPLC
1
. 
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Choice of the Best Solvent for the Colorimetric Test 
 
1 mg of aniline yellow was dissolved in 1 mL of the following solvents: water, DMSO, 
DMF, dioxane, ethyl acetate, THF, acetonitrile and methanol to obtain the 5.1 mM 
batch solutions. These solutions were diluted to  20 µM aniline yellow in the different 
solvents. The 20 µM solution in DCM was obtained from the 5.1 mM dye solution in 
methanol. The diluted solutions were titrated by the addition of increasing amounts of 
AMPS from 1 eq to 10 eq. Since AMPS is not soluble in ethyl acetate, dioxane and DCM, 
the titrations in these solvents were performed with the AMPS batch solution 
respectively in 1:1 DMF:ethyl acetate, in 1:1 DMF:dioxane and 1:1 MeOH:DCM. 
The UV-visible spectrum from 300 nm to 600 nm was recorded without AMPS and after 
each addition of functional monomer. The titration in acetonitrile was repeated also 
with 10 µM dye. 
In order to find  the maximum quantity of water that the system can support, 20 µM 
protonated aniline yellow in acetonitrile was titrated with increasing concentrations of 
water from 0.5% to 10%. Protonated aniline yellow was obtained adding AMPS in 
acetonitrile until complete protonation. The UV spectrum was recorded from 280 nm to 
600 nm after every addition. 
 
Recover of Irinotecan from Dried Plasma 
 
5 µL of plasma containing irinotecan from 3.7 µM to 15 µM were dried in a glass vial 
and  acetonitrile was added to recover irinotecan. The UV spectrum of the obtained 
mixture was recorded before and after sonication. The drug concentration in solution 
was quantified by a calibration curve of irinotecan from 0 to 15 µM  (irinotecan batch 
solution 2.36 mM in AcCN). However the amounts of drug recovered from dried 
samples were very low, so an additional step was added to the test. In particular 
irinotecan solutions in plasma from 1 µM to 30 µM were obtained by dilution with 
plasma of the 2.07 mM (1.4 mg, 2.07 µmol in 1 mL) drug in water. 600 µL of methanol 
were added to 200 µL of irinotecan solutions in plasma, a white solid precipitated and 
the mixture was centrifuged at 13000 rpm for 10 min at 4 °C. After collecting the 
supernatant, the centrifugation and removal of the white solid was repeated twice to 
obtain a clear solution of treated plasma containing irinotecan. 200 µL of drug solutions 
in 3:1 methanol:plasma were spotted on the bottom of a glass vial and the solution was 
dried at room temperature under flux of air. After drying, 200 µL of acetonitrile were 
added and the mixture was left into an ultrasonic bath for 45 min. 50 µL of the solution 
were injected into an HPLC to quantify irinotecan.  
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First Qualitative Colorimetric Test with MIP 4.15d 
 
2 mg of MIP 4.15d containing 5% of AMPS were suspended in 1 mL of AcCN in a vial and 
irinotecan free base was added to obtain a 400 µM drug concentration in the vial. After 
10 min, 40 µM (7.8 µL of 5.1 mM in AcCN ) aniline yellow was added to the mixture. As 
reference 2 mg of the same polymer were suspended in 1 mL of AcCN and treated with 
40 µM aniline yellow without drug. 
Pictures of both the samples were taken immediately before the addition of dye, after 
1 h and after 12 h. 
 
UV-titration of MIP 4.15c  
 
1 mg of MIP 4.15c was suspended in 1 mL of AcCN and the mixture was left in an 
ultrasonic bath for 15 min. After the addition of 40 µM aniline yellow (7.8 µL of 5.1 mM 
in AcCN ), increasing amounts of irinotecan free base were added from 150 µM to 600 
µM (36.1 µL of 4.16 mM irinotecan in AcCN for each addition). UV-visible spectra were 
recorded at each step. 
 
Titration of MIP 4.15e 
 
2 mg of polymer were suspended in 8 mL of AcCN and left into an ultrasonic bath for 90 
min. 1 mL of the suspension was placed in both the reference and the sample cuvette 
to record the baseline correction.  Aniline yellow was  added to the sample cuvette, 
from a 5.63 mM batch solution in acetonitrile to reach final concentrations  from 20 µM 
to 320 µM with 20 µM increments . The UV spectrum was recorded after each addition. 
 
Colorimetric Test with MIP 4.15e 
 
The colorimetric test was performed at different polymer concentrations: 0.25 mg/mL 
(4.0 mg of MIP 4.15e in 16 mL of acetonitrile), 0.4 mg/mL (4.0 mg of MIP 4.15e in 10 mL 
of acetonitrile) and 0.5 mg/mL (5.0 mg of MIP 4.15e in 10 mL of acetonitrile). Each 
polymer suspension was  placed into an ultrasonic bath for 90 min and the baseline 
correction was made with both the reference and the sample cuvette filled with 1 mL 
of the polymer suspension.  
The samples containing 0.25 mg/mL MIP were treated with different amounts of a 
freshly prepared 2.6 mM solution of irinotecan free base in acetonitrile with 28.6% of 
dichloromethane, in order to obtain final drug concentrations from 2 µM to 20 µM. 
After 5 min, 35.5 µL of a freshly prepared 5.63 mM solution of aniline yellow, were 
added to obtain a 200 µM dye concentration. The UV spectrum was recorded from 200 
nm to 800 nm. The samples containing 0.4 mg/mL MIP were treated with irinotecan 
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free base from 4 µM to 80 µM using a 2.6 mM batch solution of drug in acetonitrile 
with 28.6% of dichloromethane. After 5 min aniline yellow was added to the sample 
and the UV spectrum was measured from 200 nm to 800 nm. The final dye 
concentration in cuvette was 320 µM (56.9 µL of 5.63 mM batch solution in 
acetonitrile). 
Finally, to 1 mL of 0.5 mg/mL polymer suspension different concentration of irinotecan 
free base, from 4 µM to 120 µM were added using a 2.6 mM batch solution of 
irinotecan free base in acetonitrile with 28.6% of dichloromethane. After 5 min, 71.1 µL 
of aniline yellow 5.63 mM were added to obtain a 400 µM solution of dye in cuvette. 
The UV spectrum of each sample was recorded from 200 nm to 800 nm maintaining the 
0.5 mg/mL suspension of MIP 4.15e in acetonitrile in the reference cuvette. The peak 
corresponding to the protonated dye is visible at 520 nm. 
 
 
6.6 Characterization of Drugs 
 
(Z)-N-(2-(diethylamino)ethyl)-5-((5'-fluoro-2'-oxoindolin-3'-ylidene)methyl)-2,4-
dimethyl-1H-pyrrole-3-carboxamide (Sunitinib, 1) 
 
 
 
 
1
H-NMR (500 MHz, [D6]DMSO, 25°C, ppm) δ= 0.99 (t, 
3
J = 7 Hz, 6H, N(CH2CH3)2), 2.44 (s, 
3H, CH3C-4), 2.46 (s, 3H, CH3C-2), 2.50-2.57 (m, 6H, CH2N(CH2CH3)2), 3.27 (q, 
3
J = 7 Hz, 
2H, CH2CH2N(CH2CH3)2), 6.85 (dd, 
3
J = 8 Hz, 
4
J = 4 Hz, 1H, CH-7’), 6.93 (dt, 
3
J = 9 Hz, 
4
J = 3 
Hz, 1H, CH-4’), 7.43 (t, 
3
J = 6 Hz, 1H, CO-NH- CH2CH2N(CH2CH3)2), 7.71 (s, 1H, CH-6), 7.76 
(dd, 
3
J = 9 Hz, 
4
J = 2 Hz, 1H, CH-6’), 10.89 (s, 1H, NH-1’), 13.69 (s, 1H, NH-1). 
13
C-NMR (500 MHz, [D6]DMSO, 25°C, ppm) δ= 10.48 (1C, CH3C-4), 11.81 (2C, 
N(CH2CH3)2), 13.32 (1C, CH3C-2), 46.45 (2C, N(CH2CH3)2 ), 51.75 (1C, CH2N(CH2CH3)2), 
36.78 (1C, CH2CH2N(CH2CH3)2), 109.58 (1C, CH-7’), 124.78 (1C, CH-6), 105.47 (1C, CH-6’), 
112.11 (1C, CH-4’), 120.64 (1C, C-3), 124.3 (1C, C-3’a), 125.81 (1C, C-5), 127.54 (1C, C-
3’), 130.09 (1C, C-4), 136.58 (1C, C-1’a), 134.37 (1C, C-2), 164.46 (1C, NHCOC-3), 169.63 
(1C, C-2’), 159.59 (1C, C-5’). 
IR (cm
-1
): 1650 (C=O), 1674.1 (C=O), 2966 (C-H), 3289.9 (N-H). 
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(S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-
3,14(4H,12H)-dione (SN-38, 2) 
 
 
 
 
1
H-NMR (500 MHz, [D6]DMSO, 25°C, ppm) δ= 0.89 (t, 
3
J= 7 Hz, 3H, CH3-15), 1.31 (t, 
3
J= 7 
Hz, 3H, CH3-17), 1.88 (m, 2H, CH2-14), 3.10 (q, 
3
J= 7 Hz, 2H, CH2-16), 5.29 (s, 2H, CH2-12), 
5.43 (s, 2H, CH2-1), 6.49 (s, 1H, OH-C4), 7.26 (s, 1H, CH-5), 7.41 (s, 1H, CH-10), 7.43 (m, 
1H, CH-8), 8.04 (dd, 
3
J= 8 Hz, 
4
J= 2 Hz, 1H, CH-7), 10.31 (s, 1H, OH-C9). 
13
C-NMR (500 MHz, [D6]DMSO, 25°C, ppm) δ= 7.72 (1C, CH3-15), 13.4 (1C, CH3-17), 22.3 
(1C, CH2-16), 30.11 (1C, CH2-14), 49.32 (1C, CH2-12), 65.09 (1C, CH2-1), 72.28 (1C, C-4), 
95.6 (1C, CH-5), 104.45 (1C, CH-10), 117.96 (1C, C-13a), 122.42 (1C, CH-8), 128.06 (1C, 
C-10a), 128.23 (1C, C-11a), 131.47 (1C, CH-7), 140.8 (1C, C-11), 142.68 (1C, C-7a), 
143.55, 146,38 (1C, C-5a), 149.97 (1C, C-4a), 150.05 (1C, C-9), 156.82 (1C, C-13), 172.47 
(1C, C-3).  
IR (cm
-1
): 1583.9 (C-C aromatics), 1653.02 (C=O), 1732.4 (C=O), 2918.1 (C-H), 3350 (O-
H). 
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(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-
phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-
methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b-diyl diacetate   
(Paclitaxel, 3) 
 
 
 
 
1
H-NMR (500 MHz, [D6]DMSO, 25°C, ppm) δ= 1.15 (s, 3H, CH3-16), 1.27 (s, 3H, CH3-17), 
1.69 (s, 3H, CH3-19),  1.80 (s, 3H, CH3-18), 2.25 (s, 3H, CH3COOC-10), 2.33 (m, 2H, CH2-
14), 2.40 (s, 3H, CH3COOC-4), 2.45 (s, 1H, OH), 2.56 (m, 2H, CH2-6), 3.53 (d, 
3
J = 4 Hz, 1H, 
NH), 3.81 (d, 
3
J = 7 Hz, 1H, CH-3), 4.20 (d, 
2
J = 9 Hz, 1H, CH2-20a), 4.30 (d, 
2
J = 9 Hz, 1H, 
CH2-20b), 4.41 (dd, 1H, 
3
J = 8 Hz, 
3
J =11 Hz, CH-7), 4.80 (m, 1H, CH-2’), 4.96 (dd, 
3
J = 10 
Hz, 
4
J = 1 Hz, 1H, CH-5), 5.68 (d, 
3
J = 7 Hz, 1H, CH-2), 5.80 (dd, 
3
J = 9 Hz, 
3
J = 2 Hz, 1H, CH-
3’), 6.24 (t, 
3
J = 9 Hz, 1H, CH-13), 6.28 (s, 1H, CH-10), 6.98 (d, 
3
J = 9 Hz, 1H, NH), 7.36 (dt, 
3
J = 8 Hz, 
4
J =2 Hz, 1H, CHp-Ph2), 7.40 (m, 2H, CHm-Ph1), 7.42 (m, 2H, CHm-Ph2), 7.46 (m, 
2H, CHo-Ph2), 7.50 (m, 1H, CHp-Ph1), 7.51 (m, 2H, CHm-Ph3), 7.60 (dt, 
3
J = 8 Hz, 
4
J =2 Hz, 
1H, CHp-Ph3), 7.74 (dd, 
3
J =8 Hz, 
4
J =2 Hz, 2H, CHo-Ph1), 8.13 (dd, 
3
J = 8, 
4
J =2 Hz, 2H, 
CHo-Ph3).   
13
C-NMR (500 MHz, [D6]DMSO, 25°C, ppm) δ= 9.48 (1C, CH3-19), 14.72 (1C, CH3-18), 
20.44 (1C, CH3COOC-10), 21.85 (1C, CH3-16), 22.27 (1C, CH3COOC-4), 26.92 (1C, CH3-17), 
35.58 (1C, CH2-14), 42.42 (1C, C-15), 45.26 (1C, CH-3), 55.01 (1C, CH-3’), 58.64 (1C, C-8), 
72.06 (1C, CH-7), 72.26 (1C, CH-13), 73.18 (1C, CH-2’), 74.99 (1C, CH-2), 75.47 (1C, CH-
10), 76.35 (1C, CH2-20), 79.05 (1C, C-1), 81.15 (1C, C-4), 84.3 (1C, CH-5), 126.95 (2C, 
CHo-Ph1),127.03 (2C, CHo-Ph2),128.43 (1C, CHp-Ph2), 128.58 (2C, CHm-Ph3), 128.81 (2C, 
CHm-Ph1), 128.95 (2C, CHm-Ph2), 130.1 (1C, C-Ph3), 130.20 (2C, CHo-Ph3), 131.90 (1C, 
CHp-Ph1), 133.5 (1C, C-Ph2), 133.68 (1C, CHp-Ph3), 134.1 (1C, C-Ph1), 134.3 (1C, C-11), 
140.1 (1C, C-12), 166.2 (1C, COOC-2), 167.31 (1C, CONH), 171.07 (1C, COO), 170.37 (1C, 
COO), 180.39 (1C, C-1’), 201.85 (1C, C-9). 
IR (cm
-1
): 1250 (C-O), 1660 (C=C), 1730 (C=O), 2943 (C-H), 3433.1 (O-H). 
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(S)-1-(1-(((4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-
pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl)oxy)carbonyl)piperidin-4-yl)piperidin-1-
ium   (protonated irinotecan, 4) 
 
 
1
H-NMR (500 MHz, CDCl3, 25 °C, ppm): δ= 1.04 (t, 
3
J= 7 Hz, 3H, CH3-15), 1.41 (t, 
3
J= 7 Hz, 
3H, CH3-17), 1.46 (m, 1H, CH2-26ax), 1.88 (q, 
3
J= 7 Hz, 2H, CH2-14), 1.92 (m, 2H, CH2-20ax, 
22ax), 1.95 (m, 1H, CH2-26eq), 2.24 (m, 4H, CH2-25, 27), 2.39 (d, 
3
J= 9 Hz, 2H, CH2-20eq, 
22eq), 2.78 (m, 2H, CH2-24ax, 28ax), 2.96 (t, 
2
J= 12 Hz, 1H, CH2-19ax), 3.13 (m, 1H, CH2-
23ax), 3.15 (q, 
3
J= 7 Hz, 2H, CH2-16), 3.42 (t, 
3
J=11 Hz, 1H, CH-21), 3.59 (d, 
2
J= 10 Hz, 2H, 
CH2-24eq, 28eq), 3.83 (s, 1H, OH), 4.52 (d, 
2
J= 12 Hz, 1H, CH2-19eq), 4.59 (d, 
2
J= 12 Hz, 1H, 
CH2-23eq), 5.26 (s, 2H, CH2-12), 5.31 (d, 
2
J= 17 Hz, 1H, CH2-1a), 5.74 (d, 
2
J= 17 Hz, 1H, 
CH2-1b), 7.56 (dd, 
3
J= 9 Hz, 
4
J=2 Hz, 1H, CH-8), 7.65 (s, 1H, CH-5), 7.84 (d, 
4
J= 2 Hz, 1H, 
CH-10), 8.21 (d, 
3
J= 9 Hz, CH-7), 12.02 (br, 1H, NH). 
13
C-NMR (500 MHz, CDCl3, 25 °C, ppm): δ= 7.80 (1C, CH3-17), 13.97 (2C, CH3-15), 22.35 
(1C, CH2-26), 22.83 (2C, CH2-25, 27), 23.12 (1C, CH2-14), 26.35 (2C, CH2-20, 22), 31.58 
(1C, CH2-16), 42.66 (2C, CH2-19, 23), 49.24 (1C, CH2-12), 49.27 (2C, CH2-24, 28),  63.39 
(1C, CH-21), 66.18 (1C, CH2-1), 72.65 (1C, C-4), 98.12 (1C, CH-5), 114.53 (1C, CH-10), 
118.36 (1C, C-13a), 125.34 (1C, CH-7), 127.18 (1C, C-10a), 127.21 (1C, C-11a), 131.60 
(1C, CH-8), 145.36 (1C, C-11), 145.94 (1C, 7a), 147.6 (1C, C-5a), 150.05 (1C, C-9), 151.44 
(1C, C-6a), 156.99 (1C, C-18), 157.47 (1C, C-13), 173.72 (1C, C-3). 
IR (cm
-1
): 1654 (C=O), 1718.9 (C=O), 1745.4 (C=O), 2927.5 (C-H), 3389 (O-H). 
 
 
                                                          
1
 For rebinding test of SN38, the 50 M solution was obtained by dilution in water of  
the 2.55 mM mother solution (1 mg of SN38, 2.55
 
µmol, in 1 mL of DMSO). The 
reference used was 1 mM quinolinone  in acetonitrile. Samples were analysed by HPLC 
with a 78:22 water:acetonitrile mobile phase with 0.05% of TFA. The UV-visible 
detector was set to 208 nm wavelength and the flux was fixed at 1 mL/min. For the 
Experimental Section 
 
202 
 
                                                                                                                                               
rebinding test of sunitinib, the 50 M solution of the drug was made by dilution in 
water of a 2.51 mM mother solution (1 mg of sunitinib, 2.51 µmol dissolved in 1 mL of 
1:1 water:acetonitrile). The reference used was 1 mM caffeic acid in water, obtained by 
dilution of a 15 mM mother solution (2.7 mg, 15 µmol in 1 mL of 1:1 water:acetonitrile 
mixture). For each HPLC run, 50 L of the supernatant were injected (mobile phase: 
75:25 water:acetonitrile with 0.05% of TFA, UV wavelength: 265 nm). For rebinding 
tests of paclitaxel, the 50 M solution of the drug was made by dilution in water of a 
10.5 mM mother solution (4.5 mg of paclitaxel, 5.27 µmol in 500 L of acetonitrile), 
while the reference was 1 mM quinolinone in acetonitrile. For HPLC analysis a 55:45 
water:acetonitrile mobile phase was used with 0.05% of TFA, UV-visible wavelength 
230 nm. Finally, for the rebinding test of irinotecan, the 50 M drug solution was 
obtained diluting in water the 1.48 mM mother solution (1 mg of irinotecan, 1.48 µmol 
in 1 mL of water). 50 L of the supernatant was centrifuged before injection into the 
HPLC. The amount of irinotecan captured by the polymer was calculated from a 
calibration curve from 0 µM to 100 µM drug in water. These drug solutions were 
obtained by dilution in water of a 2.95 mM irinotecan mother solution (2 mg, 2.95 µmol 
in 1 mL). The HPLC method used for both the experiment and the calibration curve 
consists on a mobile phase of 75:25 water:acetonitrile with 0.05% of TFA and UV 
detection at 363 nm. The rebinding test for the MIPs 4.5 and 4.6 were also performed 
in citrate buffer (pH=3). In this case the 50 M drug solution was obtained diluting in 
citrate buffer the 3.4 mM mother solution (2.3 mg of irinotecan, 3.4 µmol, in 1 mL of 
citrate buffer). The mobile phase was 75:25 water:acetonitrile with 0.05% of TFA, UV 
wavelength: 363 nm.  
The retention times of quinolinone and SN38 in 78:22 water:acetonitrile were 7.01 min 
and 12.56 min respectively. The retention times of caffeic acid and sunitinib in 75:25 
water:acetonitrile were 2.70 min and 12.67 min. The retention times of quinolinone 
and paclitaxel in 55:45 water:acetonitrile were 2.61 min and 13.64 min respectively. 
Finally the retention time of irinotecan in 75:25 water:acetonitrile was 4.56 min. 
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In this thesis, about 30 MIPs have been studied. 
Among fluorescent polymers, the most promising result has been obtained with 
coumarin as sensing monomer, namely on the recognition of sunitinib. The 
performance of the MIPs as binders resulted from moderately good to very good, and 
their selectivity against other anticancer drugs was satisfactory in particular against 
large molecules as paclitaxel. MIPs showed also a satisfactory stability in methanol : 
plasma mixture without need to further optimization of MIP structure. The fluorimetric 
system based on coumarin was tested in plasma samples treated with four volumes of 
DMSO and turned out to be robust, satisfactory as to its precision and accuracy. It was 
possible to demonstrate its ability to recover sunitinib from spiked plasma samples and 
to quantify the drug within 5 µmol·L
-1 
- 100 µmol·L
-1 
range with a LOD of 400 nmol·L
-1
, 
using a calibration curve obtained in 4:1 DMSO : water mixture. These results are 
currently under submission and are similar to that obtained by Zhang and co-workers 
with a bulk MIP containing 7-acryloyloxy-4-methylcoumarin as fluorescent functional 
monomer, ethylene glycol dimethacrylate as crosslinker and methacrylic acid as co-
monomer. Measuring the quenching of MIP fluorescence, the sulfadiazine antibiotic 
was quantified within 1 µmol·L
-1 
and 40 µmol·L
-1 
range with a LOD of 0.48 µmol·L
-1
 in 
both acetonitrile and milk.
1
 The results can be also compared to that of Li and co-
workers for the alachlor herbicide quantification by a fluorescent sensor based on bulk 
MIP. The MIP fluorescence decreases linearly upon binding the target in the 1 µmol·L
-1 
– 
150 µmol·L
-1 
range with a LOD of 0.5 µmol·L
-1
.
2
   
 
Two different fluorescence tests for irinotecan quantification in 3:1 methanol:plasma 
mixture were developed as proof on concept of fluorimetric sensors.  The first test 
employed a MIP containing tyrosine methyl ester to quenching the intrinsic 
fluorescence of irinotecan. The test turned out to be robust, since the same 
performance was obtained in 3:1 DMSO:plasma mixture and the obtained calibration 
curve showed a linear response between  0.5 µmol·L
-1 
to 8 µmol·L
-1
 drug. Conversely 
the second fluorimetric system is based on a fluorescent MIP containing a 
naphthalimide-based functional monomer as fluorescent label, whose fluorescence is 
quenched upon binding of irinotecan. Using this system the sensitivity has been greatly 
increased than other fluorescent MIPs, showing a linear response between 20 nmol·L
-1
 
and 100 nmol·L
-1
. Moreover these results are better than that obtained by Syu and co-
workers for a MIP film imprinted for creatinine detection, having a similar composition 
and a similar functional monomer than ours. In fact the linear range of their calibration 
curve was within 177 µmol·L
-1 
and 885 µmol·L
-1
 with an LOD of 56 µmol·L
-1
.
3
 While 
synthesizing a core shell MIP on the extremity of an optical fiber, Ton and co-workers 
obtained a more sensitive fluorescent sensor able to quantify the 2,4-
dichlorophenoxyacetic acid herbicide in nM concentrations in water, with a LOD of 2.5 
nM. The polymer had a core of poly-pentaerythritol triacrylate (PETIA) and a shell of 
MIP containing 4-vinyl pyridine, EGDMA as crosslinker and a fluorescent piperazinyl 
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naphtalimide monomer whose fluorescence is enhanced upon interaction with the 
target molecule.
4
 
 
The FRET-based MIP specific for paclitaxel has been exploited to setup a competitive 
test in DMSO. The resulting calibration curve has a linear behavior from 1 µmol·L
-1 
and 
30 µmol·L
-1 
and represents a valid starting point for the development of a FRET sensor 
for paclitaxel quantification in patients samples. This preliminary test is similar but less 
sensitive than that obtained by Carrasco and coworkers for enrofloxacin quantification 
by a fiber-optic sensor based on a dye displacement technique where the linear range 
was between 0.29 µmol·L
-1 
and 21.5 µmol·L
-1
. 
5
 However our test is enough sensitive to 
quantify the higher paclitaxel concentrations found in real samples and it is not 
optimized on a sensor device. 
 
In principle, it is possible to setup also a colorimetric test for irinotecan quantification in 
real samples. The dye displacement technique has been employed to develop a test 
based on a MIP containing 2-acrylamido-2-methylpropane sulfonic acid functional 
monomer able to interact with aniline yellow leading to a change of colour. The colour 
intensity is proportional to the amount of drug captured. The resulting calibration curve 
in acetonitrile showed a linear response between 3.6 µmol·L
-1
 and 75 µmol·L
-1
. Since 
the irinotecan concentrations usually found in patients samples are within the dynamic 
range of this curve, this colorimetric test represent a potentially good system for the 
drug quantification in real samples. Moreover, it has been verified the possibility to dry 
small amounts of treated plasma samples and recover the drug in acetonitrile, 
necessary to perform the colorimetric test. The colorimetric system showed a higher 
sensitivity and a similar dynamic range than that obtained by McNiven and co-workers 
for a colorimetric competitive test based on MIP for chloramphenicol quantification. In 
fact they obtained a linear range between 12 µmol·L
-1 
and 93 µmol·L
-1
 with a LOD of 9.3 
µmol·L
-1
.
6
 
 
As future perspective, in collaboration with Center of Excellence for Biosensors, 
Instrumentation and process Control (COBIK), the most promising fluorescent MIPs will 
be immobilized or deposited on glass wells to be used for the setup of a point of care 
system using the fluorimetric devices developed by COBIK. 
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